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Introduction and Objective of the Thesis 
 
 
Abstract 
 
In the general introduction, vascular grafts for the replacement of blood vessels and 
approaches for their improvement concerning the main problems graft infection, 
thrombogenicity, and intimal hyperplasia were discussed. A focus was on the 
special role of endothelial cells in vessel replacement and graft healing after 
implantation. The approaches for performance improvement of these prostheses 
were highlighted concentrating on the problems surrounding the endothelialization 
of the inner vascular graft surface, due to its importance for the long term patency of 
prostheses. Furthermore, polymers for the potential modification of vascular grafts 
were introduced describing their relevance in the field of controlled release 
applications.  
 
 
Keywords: vascular graft, Dacron®, ePTFE, collagen, PLGA, endothelial cell 
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1 Introduction 
The use of vascular grafts in vessel replacement is not a modern age occurrence. 
Vascular surgery, a necessary prerequisite for vessel replacement, dates as far 
back as 130 AD when first surgeons used vascular ligature to stop and control 
bleedings from vessels. Early prostheses were made of metal, glass or ivory, which 
rapidly blocked due to blood clotting [1]. It was not until Carrel reported a reliable 
method for suturing cut ends of blood vessels together with appropriate patency 
rates in 1912 that extensive vascular surgery became available and was no longer 
the exclusive domain of a few [2]. From there on, the use of autologous vein grafts 
was a common procedure. During World War I and II and the Korean War there was 
significant improvement in the techniques used for vascular surgery and vessel 
replacement [3-4].  
Ever since, vascular grafts have been extensively used and today coronary and 
peripheral vascular bypass grafting is performed on a daily basis in the United 
States and Europe [5]. Nevertheless, it is not without significant constraints and 
complications that these procedures are performed. Ever since the first bypass 
surgery the ultimate goal was to achieve complete revascularization with patency of 
the transplanted grafts for the duration of a patient‟s lifetime [6]. However, most 
attempts, especially in the field of small diameter vascular grafts (< 6 mm) and low 
blood flow locations have failed. These failures are due to the occurrence of 
adverse events, such as graft infection, thrombogenicity of the internal graft surface 
or growth of smooth muscle cells leading to intimal hyperplasia resulting in 
occlusion. 
Therefore, there is a tremendous momentum in the vascular community to develop 
synthetic small-diameter grafts that have high long-term patency rates. Off-the-shelf 
availability in various diameters and lengths, uncomplicated storage or preparation 
requirements, and ease of handling are the main advantages of such grafts [7]. 
Several improvements to vascular grafts have been made in the laboratory setting, 
but failed to convince in the clinic, which is the reason that to this day the majority of 
surgeons continue to implant the well-established products of the past decades [8]. 
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2 Vascular grafts 
2.1 Materials used for vascular grafts 
The first materials used for vessel replacement were made of metals, glass or ivory. 
However, the materials used in modern day vessel replacement have undergone a 
tremendous development, comparable to the surgical techniques employed to place 
them. In contemporary surgeries the use of autologous, homologous, heterogenous 
and alloplastic vessel prostheses is common practice. However, the most preferred 
material to date by surgeons is still the autologous vein graft such as the saphenous 
vein or, for coronary artery grafting, the internal mammary artery [9-10]. Yet, in at 
least 30% of the patients, these veins or others can not be used due to earlier 
removal or other pre-existing conditions. In the absence of suitable autologous 
veins, homologous and heterogenous alternatives can be considered as substitutes. 
The so called Dardik prostheses makes use of the human umbilical vein 
(homologous graft) in combination with a polyester mesh and has been used for 
replacements. However, its difficult preparation process, which includes 
intraoperative irrigation with large volumes of heparinized solutions and the difficulty 
of sewing make it an unattractive alternative [11]. Bovine and ovine arteries 
(heterogenous grafts) have also been used for vessel replacement. However, first 
promising results concerning their effectiveness had to be put in perspective, since 
long term follow up documented aneurysm formation and decreased resistance to 
infection [11].  
The development of alloplastic alternatives started with the accidental observation 
of a pseudointima formation around a silk suture [12-13]. A continuous search for 
better, more blood-compatible materials and improved manufacturing processes 
resulted in prostheses of many different substances and fabrics in a short time. 
Prostheses were made of Nylon®, Teflon®, Orlon®, Dacron®, plastic and 
polyurethane [1]. Nylon was soon abandoned, due to the rapid degeneration after 
implantation, resulting in aneurysm formation [1, 14]. Teflon® (Polytetrafluoro-
ethylene) and Dacron® (Polyethylene terephthalate) showed the most suitable and 
superior properties [14] and represent the gold standard of synthetic vascular grafts 
nowadays. 
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2.1.1 Dacron® 
Dacron® is a form of multiple filaments either woven or knitted into vascular grafts 
(compare Figure 1-1). While woven grafts have smaller pores, knitted grafts formed 
by looping fibers together have larger pores which promote greater tissue ingrowth 
[15]. They are commonly used for larger vessel replacements in regions of high 
blood flow. Before application, porous alloplastic Dacron® grafts are impregnated 
with connective tissue proteins or preclotted with the patient`s blood in order to 
reduce blood loss, aid clotting, and stimulate tissue ingrowth [13, 15]. 
(a) (b) 
  
Figure 1-1: Scanning electron microscopical appearance of a Dacron
®
 prosthesis with large 
folds of Dacron
®
 material (a) and fiber bundles (b). 
 
2.1.2 ePTFE 
PTFE or Teflon® was first used for artificial heart valves and subsequently a more 
microporous material was developed by extrusion and sintering to form expanded 
PTFE (ePTFE) for vascular grafts [15]. It is characterized by circumferentially 
aligned, thin and irregular-shaped solid membranes, the so-called „„nodes‟‟, and a 
dense meshwork of fine fibrils stretching between the nodes (Figure 1-2) [8]. The 
porosity of ePTFE grafts is defined by internodual distance (IND), therefore “low 
porosity” (30 µm IND) and “high porosity” (60 µm IND) grafts are available. Tissue 
ingrowth is only possible down to an IND of approximately 45 µm, which leaves “low 
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porosity” grafts impermeable for tissue ingrowth such as transmural capillarization 
[8]. 
(a) (b) 
  
Figure 1-2: Expanded polytetrafluoroethylene (ePTFE) prosthesis as seen with scanning 
electron microscope of the regular pattern at the inner surface (a) and numerous and densely 
packed fine internodular fibrils (b). 
 
2.2 Failure of vascular grafts 
It is well known that autologous vein grafts are still the graft of choice by surgeons in 
peripheral arterial bypass procedures due to superior patency rates when compared 
to prosthetic grafts [16]. Most of the above described materials show good 
performances and patency in high blood flow regions and with large inner diameters 
(> 6 mm). However, when implanted in regions with low blood flow and smaller 
diameters, vascular grafts start failing. When looking at patency rates of vascular 
prosthesis, synthetic materials have yet to match those of autologous grafts [10]. 
Therefore, synthetic grafts are only used when the use of autologous material is 
contraindicated. Some of the reasons include compliance mismatch, 
thrombogenicity and poor haemodynamics. The main problems that occur during 
the use of artificial vein grafts that have been reported are graft infection [17], 
thrombogenicity of the internal graft surface [18], or growth of smooth muscle cells 
resulting in intimal hyperplasia leading to occlusion [19]. Graft infection is a 
devastating complication with incident rates of 1 % to 6 % [13]. Significant mortality 
and limb amputation rates have been reported for infections occurring in vessel 
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replacement therapy [17]. However, the main reasons for low patency rates are 
thrombogenicity and intimal hyperplasia, with thrombogenicitiy being responsible for 
early graft occlusion [20]. Upon implantation of a vascular graft, plasma proteins 
immediately adsorb to the wall. They present binding sites for integrin receptors, 
which are to be found on platelets and many other cells [21]. Adhesion to these, as 
well as, to the vessel wall itself may cause activation of the platelets [18], resulting 
in thrombosis. Intimal hyperplasia, the reason for late graft occlusion, which is 
associated with the abrupt change in distensibility between native vessel and stiff 
prosthesis at the anastomosis [22], is commonly caused by smooth muscle cell 
proliferation and extracellular matrix deposition [23]. Several of these causes have 
their origin in the lack of a functional endothelial cell lining on the inner surface of 
grafts, especially in mid graft sections after even long periods of implantation [8]. 
Despite the shortcomings of contemporary vascular prostheses, no alternative 
concept has yet emerged that promises to replace the current generation of 
synthetic grafts. 
 
2.3 Improvement of vascular graft performance 
Several approaches to overcome the limitations and complications connected with 
the use of small caliber vascular grafts and their endothelialization have been 
undertaken. Concerning vascular graft infection, it has been reported that even high 
local concentrations of antibiotics can not completely eradicate bacteria in 
established biofilms on vascular grafts [24-25], therefore avoiding the bacterial 
adhesion on vascular grafts is of high importance [13, 26]. In order to achieve this, 
the coating of vascular graft surfaces with antibiotics has been established. Several 
antimicrobial agents [27-28] have been employed, as well as, different ways of 
attachment on the graft surface. Common methods are the use of surfactant 
mediated agents or the incorporation of drugs in biodegradable polymer carriers 
[13, 29-30]. 
In order to reduce thrombogenicity and enhance the blood compatibility of vascular 
graft materials, and therefore one of the reasons for early graft occlusion [18], 
several approaches using Heparin have been undertaken [16, 31]. However, 
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different results were obtained in dependence of the method of bonding, with 
covalent bonding being responsible for a lasting reduction in thrombogenicity in 
vascular grafts made of PTFE [32] and Dacron® [33]. Yet, transient coatings did not 
result in an improvement of patency [18]. These findings have lead to the 
development of a commercially available vascular ePTFE graft (GORE-TEX 
PROPATEN® Vascular graft, W.L. Gore and Associates, Flagstaff, AZ) with long-
term bonding of heparin accomplished by covalent linkage of the anticoagulant [16]. 
Another approach that has been utilized or the reduction of thrombogenicity of 
vascular grafts is the impregnation with carbon [34]. Due to its hydrophobic nature 
and negative charge these coatings lower platelet deposition. However, this 
approach has shown no real advantage in comparison to standard ePTFE grafts 
[35-36]. Other attempts to improve graft patencies have involved the coating with 
albumin, gelatin, and collagen [37-39]. Several other investigations aim at the 
establishing of a functional endothelial cell lining on the inner surface of the vascular 
graft material to mimic the natural conditions via endothelial cell seeding or the 
improvement of endothelial cell adhesion on the graft surface (compare 3.2). 
 
3 Endothelial cells and their role in vessel replacement 
Endothelial Cells (ECs) were once thought to be a monolayer of passive cells lining 
the vasculature [40]. Nowadays, it is known that this endothelial monolayer that 
lines the healthy blood vessel serves as regulator of cardiovascular physiology [5]. It 
provides structural integrity by forming a thromboresistant barrier between 
circulating blood and the arterial wall [41]. It controls blood flow and vessel tone 
[42], platelet activation, adhesion and aggregation, leukocyte adhesion [43] and 
smooth muscle cell (SMC) migration, and proliferation [5]. Therefore, the lack of a 
functional endothelial cell lining on the inner surface of vascular grafts is considered 
to be one of the main factors for small caliber vascular graft failure [5]. 
Consequently, ECs are interesting as coverage of inner prosthetic graft surfaces 
with the idea behind EC seeding or attraction to improve the patency of small 
diameter vascular grafts by establishing a functional biological lining on the luminal 
surface.  
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3.1 Endothelial cell related problems 
Most of the problems occurring during the use of vascular grafts (compare 2.2) are 
related to the lack of an endothelial cell lining, independent of the origin of graft 
material. In case of autologous vein grafts, one would expect a functional 
endothelial cell lining to be present on the inner graft surface since these vessels 
were removed from other regions in a patient‟s body prior to their use and were 
functional until the time of removal. However, even in the case of autologous grafts, 
vascular endothelium related problems occur [10]. During the excision of autologous 
veins for use as vein grafts, in both the arterial and venous circulations, the 
endothelium of the vessel is thought to be traumatized with a resulting reduction in 
its functional capability [44], which causes the aforementioned complications. 
In case of alloplastic vascular grafts, endothelialization mainly occurs at the 
anastomotic region of prosthetic grafts with a maximum depth of penetration of 
endothelial cells into the graft of approximately 10 - 20 mm, even after years of 
implantation [8] leaving the inner part of the grafts permanently without endothelium 
and its resulting complications. Another way of endothelialization of the vascular 
graft surface is transmural migration of endothelial cells in case of ePTFE grafts with 
high IND and Dacron® grafts with sufficient porosity. This effect is responsible for the 
majority of confluent endothelium forming in animal models [18], however only to a 
negligible extent in humans [8, 45]. A further mechanism that has gained interest in 
recent years is the endothelialization of vascular grafts by the transformation of 
endothelial progenitor stem cells (EPCs) with the identification and origins of EPCs 
to be defined [18, 46]. 
 
3.2 Approaches for endothelialization 
A functioning endothelial cell lining on the inner graft surface is the prerequisite for 
long patency rates of vascular grafts [5]. Therefore, the establishing of a thin layer of 
endothelial cells on vascular grafts has been the interest of research groups for a 
long time. 
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3.2.1 In vitro endothelialization 
Endothelial cell seeding seemed a promising approach and first successful 
approaches for seeding vascular grafts in dogs were reported by Herring et al. [47]. 
Several studies in dogs followed implementing different harvesting techniques [40]. 
Two principal methods for the harvest were described: mechanical and chemical. 
The first method was the scraping of endothelial cells from the intima, with the 
drawback of cell damage and possible contamination with smooth muscle cells, 
which could lead to intimal hyperplasia. Latter techniques involved the incubation of 
endothelium with collagenase to separate the cells from the extracellular matrix and 
basement membrane [40, 48]. First studies of seeded cells in humans were 
reported in 1984 [49] with several studies following, however the results were 
controversial [50-52].  
In the following years, different seeding techniques were implemented with the two 
stage seeding technique that makes use of cultured endothelial cells to be seeded 
on grafts [40, 53] and the in vitro culturing of cells on the prosthetic graft. This way, 
the amount of cells and the resistance of cells to shear stress were achieved [54], 
which were thought to be the reason of failure for the previously described attempts 
to seed cells. Despite strong evidence that the effect of endothelial cell seeding [55-
57] is beneficial for the performance of vascular grafts, a major drawback of all 
studies is the labor intensity. There is a 4 to 5 week delay between cell harvest and 
graft implantation, making this an unfeasible alternative for emergency applications. 
In addition, growth and infection problems can occur and the costs of cell culture 
under good manufacturing practice are substantial [40, 58]. In order to avoid these 
risks, a search for other cell types and for other EC sources has been started, with a 
focus on mesothelial cells, microvascular endothelial cells, and endothelial 
progenitor cells [40]. 
 
3.2.2 In vivo endothelialization 
In order to overcome the limitations of in vitro endothelial cell seeding, as mentioned 
above, but still establish a functional endothelial cell lining on the inner surface of 
vascular grafts, in vivo endothelialization has been a focus for several years. The 
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goal is to increase the transanastomotic ingrowth of endothelial cells and to capture 
endothelial progenitor cells present in the blood stream and stimulate their growth 
and attachment. Several approaches to achieve this endeavor have been 
undertaken using a multitude of modifications of the graft surface. The modification 
of graft surfaces using plasma have been shown to enhance the cell compatibility 
properties of ePTFE grafts [59]. Another approach is the attachment of RGD peptide 
sequences to vascular graft surfaces, as they are widely acknowledged as cell-
binding signals [60]. 
Several other approaches include the use of growth factors to induce endothelial 
cell growth and attraction. Among the growth factors investigated, the family of 
fibroblast growth factors, especially basic fibroblast growth factor (bFGF), has been 
investigated for the use to enhance endothelialization [61]. However bFGF has also 
been shown to have stimulatory effects on smooth muscle cell growth, which in turn 
can lead to intimal hyperplasia and vessel occlusion [62-63], making it a less ideal 
candidate. Another widely investigated growth factor is the Vascular Endothelial 
Growth Factor (VEGF). VEGF is a secreted protein ligand that activates 
transmembrane receptors on endothelial cells. It is a disulfide-linked homodimer 
and exists in several isoforms, four of which consist of 121, 165, 189 and 206 amino 
acids [64] and are produced from a single human gene as a result of alternate 
splicing [65]. This growth factor has been shown to have very high endothelial cell 
specificity without mitogenic activity for other cell types [66], making it an ideal 
candidate for the specific stimulation of endothelial cell growth in vascular graft 
applications. Multiple ways of presenting these growth factors have been 
investigated, including extracellular matrix coatings [67], electrostatic interaction 
[45], and fibrin matrices [65, 68], all of which have shown promising results.  
The controlled release of therapeutic agents from the vascular graft surface 
constitutes a promising approach for the improvement of vascular graft patency and 
the establishing of a functioning endothelial cell lining. A coating with biocompatible 
and biodegradable polymers for this approach and the subsequent local drug 
delivery for modifying the response of the surrounding tissue could induce 
spontaneous endothelialization and/or inhibit smooth muscle cell proliferation and 
therefore overcome the limitations of small caliber vascular grafts. 
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4 Polymers for controlled release applications 
As mentioned above (compare 3.2) the establishing of a functioning endothelial cell 
lining on the vascular graft surface is an important prerequisite for the long term 
patency of small caliber grafts. The controlled release of endothelial cell specific 
growth factors, such as VEGF, from film coatings on vascular grafts presents a 
promising approach to overcome the problems encountered in in vitro and in vivo 
endothelialization. This paragraph discusses commonly used biocompatible and 
biodegradable polymers for controlled release applications and their potential use 
for vascular graft coatings. 
 
4.1 Natural polymers - collagen 
The class of natural polymers can be divided in two main groups polysaccharide 
and protein based polymers. The polysaccharide based polymers comprise of 
chitosan, starch, alginate, hyaluronic acid and chondroitin sulphate [69-70] and can 
be obtained from different sources, such as microbial, animal, or vegetal and show 
good hemocompatibility and non-toxicity [71]. Protein based polymers include 
collagen, gelatin, fibrin, and albumin [69, 72]. The availability of large quantities and 
the good biocompatibility of these natural polymers makes them an attractive 
alternative for drug delivery devices [72]. However, due to their natural origin, batch 
to batch variations in their composition can occur [73].  
A commonly used biopolymer in controlled release and biomaterial applications is 
collagen [74-79]. Collagen is the primary and major structural protein of vertebrates, 
representing almost 30% of total protein present in a body [80]. Due to its 
mechanical and biochemical properties, it can primarily be found in areas of high 
mechanical strain. Hence, 90% of extracellular protein in tendon and bone, and 
more than 50% in skin, consist of collagen [81]. Most of the structural support in 
mammals is achieved by collagen, its primary function in the extracellular matrix. 
Nevertheless, to date 27 collagen types have been isolated with a variety of 
functions [82]. However, collagen type I is the most investigated for biomedical 
applications. 
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4.1.1 Structure of collagen 
Collagen is characterized by a very high mechanical strength and stability caused 
by the characteristic triple helical structure [83-84]. These helices are composed of 
three polypeptide α-chains each consisting of more than 1000 amino acids, which 
are arranged in a characteristic repetitive unit glycine-X-Y (Gly-X-Y) (Figure 1-3a). 
The absence of a side chain in glycine results in the formation of a typical left-
handed triple helix as closest packing with glycine oriented in the core [72], 
representing the secondary structure of collagen (Figure 1-3b). The X- and Y- 
positions can be occupied by any amino acids, however about 35% of the non-
glycine positions are dominated by proline in the X-position and 4-hydroxyproline in 
the Y-position [83]. Three triple helical polypeptides then form a rope-like right 
handed supercoil, also know as tropocollagen, with a length of approximately 
300 nm and a diameter of 1.5 nm (Figure 1-3b). In addition, there are regions of 
about 9-26 amino acids at the amino and carboxyl terminal ends that are not 
incorporated in the helical structure, the so called telopeptides, which are the main 
molecular sites involved in collagen cross linking [85]. These tropocollagen 
molecules form longitudinal and bilateral microfibrils and further fibrils with distinct 
periodicity [79] (Figure 1-3c). These collagen fibrils organize into fibers which on 
their part can form even larger fiber bundles [83]. 
    
   
 
   
(a)
  ) 
(b)
  ) 
(c)
  ) 
 
Figure 1-3: Chemical structure of collagen type I with primary amino acid sequence (a), 
secondary left handed helix and tertiary right handed triple-helix structure (b) and staggered 
quaternary structure (c) [80]. 
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4.1.2 Crosslinking of collagen 
Natural crosslinking gives high tensile strength and proteolytic resistance to 
collagen. Due to dissociation of crosslinks in the course of the isolation processes, 
reconstituted forms of collagen such as films, fibers, or sponges can lack sufficient 
strength and may disintegrate upon handling or collapse under the pressure from 
surrounding tissue in vivo [83]. In addition, the biodegradation and therefore the 
release of incorporated compounds may need to be customized, which can be 
achieved by crosslinking of collagen by means of chemical or physical methods. 
The amount of penetrating water responsible for the swelling of the collagen 
decreases in correlation to the increase of crosslinking degree [86], thus limiting the 
release of high molecular weight compounds due to the entrapment of such 
compounds in the crosslinked matrix in contrast to low molecular weight compounds 
[83]. Chemical crosslinking of collagen can be performed using a variety of 
reagents. Aldehydes (e.g. glutaraldehyde) have been extensively used due to their 
good efficiency, inexpensiveness, and short treatment times [83, 87]. However, 
crosslinking may sometimes be restricted to the surface and heterogenous 
crosslinking can occur. In addition, glutaraldehyd is incorporated in the new linkage 
raising the question of cytotoxicity and biocompatibility [87]. Carbodiimides (e.g. 
Ethyl(dimethylaminopropyl)-carbodiimide) and acyl azides represent zero-length 
crosslinking methods, where the chemical is not integrated in the newly formed 
bond, but acts as an initiator for the linkage of free carboxylic and amino groups to 
form amide bonds. Furthermore, crosslinking can be performed by the use of tannic 
acid [88], polyepoxy compounds [89], and hexamethylene-diisocyanate [90]. In 
addition to chemical crosslinking methods, physical procedures such as 
dehydrothermal treatment [79, 83, 91] and UV radiation have been reported [83, 
92]. 
These methods of crosslinking can be applied in order to prevent rapid degradation 
of collagen based biomaterials during in vivo application, improve its mechanical 
stability [93] and reduce tissue response [94]. Crosslinking is especially useful when 
using collagen in controlled release applications. By means of crosslinking the 
release of compounds entrapped in the collagen matrix can be tailored to the 
specific needs of the application. 
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4.2 Synthetic polymers - PLGA 
Synthetic polymers have been widely used in the field of controlled release 
applications and biomaterials [95-98]. They comprise of poly(amides), poly(amino 
acids) poly(alkyl-α-cyano acrylates), poly(acrylamides), and poly(esters) [99]. 
Amongst them, the aliphatic poly(esters) polylactides (PLA), polyglycolides (PGA), 
and especially PLGA have been of great interest due to their good biocompatibility 
and biodegradability [100-102]. They are the most widely known, studied, and used 
bioabsorbable synthetic polymers in medicine. Polyglycolide and polylactide (PLA) 
homopolymers and their copolymers (PLGA) are all poly (α-hydroxyacids). Poly (α-
hydroxy acids) can be polymerized via condensation, although only low molecular 
weight polymers are produced [103]. In order to obtain a higher molecular weight 
and thus mechanical strength and longer degradation time, the polymers are 
polymerized from the cyclic dimers dilactide and diglycolide via ring-opening 
polymerization using appropriate initiators and co-initiators [104]. The general 
chemical structure is displayed in Figure 1-4. 
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polylactic acid (PLA):   R1, R2 = -CH3 
polyglycolic acid (PGA):  R1, R2 = H 
poly(lactic-co-glycolic) acid (PLGA): R1 = H, R2 = -CH3 
non end-capped versions:  R3 = H 
end-capped versions:   R3 = -alkyl 
Figure 1-4: General chemical structure of poly(α-hydroxyacids). 
 
By modification of molecular weight [105], ratio of the used monomers, and degree 
of crystalllinity [106-107] the degradation and release properties of the copolymers 
can be tailored to the specific needs of the application. Furthermore, the release 
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properties can be altered by esterification of the carboxylic end groups of the 
polymer using long chain alcohols in order to obtain end capped polymers with a 
more hydrophobic character in contrast to the more hydrophilic properties of the 
non-end-capped varieties [108]. The degradation of these polymers is mainly driven 
by hydrolysis of the polymer chains in smaller fragments [109-110] down to lactic 
and glycolic acid [111] that can be eliminated by the kidneys or in form of carbon 
dioxide via the lungs. Enzymatic involvement in the degradation of the polymers is 
unclear [106]. The rate of hydrolysis and therefore the rate of degradation is mainly 
controlled by the amount of penetrating water [112-113]. It has been shown that this 
rate is decreased for pure crystalline poly-l-lactide and polyglycolide and that it 
increases with an increasing ratio of glyoclid in the copolymer and increasing 
hydrophilicity [114-115]. Therefore, a whole range of polymers with varying 
properties and applications is commercially available from Boehringer Ingelheim 
under the name of Resomer® [116-117]. However, PLGA copolymers as well as PLA 
and PGA are also available from other suppliers, such as Birmingham Polymers or 
Purac Biomaterials. 
Despite the wide range of polymers available, their release rates are difficult to 
predict and dependent on the compounds incorporated and the geometry of the 
device [118]. In general, their release profiles are characterized by an initial burst 
release of drug that is deposited near the surface and is caused by its dissolution 
[119], followed by a sustained release phase characterized by zero order kinetics 
[120]. Consequently, release mechanisms with different stages are proposed for 
devices made of PLGA [121]. Other limitations of PLGA based release systems for 
protein delivery are the use of organic solvents during the manufacturing process 
and the decrease in pH caused by acidic erosion products that may cause harm to 
the incorporated protein [122]. Nevertheless, PLGA is considered the “gold 
standard” of biodegradable polymers [73]. 
 
The described polymers, collagen, and PLGA have been widely used in controlled 
release applications due to their good biocompatibility and biodegradability. 
Collagen in particular has been investigated for the release of growth factors for 
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vascular graft application [61] with promising results. Both polymers have been 
shown to be suitable for vascular applications [112, 123] and intravenous drug 
delivery. Therefore, these polymers present a promising tool for the controlled 
release of endothelial cell specific growth factors from film coatings on vascular 
grafts as a device to overcome the problems encountered in in vitro and in vivo 
endothelialization. 
 
5 Conclusions 
The use of alloplastic prothestic vascular grafts in vessel replacement therapy is 
inevitable and many approaches to overcome the limitations, especially in the field 
of small diameter grafts in low blood flow regions, have been undertaken. The lack 
of a functioning endothelial cell lining, being one of the main contributors to these 
limitations, has been addressed by a multitude of studies and several promising 
attempts have been carried out. Yet, some are inapplicable in emergency situations 
due to long preparation times and difficult preparation procedures. Therefore, 
despite all the research in this field no alternative concept has yet emerged that 
promises to replace the current generation of synthetic grafts, which enables off-the-
shelf availability and supports complete endothelialization of the inner surface and 
complete healing of the vascular graft to ensure patency for a patient‟s lifetime. 
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6 Objectives of the Thesis 
The goal of the thesis was the investigation of functional coatings for the 
improvement of vascular graft performances, especially in regards of 
endothelialization with the help of endothelial cell specific growth enhancers.  
It was of interest to be able to apply these modifications on existing commercially 
available vascular grafts; therefore a suitable model system for the investigations 
needed to be developed. Due to the low adhesion of coatings on the model surface 
PTFE, it was necessary to enhance its coating accessibility. Therefore, the first 
objective was the investigation and implementation of the plasmabrush® for argon 
plasma treatment of the PTFE surfaces and the characterization thereof 
(Chapter 2).  
For the presentation of cell growth enhancers to the endothelial cells two 
approaches were considered: 
The first approach was the incorporation of the cell growth enhancer in matrices and 
the controlled release thereof within an appropriate period of time. Therefore, the 
second main objective of the thesis was the investigation of biodegradable film 
coatings for the controlled release of the growth enhancers. The polymers of choice 
were PLGA and collagen. The influences of several parameters on the release 
needed to be investigated, specifically in the case of collagen, the influence of 
crosslinking on the release rate. The coating cell compatibility and the cell growth 
enhancement of the released protein were to be studied and quantified (Chapter 3 
and 4). 
For the second approach, the presentation of a cell growth enhancer at the surface, 
the covalent linkage of an enhancer to modified films was investigated. Thus, the 
third objective was the chemical modification of PLGA and collagen using a 
functional polyethylene glycol (PEG) spacer and the covalent linkage of the 
enhancer to the surface of a film consisting thereof. Furthermore, detection methods 
for the surface bound protein needed to be evaluated and developed. After 
successful linkage, the influence of the covalently attached protein was to be 
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evaluated in a cell assay concerning its effect on endothelial and smooth muscle 
cells (Chapter 5 and 6). 
 
Thus, in summary the main objectives of the thesis were: 
1. Implementation of the plasmabrush® and establishing a method for surface 
modification of PTFE to enhance the coating accessibility, and understanding 
the change in physical properties induced by plasma modification by means of 
surface sensitive analytical techniques (Chapter 2). 
2. Investigation and modification of PLGA and collagen films for the controlled 
release of the endothelial cell specific growth enhancer VEGF165. Establishing 
an in vitro cell culture system and quantification of the stimulatory effect of the 
developed release systems (Chapter 3 and 4). 
3. Covalent attachment of VEGF165 to chemically modified PLGA and collagen 
films by the use of a bifunctional PEG-spacer and the identification of analytical 
methods to detect surface bound protein. Evaluation of developed systems 
concerning their cell growth enhancing properties (Chapter 5 and 6). 
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Chapter 2 
 
Modification of PTFE using atmospheric plasma and its 
characterization 
 
 
Abstract 
 
The implementation of the plasmabrush® (Reinhausen Plasma GmbH, Regensburg, 
Germany) and the optimization of the plasma treatment process for polytetrafluoro-
ethylene (PTFE) to enhance coating adhesion was studied. Furthermore, the 
changes induced by the atmospheric argon plasma treatment process were 
characterized using surface sensitive techniques, such as scanning electron 
microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy, X-ray 
photoelectron spectroscopy (XPS), and surface energy determination. Scanning 
electron microscopy did not reveal any changes in surface morphology and FT-IR 
was not sensitive enough to detect alterations in surface chemistry. XPS revealed 
minor variations in the binding energy region of oxygen; however, a decrease was 
shown for plasma treated samples, which suggested a cleansing effect of the argon 
plasma treatment for the PTFE samples. A change in surface energy was 
detectable for the treated samples using test inks. In addition, it was shown that the 
treatment significantly increased coating adhesion of applied collagen and 
poly(lactic-co-glycolic acid) (PLGA) films, as well as, cell adhesion of human 
umbilical vein endothelial cells (HUVECs) in comparison to untreated PTFE. 
 
Keywords: PTFE, atmospheric argon plasma, surface energy, endothelial cells 
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1 Introduction 
Synthetic polymeric materials have been widely used in the field of biomaterial 
applications. Polymers such as polyurethane, poly(methylmethacrylate), ultrahigh 
molecular weight polyethylene, polyetheretherketone (PEEK), polyethylene 
terephthalate (PET), and PTFE have been used for bone plates, screws, artificial 
lenses, bone cements, abdominal wall prostheses, and vascular grafts [1-2]. 
However, most of these materials do not meet the demands for both their surface 
and bulk properties when used as biomaterials [3]; a very low surface energy and 
resulting poor adhesion being one crucial factor. Adhesion is generally considered 
to be a surface property, where only molecular layers at the surface of the material 
are responsible for the effect [4]. Several approaches have been undertaken to 
change the surface properties of polymeric surfaces, with the most obvious being a 
surface roughening by sand blasting or etching in order to increase the surface area 
for enhanced adhesion [5]. Other methods applied are oxidation [6], ion implantation 
[7], or graft polymerization [8]. In recent years, plasma treatment of polymer 
surfaces has been employed as an interesting alternative for surface modification 
[4]. Depending on the gas composition and plasma conditions, ions, electrons, fast 
neutrals, radicals, and UV radiation contribute to the polymer treatment, resulting in 
etching, activation, and/or cross-linking [9]. Since these changes generally occur 
within the top layers of the treated materials [10], plasma treatment is an interesting 
approach to modify the near surface region without modifying the bulk properties of 
the polymers. 
Therefore, the goal of this study was the implementation of the atmospheric plasma 
treatment torch plasmabrush® for the modification of PTFE surfaces, and the 
enhancement of its coating accessibility and cell compatibility. For this purpose, 
changes induced by atmospheric plasma treatment were characterized by various 
surface sensitive techniques, such as SEM, FT-IR spectroscopy, XPS, and surface 
energy determination. To get insight in the cell compatibility and attachment, cell 
studies using human umbilical vein endothelial cells (HUVECs) were performed. 
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2 Materials and Methods 
2.1 Materials 
PTFE was obtained from GM GmbH (Freiham, Germany), argon process gas and 
nitrogen from Linde AG (Pullach, Germany), collagenase A from Roche (Penzberg, 
Germany), endothelial cell growth medium from Provitro (Berlin, Germany), heat 
inactivated fetal bovine serum from Biochrom (Berlin, Germany), buffered 
formaldehyde solution (4%) from Polysciences Inc. (Warrington, PA, USA), crystal 
violet and dichloromethane from Merck KGaA (Darmstadt, Germany), Resomer® 
(RG 502H, RG 503, RG 503H and RG 504H) from Boehringer Ingelheim 
(Ingelheim, Germany), and equine collagen type I derived from tendon from Innocoll 
GmbH (Saal/Donau, Germany). The pH of the solutions was adjusted using 
hydrochloric acid or sodium hydroxide from Merck KGaA (Darmstadt, Germany) and 
measured with a pH meter Inolab level 1 from WTW (Weilheim, Germany). 
 
2.2 Methods 
2.2.1 Plasma activation 
PTFE-discs were activated with an atmospheric plasma jet (plasmabrush®, 
Reinhausen Plasma GmbH, Regensburg, Gemany) (see Figure 2-1) using argon 
with a purity of 5.0. Gas flow was adjusted to 10 l/min. The voltages for plasma 
discharge and treatment time were evaluated. 
 
Figure 2-1: plasmabrush® atmospheric plasma jet (Reinhausen Plasma GmbH, Regensburg, 
Germany) 
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2.2.2 Characterization of surfaces after plasma modification 
2.2.2.1 Scanning Electron Microscopy 
Samples for SEM were fixed on specimen holders using conductive double sided 
tape before sputtering with a thin layer of carbon under vacuum. SEM images were 
obtained using a Philips XL Series XL20 (Philips, The Netherlands) at 4.0kV. 
 
2.2.2.2 X-ray Photoelectron Spectroscopy (XPS) 
XPS measurements were performed using a Vacuum Science Workshop (VSW) 
surface analysis chamber equipped with a VSW HA 100 hemispherical analyzer 
(Vacuum Science Workshop, United Kingdom). The analyzer was operated in Fixed 
Analyzer Transmission (FAT) mode with variable retarding potential of 22 eV. The 
base pressure during the XPS measurements was <10−7 Pa.  
 
2.2.2.3 Attenuated Total Reflection- FT-IR spectroscopy (ATR-FT-IR) 
FT-IR measurements were performed on a Tensor 27 FT-IR spectrometer (Bruker 
Optics GmbH, Ettlingen, Germany) using the Miracle ATR unit. The recorded 
spectra were obtained from 4000 to 900 cm-1 wavenumbers, in attenuated total 
reflectance (ATR) mode at 20°C. Each measurement wa s an average of 240 scans. 
While data acquisition was performed, the optical bench was purged with dry 
nitrogen to reduce interference from water vapour IR absorption and each spectrum 
was corrected for the background. 
 
2.2.2.4 Surface energy determination 
The change in surface energy of plasma treated discs was evaluated using test inks 
for surface energy determination (Plasmatreat Testtinte, Plasmatreat GmbH, 
Steinhagen, Germany) in a range of 30 – 72 mN/m. 
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2.2.3 Cell compatibility 
The cell compatibility of untreated and plasma treated PTFE-discs was evaluated 
using HUVECs. HUVECs were prepared by digestion of umbilical veins with 0.1 g/l 
collagenase A. Cells were cultured in endothelial cell growth medium supplemented 
with 10% heat-inactivated fetal bovine serum in a humidified atmosphere at 5% CO2 
and 37°C. Cells were used at passage no. 3. For vis ualization of cells on the 
different surfaces, cells were fixed with a buffered formaldehyde solution (4%) and 
nuclei were stained with crystal violet (0.5% in 20% methanol). Images were 
obtained with a SZX7 microscope and an ALTRA20 CMOS camera (Olympus, 
Hamburg, Germany). 
 
2.2.4 Film adhesion 
1% (w/v) Resomer® (RG 503 and RG 503H) solutions in dichloromethane and 0.5 
and 1% (w/v) aqueous collagen dispersions were used to coat untreated and argon 
plasma treated PTFE-discs with a diameter of 15 mm. Therefore, the discs were 
placed in 24-well aluminum well plates and covered with the different coating 
solutions. The discs were air dried for one hour and subsequently removed from the 
wells, and dried under vacuum over night or until further use. For the investigation 
of film adhesion, the coated discs were examined concerning the ablation of PLGA 
and collagen films after drying by means of visual inspection. 
 
3 Results and Discussion 
3.1 Surface characterization 
In order to gain insight in the changes of surface properties and composition of the 
atmospheric plasma treated samples, as well as, to obtain a better understanding of 
the plasma treatment in general, several methods to investigate the changes and 
the process were utilized. Therefore, the samples were plasma treated and 
subsequently analyzed by means of SEM, FT-IR spectroscopy, and XPS. In 
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addition, the change in surface energy was determined using commercially 
available test inks. 
 
3.1.1 Surface morphology 
One of the main effects reported for the treatment of polymer surfaces with plasma 
is the ablation or the etching of material of the surface, which can remove weak 
boundary layers and increase the surface area [4, 11]. Therefore, changes in 
surface morphology could potentially be visualized using scanning electron 
microscopy. For the investigations, untreated and plasma treated PTFE samples 
were prepared according to 2.2.1 and examined concerning their morphology. 
(a) (b) 
  
(c) (d) 
  
Figure 2-2: Scanning electron micrographs of untreated PTFE discs as overview (a) and 
magnification (b) and argon plasma treated PTFE discs as overview (c) and magnification (d). 
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Figure 2-2 shows the surface of plasma treated and untreated polymer by SEM. 
The overview micrographs of both samples (Figure 2-2a and c) showed similar 
scratch patterns on the surface that originated from the manufacturing process of 
the PTFE. Magnifications of both samples (Figure 2-2b and d) showed again no 
differences concerning the surface morphology, such as, smoothing of the surface 
due to etching or ablation in contrast to cases reported in literature for different 
polymers using various process gases [10, 12]. However, Park et al. reported 
similar findings when investigating the change in surface morphology of polymers 
under the influence of plasma treatment [13]. Therefore, it must be concluded that 
the short treatment times of the atmospheric argon plasma did not suffice to inflict 
changes on the surface morphology of the used PTFE samples. 
 
3.1.2 Surface chemistry analysis by ATR-FTIR 
In order to investigate the introduction of functional groups on the surfaces of 
plasma treated PTFE discs, FT-IR measurements were performed. For the 
measurements, PTFE-discs were treated with argon plasma according to 2.2.1 with 
a constant nozzle to surface distance of 10 mm, an excitation voltage of 4.5 kV, and 
a treatment time of 15 s. FT-IR spectra were recorded prior to treatment for pristine 
PTFE samples and immediately after plasma treatment. 
900140019002400290034003900
wavenumber [cm-1]
 
Figure 2-3: FT-IR spectra of untreated ( ) and plasma treated ( ) PTFE discs using 
argon with adjusted intensity for better comparability. 
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Figure 2-3 shows the recorded ATR-FTIR spectra of untreated and argon plasma 
treated samples. No differences of the recorded spectra were observable over the 
range of wavenumbers investigated. It has been reported in literature that plasma 
treatment of polymer surfaces with various process gases results in the removal of 
hydrogen atoms especially for inert gas plasmas [14] or in the case of PTFE the 
removal of fluorine atoms from the polymer surface and the formation of carbon 
radicals. Most carbon radicals will then be oxidized into oxygen functional groups, 
when the polymer specimen are exposed to air in case of low pressure plasma or 
during the treatment process in case of atmospheric plasma treatment [8, 15-16]. 
The results demonstrate that in case of plasmabrush® treatment of PTFE, oxygen 
functional groups are not introduced due to the very high bond strength between 
carbon and fluorine atoms [17] or are introduced at a concentration which is below 
the limit of detection for FT-IR spectroscopy. The depth of penetration for FT-IR of 
several microns [18] might be responsible for a reduced sensitivity as argon plasma 
affects the 30 nm region of surfaces treated [10]. It has also been reported that the 
main effect of argon plasma on polymer surfaces is ablation and etching [10], but 
could not be confirmed using SEM. 
 
3.1.3 Surface composition 
XPS has been widely used in the investigation of the influence of plasma 
modification on polymer surfaces [19-21]. It is a method sensitive to minor changes 
in the surface composition of studied materials, which made it a promising tool for 
the investigation of the upper layers within the top 3-6 nm of the investigated 
polymer [22]. For the investigations, untreated and plasma treated PTFE samples 
were prepared according to 2.2.1 and were examined concerning their surface 
composition (compare 2.2.2.2). 
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Figure 2-4: Overview XPS spectra of untreated (  ) and argon plasma treated (  ) PTFE discs 
with adjusted intensity for better comparability. 
 
The overview XPS spectra recorded for the untreated and treated PTFE samples 
are shown in Figure 2-4. The peak that occured at 294 eV could be ascribed to the 
C1s spectrum attributed to the CF2 species and was present in both untreated and 
argon plasma treated polymer species. The second characteristic peak at 691 eV 
could be ascribed to the F1s spectrum and was observed in both polymer species 
as well. In order to further investigate the influence of argon plasma on the chemical 
composition of the polymer surface, the areas of the XPS spectra for the peaks 
representing the C1s, F1s, O1s and N1s were analyzed at higher resolution. The 
later were investigated with the intention of studying the introduction of functional 
groups including oxygen and nitrogen. 
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Figure 2-5: Magnification of XPS spectra of untreated (  ) and argon plasma treated 
( ) PTFE discs of binding energy regions of F1s (a), C1s (b) and O1s (c).  
 
The magnification of the binding energy regions for the F1s spectrum (Figure 2-5a) 
revealed no differences for the untreated and plasma treated PTFE samples. The 
same result was obtained when investigating the magnification of the binding 
energy region of the C1s spectrum (Figure 2-5b) and the N1s region (data not 
shown). When studying the magnification of the O1s region of the binding energy 
minor differences were observable that were hardly delimitable from background 
noise. However, contrary to the expectations, a decrease of oxygen content was 
detected for the plasma treated samples in comparison to the unmodified PTFE 
(Figure 2-5c). The introduction of oxygen containing species by the formation of 
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radicals during the plasma treatment process and subsequent saturation by oxygen 
present during the plasma treatment process or post treatment with ambient air 
have been reported in literature [23-24]. A decrease in oxygen content for the 
plasma treated samples could be ascribed to cleansing of the surface by ablation of 
weak boundary layers [4] contaminated with oxygen. A removal of plasma activated 
layers and the exposure of untreated polymer as reported in literature [25] might 
have added to that effect. 
 
3.1.4 Determination of surface energy - hydrophilicity 
For the determination of surface energy of the untreated and argon plasma treated 
PTFE samples, commercially available test inks were used. It is a simple, quick, 
and easy to use method for measuring surface energy on materials such as plastic, 
metal, or glass. In order to determine the surface energy of samples, the test inks 
were applied to the surface. In case good wetting occurred after application, the 
surface energy of the material being tested was higher than the corresponding 
surface tension value of the ink applied. The test was repeated with the next higher 
test value until wetting failed to occur. Accordingly, the surface energy of the 
material corresponds to the value of the test ink that last wetted it for at least 2 
seconds. Obtained values for surface energies are relative values and can not be 
directly compared to values acquired with other methods. 
(a) (b) 
    
Figure 2-6: Determination of surface energy of PTFE discs using 30 mN/m test inks of a disc 
prior to treatment (a) and after argon plasma treatment (b). 
 
Figure 2-6 shows the results obtained for an untreated and plasma treated sample. 
Prior to treatment PTFE, had a surface energy of below 30 mN/m (Figure 2-6a), the 
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lower limit of detection for the applied test inks, as could be seen by the bad wetting 
of the applied test ink. These results are in accordance to values reported in 
literature for pristine PTFE of approximately 15 – 20 mN/m [17, 26-27]. Following 
plasma treatment, the surface energy of the samples increased to values above 
30 mN/m as could be seen by the good wetting of the applied test ink (Figure 2-6b). 
This increase in surface energy for plasma treated samples was in accordance to 
studies reported in literature [23, 28-29].  
Thus, despite the fact that neither XPS, ATR-FTIR, nor SEM could prove chemical 
or surface morphology changes, the important parameter for coating [30] or cell 
adhesion [31], surface energy could be significantly increased by atmospheric 
plasma treatment.  
 
3.2 Optimization of the plasma activation process using the plasmabrush® 
In order to optimize the procedure for atmospheric plasma treatment using the 
plasmabrush®, the aforementioned method to determine changes in surface energy 
using test inks was employed to characterize the treated surfaces and to optimize 
the treatment parameters. The effect of changes in parameters, such as, ignition 
voltage of the plasma, treatment time, and aging of the treated surfaces were 
investigated. 
 
3.2.1 Optimization of ignition voltage 
For the optimization of the ignition voltage of the plasma, treatment time for all 
PTFE samples was kept constant at 10 s, as well as, the nozzle to surface distance, 
which was 10 mm. Samples were plasma treated using argon gas at a flow rate of 
10 l/min with different ignition voltages ranging from 3.5 kV, the lowest voltage 
applicable due to non ignition of plasma at lower voltages, and 8.0 kV, the highest 
voltage applicable due to arc discharges occurring at higher voltages. Surface 
energy of the treated samples was measured immediately after the plasma 
treatment. 
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Figure 2-7: Development of surface energy in correlation to treatment voltage for argon 
plasma treated PTFE discs. (average ± SD; n=3) 
 
Figure 2-7 shows the development of the surface energy of the plasma treated 
samples in accordance to the ignition voltage. The activation started at 3.5 kV with a 
surface energy of the treated samples of approximately 31 mN/m and reached a 
maximum of activation at 34 mN/m for the samples treated with 4.0 and 4.5 kV. 
Surface energies for the samples treated with voltages higher than 4.5 kV 
decreased to 32 mN/m for those treated with 5.5 and 6.0 kV. A further decrease to 
approximately 31.5 mN/m was experienced for the samples treated with a higher 
voltage than 6.0 kV up to 8.0 kV, the highest voltage applicable. 
Contrary findings have been reported in literature. Water contact angles, the basis 
for the calculation of surface energy based on the method of Owens and Wendt 
[32], were measured in dependence of different acceleration voltages in a low 
pressure plasma setting [33]. Water contact angles increased with low voltages 
leading to lower surface energies and decreased with higher voltages, reflecting 
higher surface energies. Similar findings were also reported by Liu et al [34] for 
atmospheric plasma treatment. 
In this case the ignition voltage of up to a 4.5 kV in combination with the short 
treatment time of 10 s might be responsible for a cleansing and modification of the 
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surface of the PTFE film leading to an increased surface energy. Further increase of 
the ignition voltage could then cause a removal of activated polymer layers and the 
exposure of untreated polymer, as reported in literature [25], resulting in a 
subsequent decrease of surface energy, as observed during the optimization 
process. 
 
3.2.2 Optimization of treatment time 
In order to optimize treatment times of the plasma treatment process nozzle to 
surface distance for all PTFE samples was kept constant at 10 mm and two ignition 
voltages 3.5 and 4.5 kV were investigated. Samples were plasma treated using 
argon gas at a flow rate of 10 l/min with different treatment times ranging from 5 s to 
60 s. Surface energy of the treated samples was measured immediately after the 
plasma treatment. 
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Figure 2-8: Development of surface energy in correlation to treatment time for 3.5 kV (  ) 
and 4.5 kV (  ). (average ± SD; n=3) 
 
It was expected that increasing treatment times could result in increasing 
modification of the surface, in this case the surface energy, as reported in literature 
[17, 35]. For both excitation voltages, an increase in surface energy was detected in 
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the first 15 s of treatment time, with surface energies of 30.0 and 30.5 mN/m for 3.5 
and 4.5 kV respectively after 5 s of treatment and a maximum of 32.0 and 
34.0 mN/m after 15 s (Figure 2-8). Increasing the treatment times did not result in a 
further increase of surface energy, but in a decrease to 30.5 mN/m for both voltages 
after a treatment time of 30 s. A further reduction of surface energy to 30 mN/m after 
treatment times of 60 s, irrespective of the excitation voltage was observed. The 
decrease in surface energy might indicate that other processes, such as, molecular 
turn-over, weak boundary layers, and etching were dominating the treatment [36] 
and were therefore leading to the ablation of plasma activated layers and the 
exposure of untreated polymer [25]. 
 
3.2.3 Influence of aging time post treatment on surface energy 
With the aim of bulk production of plasma treated samples, it was important to 
investigate the influence of aging time post treatment on plasma modified PTFE 
samples. Therefore, PTFE discs were treated with atmospheric plasma using argon 
gas as process gas at a flow rate of 10 l/min, a nozzle to surface distance of 10 mm, 
an excitation voltage of 4.5 kV, and a treatment time of 15 s. For the investigations 
sufficient, amounts of PTFE samples were plasma treated and stored at room 
temperature under a fume hood until measurement using the test inks. For each 
time point new samples were measured and discarded afterwards in order to 
eliminate the effect of the test ink on the surface. 
 
The results for the effect of aging time on the surface energy of argon plasma 
treated samples are shown in Figure 2-9. A maximum of activation could be 
observed 60 min post treatment that decreased with increasing aging time and 
stabilized at a surface energy of 32 mN/m that was maintained for several weeks 
(data not shown). Similar results have been described using low pressure plasma. 
Koenig et al. reported that in dependency of storage conditions post treatment the 
changes in surface properties on PTFE samples were reversible [18]. The same 
phenomenon has also been reported for other polymers, for example polycarbonate 
[9]. 
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Figure 2-9: Development of surface energy of PTFE discs in correlation to aging time after 
argon plasma treatment. (average ± SD; n=4) 
 
It has been shown that O2 plasma treated surfaces generally show short aging 
times and recover hydrophobicity partially or even completely. The possible 
mechanisms for this are believed to be reorientation or migration of treated polymer 
chains from the surface to the bulk. The driving force is the minimization of 
interfacial energy, and this irreversible recovery is found in most plasma-treated 
polymer surfaces [37]. A similar process in case of the argon plasma treated 
samples could be responsible for the recovery of hydrophobicity over time.  
However, the effect achieved by argon plasma treatment was stable throughout 
several weeks and a surface energy of 32 mN/m could be maintained during the 
investigated time period. In contrast to the initial surface energy of pristine PTFE of 
15 – 20mN/m, this represents a significant increase in hydrophilicity by means of 
plasma treatment. 
 
3.3 Cell compatibility of plasma treated surfaces 
For the intended application of the plasma treatment process for the modification of 
vascular grafts in order to enhance adhesion of polymer film coatings for the 
controlled release of endothelial cell specific growth enhancers, an important 
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prerequisite is the cell compatibility of the plasma modified surfaces. Therefore, 
argon plasma activated PTFE samples were tested concerning their HUVEC 
compatibility in an in vitro setting. Unmodified and plasma modified PTFE samples 
were incubated with endothelial cells for 3 days and cells were subsequently 
visualized according to 2.2.3. In addition, control samples of HUVECs were grown 
on collagen coated well plates and treated accordingly. Cells were analyzed 
concerning cell morphology, cell viability, and proliferation on the disc. 
(a)       (b)      
    
Figure 2-10: HUVEC compatibility and growth on collagen coated well plate (a) as control and 
argon plasma treated PTFE disc (b). 
 
Figure 2-10 shows pictures of the stained cells after a three day incubation period. A 
confluent monolayer of endothelial cells grown on the argon plasma treated PTFE 
discs was found. Cell viability and proliferation were comparable to cells grown on 
collagen coated control wells. Unmodified PTFE discs did not support endothelial 
cell attachment and cell growth by any means (data not shown). These findings are 
in accordance to studies reported in literature that demonstrated the non adherence 
of endothelial cells with increasing hydrophobicity of the polymer [38], and an 
increase in cell growth and attachment could be shown for plasma modified polymer 
surfaces [39]. 
 
3.4 Film adhesion 
In order to investigate the film adhesion of collagen and PLGA films on plasma 
treated and untreated PTFE discs, films were prepared according to 2.2.4. After 
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coating of the surfaces, the film adhesion was investigated by visual inspection and 
rated according to the following scaling: Films that exhibited very good adhesion of 
close to 100% of the film on the PTFE surface were rated as “++”. In case minor 
ablation of the films occurred around the edges of the PTFE discs, the film adhesion 
was considered good and rated as “+”. In case of poor film adhesion with more than 
just the edges of the film detaching from the surface, the adhesion was considered 
poor and was rated as “-“. In case more than 50% of the film did not adhere to the 
surface, the adhesion was considered very poor and was rated as “--“. 
 
Table 2-1: Evaluation of PLGA and collagen film adhesion on plasma treated and untreated 
PTFE discs. (++ = very good adhesion; + = good adhesion; - = poor adhesion and -- = very 
poor adhesion). 
 plasma treated PTFE untreated PTFE 
RG 503 ++ -- 
RG 503H ++ -- 
0.5% collagen + -- 
1% collagen + -- 
 
Table 2-1 provides an overview of the results obtained for the investigated collagen 
and PLGA materials on PTFE discs. Both PLGA materials exhibited very poor 
adhesion on the untreated PTFE surfaces, in both cases showing ablation of more 
than 50% of the film applied on the surface. However, after plasma treatment, both 
PLGA materials exhibited very good adhesion to the plasma modified polymer 
surface. Collagen exhibited very poor adhesion, irrespective of the dispersion 
concentration on untreated PTFE surfaces with more than 50% of the film detaching 
after drying, and in some cases showing complete ablation of the film. After plasma 
treatment of the PTFE surface collagen materials exhibited a good adhesion with 
only minor ablation visible at the edges of the coated discs. 
These results demonstrate the increased coating adhesion of PLGA and collagen 
films on plasma modified PTFE surfaces. Plasma treatment of polymer surfaces, in 
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this case PTFE, has been proven to be an easy and cost effective approach to 
enhance the adhesion of coatings on modified surfaces in a lab setting. 
 
4 Conclusions 
The aim of this study was the implementation of the plasmabrush® for plasma 
modification of PTFE substrates. The main goal was the investigation of a fast and 
straightforward method to modify the polymer with the aim of enabling coating 
accessibility. It was of interest to characterize the changes induced by the 
atmospheric plasma treatment by means of SEM, ATR-FTIR, XPS, and surface 
energy determination. In the process of this study, a plasma treatment process for 
making PTFE more hydrophilic and accessible for coating was successfully 
developed. The effect characterized by surface energy determination was stable for 
several weeks. It was possible to increase the surface energy of PTFE samples by 
10-15 mN/m depending on process conditions. The characterization of changes 
induced by atmospheric argon plasma, by means of the other methods than surface 
energy determination, did not show any variations. The improved hydrophilicity and 
wettability of the polymer was unlikely to result from surface roughening, since SEM 
revealed no differences in surface morphology for investigated samples. 
Furthermore, the introduction of functional groups containing oxygen or nitrogen 
species by the treatment process could not be confirmed using ATR-FTIR as well as 
XPS, which did not reveal any chemical alteration on the outer surface. These 
methods, however, might have not been sensitive enough to detect the changes 
induced by the atmospheric plasma treatment. 
The established plasma activation process significantly increased the coating 
adhesion of PLGA and collagen films applied on the modified surfaces in contrast to 
the non adhesion of these films on unmodified PTFE surfaces. In addition, it was 
shown that the plasma modification greatly improved the adherence of endothelial 
cells on the plasma treated surfaces. Therefore, the atmospheric plasmabrush® was 
shown to be an easy and efficient approach to modify surfaces for coating in a lab 
setting. 
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Chapter 3 
 
Investigation of PLGA films for controlled release applications 
 
 
Abstract 
The use of poly(lactic-co-glycolic acid) (PLGA) for protein drug carrying film 
coatings of vascular grafts to enhance endothelialization was investigated. The in-
vitro release of Fluorescein isothiocyanat (FITC) dextran as a model compound 
from PLGA coated discs was evaluated and the influence of the properties of a 
group of commercially available polymers was studied. Investigations revealed the 
dependency of the release rate on molecular weight and esterification of carboxylic 
end groups, as previously described. In addition, the independency of the release 
rate from the particle size of model compound suspended in the coating solution, 
especially in regards to the burst release, could be shown. 
Furthermore, the cell compatibility of PLGA coatings was shown using human 
umbilical vein endothelial cells (HUVECs) and cell quantification methods were 
evaluated. Fluorescence Activated Cell Sorting (FACS) and Propidium Iodide 
staining were found unsuitable to reproducibly detect cell growth differences in the 
desired range. Cell Titer-Blue®, a commercially available cell viability test, was 
found suitable to successfully detect differences. 
 
Keywords: PLGA, FITC-dextran, vascular graft, endothelial cell, Cell Titer-Blue® 
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1 Introduction 
Synthetic polymers are widely utilized in the fields of controlled release applications 
and biomaterials. Commonly used polymers include poly(amides), poly(amino 
acids), poly(alkyl-α-cyanoacrylates), poly(acrylamides), and poly(esters) [1]. 
Amongst them, the aliphatic poly(esters) polylactid (PLA), polyglycolid (PGA), and 
especially PLGA are of great interest due to their good biocompatibility and 
biodegradability [2-4]. These polymers have been used in a multitude of 
applications for controlled release of active ingredients, in form of micro- and 
nanoparticles [5-6], film coatings [7-8], and scaffolds [9]. PLGA, PLA and PGA were 
first used as absorbable sutures, clamps, and meshes [10] before their relevance 
for controlled release applications was discovered. This type of polymers are 
synthesized via condensation from lactic acid and glycolic acid for lower molecular 
weight polymers and ring opening polymerization of dilactide and diglycolide for the 
higher molecular weight species [11]. 
The swelling, the water uptake, the degradation, and therefore, the release 
properties can be tailored to the needs of its application. The mechanism of 
degradation of these polymers is based on the hydrolysis of the polymer chains into 
smaller fragments that can be eliminated via the kidneys in case of D-lactic acid, or 
can be metabolized via the citric acid cycle in case of L-lactic acid and glycolic acid, 
and can be exhaled via the lungs in form of carbon dioxide [12]. The rate of 
hydrolytic degradation can be controlled by altering the physical properties, such as 
molecular weight, degree of crystallinity, or glass transition temperature (Tg) [13]. In 
addition, the carboxylic end groups of the polymer can be esterified using long chain 
alcohols in order to obtain end capped polymers with a more hydrophobic character, 
in contrast to the more hydrophilic properties of the non-end-capped varieties, which 
then leads to changed release properties [14]. In general, all these modifications 
have an influence on the rate and extent of water penetration into the polymer 
structures, which are critical for the rate of degradation [8, 15], and the diffusion or 
erosion controlled release of incorporated compounds. It has been shown that e.g. 
the rates are decreased for pure crystalline poly-L-lactide and polyglycolide, and 
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that the process accelerates with an increasing ratio of glycolide to lactide in the 
copolymer and increasing hydrophilicity [16-17]. 
In this study, the influence of polymer molecular weight and the esterification of 
carboxylic functional groups on the release rates of a model compound (FITC-
dextran) from PLGA films reflecting potential coatings on vascular grafts, were 
investigated. Release rates of incorporated compound of 10 - 14 days were desired 
to enhance endothelialization in the early stages after implantation to overcome 
complications, such as intimal hyperplasia. Cell compatibility of the established 
PLGA coatings is required to be highly beneficial for cell growth and was evaluated. 
Detection methods for the quantification of endothelial cell growth, such as FACS, 
propidium iodide staining, and the use of a cell viability assay, Cell Titer-Blue®, were 
established and applied. 
 
2 Materials and Methods 
2.1 Materials 
FITC-dextran with a molecular weight of 40 kDa was purchased from Sigma Aldrich 
(Steinheim, Germany), dichloromethane and cover glasses from VWR (Darmstadt; 
Germany), Resomer® (RG 502H, RG 503, RG 503H and RG 504H) from 
Boehringer Ingelheim (Ingelheim, Germany), PTFE from GM GmbH (Freiham, 
Germany), Falcon tubes from Greiner (Frickenhausen, Germany), disposable 
Plastibrand® PMMA plastic cuvettes from Brand (Wertheim, Germany), collagenase 
A from Roche (Penzberg, Germany), endothelial cell growth medium from Provitro 
(Berlin, Germany), heat-inactivated fetal bovine serum from Biochrom (Berlin, 
Germany), buffered formaldehyde solution (4%) from Polysciences, Inc. 
(Warrington, PA, USA), propidium iodide from Fluka (Steinheim, Germany), 0.1 M 
sodium hydroxide solution from Merck KGaA (Darmstadt, Germany), Trypsin from 
PAN-Systems GmbH (Aidenbach, Germany), ethylenediaminetetraacetic acid 
(EDTA) from Carl Roth GmbH & CO. KG (Karlsruhe Germany), and Cell Titer-Blue® 
from Promega (Madison, WI, USA). 
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The pH of the solutions was adjusted using hydrochloric acid or sodium hydroxide 
from Merck KGaA (Darmstadt, Germany) and measured with a pH meter Inolab 
level 1 from WTW (Weilheim, Germany). 
 
2.2 Methods 
2.2.1 FITC-dextran size reduction 
2.2.1.1 Swing mill 
FITC-dextran with a molecular weight of 40 kDa was milled under the exclusion of 
light in a MM200 swing mill (Retsch GmbH, Hahn, Germany) in dichloromethane 
(VWR, Darmstadt; Germany) with a frequency of 30 s-1. The resulting FITC-dextran 
suspension was used for size analysis or coating and release experiments. 
 
2.2.1.2 Spray drying 
FITC-dextran 40 kDa was dissolved in water at a concentration of 1 mg/ml. The 
solution was spray dried using a Büchi Nano Spray Dryer B-90 (Büchi Labortechnik 
AG, Flawil, Switzerland). Spray dried FITC-dextran was stored in a desiccator under 
the exclusion of light until analysis or further use. 
 
2.2.2 Morphological analysis 
2.2.2.1 Scanning electron microscopy 
Samples for scanning electron microscopy (SEM) were fixed on specimen holders 
using conductive double sided tape before sputtering with a thin layer of carbon 
under vacuum. SEM images were obtained using a Philips XL Series XL20 (Philips, 
The Netherlands). 
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2.2.2.2 Laser diffraction 
Particle sizes were determined using a Horiba Laser Diffraction Particle Size 
Distribution Analyzer LA-950 (Retsch Technology GmbH, Hahn, Germany). 
Therefore samples were dispersed in dichloromethane. 
 
2.2.3 PLGA coating procedure 
Different species of Resomer® (RG 502H, RG 503, RG 503H and RG 504H) were 
used to coat PTFE-discs, argon plasma activated with a plasmabrush® (Reinhausen 
Plasma GmbH, Regensburg, Germany), or cover glasses, both with a diameter of 
15 mm. Therefore, the discs were placed in a 24-well aluminum well plate and 
covered with different concentrations of the PLGA-species dissolved in 
dichloromethane. The discs were air dried for one hour and subsequently removed 
from the wells and dried under vacuum over night or until further use. For the 
release studies, 0.01% (w/w) FITC-dextran as a model compound was suspended 
in the PLGA solutions. For the cell culture studies all these procedures were 
performed under a laminar flow workbench (Thermo, Langenselbold, Germany). 
 
2.2.4 In-vitro release studies 
For the release analysis, triplicates of coated discs were incubated in 10.0 ml 
phosphate buffered saline (PBS) pH 7.4 in 50 ml Falcon tubes in a water bath 
(Haake SWB25, Haake, Karlsruhe, Germany) at 37°C and at 25 rpm horizontal 
shaking under exclusion of light. 2 ml samples were drawn and replaced with fresh 
PBS buffer at several time points. Released FITC-dextran was quantified using 
fluorescence spectroscopy, which was performed using a Varian Cary Eclipse 
fluorescence spectrometer (Varian GmbH, Darmstadt, Germany). Therefore, 
samples were measured in disposable Plastibrand® PMMA plastic cuvettes with an 
excitation wavelength of 495 nm, an emission wavelength of 517 nm, and were 
adjusted with a PBS buffer blank. Samples were diluted using PBS buffer, if 
necessary. The amount of released FITC-dextran was calculated using a calibration 
curve. 
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2.2.5 Cell compatibility testing 
The cell compatibility of PLGA coated discs was evaluated using HUVECs. 
HUVECs were prepared by digestion of umbilical veins with 0.1 g/l collagenase A. 
Cells were cultured in endothelial cell growth medium supplemented with 10% heat-
inactivated fetal bovine serum in a humidified atmosphere at 5% CO2 and 37°C. 
Cells were used at passage no. 3. For visualization of cells on the surfaces, cells 
were fixed with a buffered formaldehyde solution (4%) and were stained with 
propidium iodide in PBS buffer with a final concentration of 50 µg/ml. Images were 
obtained with a Zeiss LSM 510 confocal laser scanning microscope (CLSM) (Zeiss, 
Oberkochen, Germany). 
 
2.2.6 Evaluation of cell quantification methods 
2.2.6.1 Propidium iodide dye 
For quantification of cells on the surfaces, cells were fixed with a buffered 
formaldehyde solution (4%) and were stained with propidium iodide in PBS buffer. 
After rinsing, propidium iodide was quantified via fluorescence spectroscopy using a 
Spectrafluor plus plate reader (Tecan, Crailsheim, Germany) with an excitation 
wavelength of 530 nm and emission recording at 635 nm. The dye was quantified in 
its bound state on the vacuum dried discs or an aliquot of the eluted dye after 
incubation with 0.1 M sodium hydroxide solution (NaOH) at 2-8°C overnight. 
 
2.2.6.2 Fluorescence activated cell sorting (FACS) 
For quantification of cells, incubated discs with cells were washed three times with 
PBS buffer pH 7.4. Subsequently, cells were covered with 300 µl of Trypsin/EDTA in 
PBS buffer, containing 0.05% Trypsin and EDTA. Discs were then incubated in a 
water bath at 37°C for 8 min. 250 µl of the cell suspension were added to 150 µl of 
a buffered formaldehyde solution (4%). 120 µl of this cell suspension were 
quantified using the BD FACSCanto II in High Throughput Screening (HTS) mode 
(Becton Dickinson GmbH, Heidelberg, Germany). 
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2.2.6.3 Cell Titer-Blue® 
Cells on the discs were quantified using Cell Titer-Blue®. Therefore, discs were 
incubated with Cell Titer-Blue® and an aliquot of the supernatant was analyzed 
using a Spectrafluor plus plate reader (Tecan, Crailsheim, Germany) with an 
excitation wavelength of 550 nm and emission recording at 595 nm. 
 
3 Results and Discussion 
3.1 FITC-dextran size reduction 
All PLGA coatings needed to be prepared in organic solvents, due to the non-
solubility of PLGA in aqueous solutions. Suitable solvents for PLGA are, amongst 
others, N-methyl-2-pyrrolidinone, ethyl acetate, acetone, dimethyl sulfoxide, and 
dichloromethane. The solvent of choice for all investigations within these studies 
was determined to be dichloromethane, due to the good solubility of PLGA in this 
solvent and the high vapor pressure of dichloromethane to enable fast and efficient 
drying. However, the model substrate used for the release investigations, FITC-
dextran, is insoluble in dichloromethane or other organic solvents suitable for the 
preparation of PLGA solutions. Therefore, the preparation of FITC-dextran 
suspensions in PLGA solutions in dichloromethane for the coating of PTFE discs 
was required. In order to guarantee reproducible results for the coatings, 
homogenous size distributions of the FITC-dextran particle was required. Therefore, 
different techniques for particle size reduction of FITC-dextran were investigated. 
 
3.1.1 Size reduction by milling 
One suitable option for FITC-dextran particle preparation in dichloromethane is 
milling. The influence of milling time on the size reduction of FITC-dextran was 
investigated. Therefore, FITC-dextran in dichloromethane was milled for a period of 
180 min and the size of the particles (d90) was analyzed at several time points using 
laser light diffraction in order to determine a suitable milling time to achieve small 
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and homogenous particle sizes. The results shown in Figure 3-1 indicated a 
correlation between milling time and average particle size.  
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Figure 3-1: FITC-dextran particle size (d
90
) in correlation to milling time. (average ± SD; n=3) 
 
The particle size determined for FITC-dextran decreases with increasing milling 
time. After 15 min of milling, a particle size of approximately 15 µm was determined 
that decreased to 12 µm, and 10 µm after milling for 30 min and 60 min, 
respectively. A further increase in milling time only resulted in little further size 
reduction. Therefore, the standard milling time for the preparation of further milled 
FITC-dextran particles was set to 60 min in order to lower the temperature stress on 
the samples and the risk of degradation due to accidental exposure to light of the 
model compound. 
 
3.1.2 Size reduction using spray drying 
In order to evaluate the influence of FITC-dextran particle size on the release rates 
from PLGA films, it was necessary to obtain a second set of FITC-dextran particles 
with a smaller particle size as achieved by milling. Therefore, a solution of FITC-
dextran in water with a concentration of 1 mg/ml was spray dried using the Büchi 
Nano Spray Dryer B-90. Spray-drying was conducted under the exclusion of light in 
order to guarantee the stability of FITC-dextran. However, the increase in 
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temperature during the spray drying process, in addition to some light exposure 
during the preparation and collection of spray dried particles, might have affected 
the stability of FTIC-dextran. Therefore, samples of spray dried FITC-dextran were 
analyzed using fluorescence spectroscopy, according to the procedures described 
in 2.2.4, to investigate any changes in excitation or emission wavelength, as well as, 
decreases in fluorescence intensity compared to standard samples that did not 
undergo spray drying. Findings (data not shown) confirmed that the spray drying 
process, as well as, accidental exposure to light did not have a negative effect on 
the stability and fluorescence properties of the fluorophore of FITC-dextran. 
 
Figure 3-2: Scanning electron micrograph of spray dried FITC-dextran particles. 
 
Samples were analyzed using SEM to investigate the size distribution and particle 
shape of the FITC-dextran particles. Figure 3-2 shows a representative particle 
population for a spray dried sample. A homogenous particle distribution in a size 
range of 1 µm could be detected. The majority of particles were of spherical shape, 
but some doughnut shaped particles could be observed. Therefore, spray drying 
can be considered a suitable method to generate FITC-dextran particles with size 
distributions in the low µm-range. 
 
3.2 In vitro release studies 
The release rates of model compound from the generated PLGA films are highly 
dependant on the polymer used for their production and its characteristic physical 
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and chemical properties, such as molecular weight, modification of the terminal 
carboxylic group of the polymer, crystallinity, and the lactide:glycolide ratio [18]. In 
order to investigate their effect on the release rates of formed films, several 
polymers varying in molecular weight and esterified end groups were used for the 
release investigations. Polymers with a low molecular weight were the focus of 
these investigations in order to guarantee a release of model compound in a one to 
two week time period. 
 
3.2.1 Influence of PLGA molecular weight on release rates 
The influence of molecular weight on the release of the model compound FITC-
dextran was investigated using the PLGAs Resomer® RG 502H, RG 503H, and 
RG 504H. The molecular weights, as well as, the inherent viscosities of these 
PLGAs can be seen in Table 3-1. In general, release profiles from biodegradable 
monolithic systems are a combination of several phases depending on the 
dominating process. Predominantly, biphasic release patterns can be observed, 
which are characterized by a strong burst release of drug or model compound that 
are deposited near the film or microparticle surface and are caused by their 
dissolution [19]. It is followed by the second phase of release which is usually 
diffusion controlled and is characterized by sustained release that can be described 
by zero order kinetics [20]. 
 
Table 3-1: Overview of molecular weight, inherent viscosity and thermal properties of PLGA 
variants used during release investigations [21-23].  
Polymer 
Mw 
[Da] 
Inherent viscosity 
[dl/g] 
Tg 
[°C] 
Resomer® RG 502H 13,500 0.16 – 0.24 42 – 46 
Resomer® RG 503H 36,000 0.32 – 0.44 44 – 48 
Resomer® RG 503 36,000 0.32 – 0.44 44 – 48 
Resomer® RG 504H 48,000 0.45 – 0.60 46 – 50 
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The release profiles for the investigated films in PBS buffer pH 7.4 at 37°C can be 
seen in Figure 3-3. Films made from Resomer® RG 502H were characterized by an 
initial burst release of approximately 20% (compare Figure 3-3a), followed by a 
continuous release of 100% FITC-dextran up to 14 days. Films made with 
Resomer® RG 503H (Figure 3-3b) exhibited the same level of burst release, 
however, the following sustained release was characterized by a slower release 
rate and complete release of almost 100% model compound took place within 21 
days. Resomer® RG 504H films showed a higher burst release compared to the 
lower molecular weight PLGAs of approximately 40%, followed by a continuous 
release of model compound that was investigated for 4.5 weeks and afterwards 
aborted, due to the unsuitability of the release profile for the intended application 
with a release of model compound within a period of one to two weeks. It was 
hypothesized that the higher inherent viscosity of the higher molecular weight 
species of PLGA was responsible for a lower sedimentation rate of the FITC-
dextran particles within the coating solution, which resulted in higher amounts of 
model compound close to the film surface, leading to higher initial burst release 
rates. 
To further elucidate this phenomenon, investigations using different FITC-dextran 
particle sizes in the coating solution were performed to be able to clarify the 
hypothesis of lower sedimentation rates in the higher viscous coating solutions 
(compare 3.2.3). It was shown, that the viscosity of both RG 503H and RG 502H 
were not high enough to circumvent sedimentation of FITC-dextran, which led to a 
depletion of model compound on the surface and resulted in lower burst release. 
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Figure 3-3: : Cumulative in-vitro FITC-dextran release from PLGA coated discs RG 502H (a), 
RG 503H (b) and RG 504H (c). (average ± SD; n=3) 
 
The observed release profiles were in accordance with reported biphasic release 
profiles for PLGA based drug delivery systems [20, 24]. Water penetration into the 
system leads to release by dissolution of surface bound compound and diffusion of 
molecules through water filled pores [19]. Specifically for lower molecular weight 
PLGA species, release based on diffusion takes place much faster in comparison to 
high molecular weight PLGAs [25]. Correspondingly, a decrease in continuous 
release was observed in dependency of the increase of molecular weight. In 
addition to the lower rate of diffusion, this is due to the water penetration into the 
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PLGA films that causes the hydrolysis of the polymer. Hydrolysis causes the 
polymer to be degraded to smaller molecular weight species which upon reaching a 
certain level of molecular weight become water soluble and erosion of the matrix 
takes place, thereby releasing incorporated compounds [18], in this case FITC-
dextran. Due to the difference in molecular weight and consequently longer polymer 
chain units for the higher molecular weight PLGAs, the degradation of these units in 
water soluble PLGA fragments is more time consuming compared to the low 
molecular weight PLGA Resomer® RG 502H. This effect caused the observed 
slower release rates for the continuous sustained release phase of the higher 
molecular weight PLGAs which, in turn, lead to longer total release times. 
Therefore, only the PLGA Resomer® RG 502H films, with a total release within the 
first 14 days of incubation, were within the desired period of release of one to two 
weeks. 
 
3.2.2 Influence of esterification on release rates 
In addition to the investigations concerning the influence of molecular weight 
differences of the applied PLGAs on the release rates, the influence of end capping 
of the carboxylic group of Resomer® RG 503 / 503H was studied. Therefore, PTFE-
discs were coated with solutions of each polymer containing 0.01% (w/w) FITC-
dextran and investigated concerning the release in vitro in PBS buffer pH 7.4 at 
37°C. The release profiles for the investigated films can be seen in Figure 3-4. Both 
PLGA species exhibit a burst release of approximately 25% of the loaded FITC-
dextran, followed by a continuous sustained release for Resomer® RG 503H up to 
day 21 when 100% of the model compound was liberated. However, Resomer® RG 
503 exhibited a lag phase of release after the initial burst for approximately 20 days 
followed by a fast release of another 50% of FITC-dextran. 
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Figure 3-4: Cumulative in-vitro FITC-dextran release from RG503 coated discs with 
endcapped carboxylic group (
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These findings are in accordance with results reported in literature for end capped 
polymers and polymers with free carboxylic groups [5]. The sigmoidal release profile 
for the films made of Resomer® RG 503 indicates bulk erosion of the polymer [26], 
as well as, diffusion controlled release of the model compound. As mentioned 
before (see 3.2.1), the penetration of water into the polymer is responsible for the 
hydrolysis of the polymer into smaller fragments that are required for achieving 
water solubility [27-28]. However, this penetration of water into the more 
hydrophobic polymer RG 503 is strongly reduced compared to the more hydrophilic 
polymer RG 503H due to the lack of hydroxyl and carboxylic groups that are present 
in RG 503H. This reduction of penetrating water leads to a significant decrease of 
hydrolysis of the polymer, which leads to slower erosion and in turn a decreased 
release of compound. In general, it can be stated that the water uptake of polymer 
increases with the hydrophilicity of the polymer, which enables more drug to be 
released and the polymer to be degraded faster [6]. Therefore, the release rate from 
the more hydrophic species of PLGA are characterized by a distinctive lag phase 
after the initial burst release as observed in the case of RG 503 and RG 503H. 
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3.2.3 Influence of FITC-dextran particle size on release rates 
The results obtained when investigating the influence of molecular weight on the 
release rate of PLGA films (compare 3.2.1) led to the hypothesis of an influence of 
FITC-dextran particle size present in the coating suspension on the release rate. 
The initial burst release for the higher molecular weight PLGA Resomer® RG 504H 
was more pronounced in comparison to the two lower molecular weight species 
RG 502H and RG 503H potentially due to sedimentation of FTIC-dextran particles 
in the lower molecular weight PLGA solutions. According to Stokes, the rate of 
sedimentation in a suspension is dependant on the square of the particle diameter. 
Therefore, film coatings made of PLGA with FITC-dextran of two different size 
distributions were investigated. Resomer® RG 503 was used for these 
investigations with an inherent viscosity between RG 502H and RG 504H. 
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Figure 3-5: Cumulative in-vitro FITC-dextran release from PLGA RG 503 coated discs with 
FITC-dextran particle size of 1µm (
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The release rates hown in Figure 3-5 were identical for both sets of PLGA coatings 
with particles of 1 and 10 µm. Burst release was low with approximately 5% FITC-
dextran released within the first 24 hours. After a pronounced lag phase 
characteristic for PLGAs with end capped carboxylic groups, release continued with 
a fast release of approximately 40%, followed by slow continuous release until the 
end of the investigation period. The findings did not support the hypothesis of a 
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reduced exposure of FITC-dextran particles at the surface of the coatings of 502H 
and 503H due to sedimentation. 
A possible other explanation could be the difference in Tg of the polymers. The Tg 
for RG 502H and RG 503H is lower than that of RG 504H (compare Table 3-1). It is 
reported in literature that incubation of PLGA devices at temperatures above Tg 
leads to increased mobility of compounds, and diffusivity of both penetrating water 
and drug are higher [5, 17]. Consequently, faster hydrolysis and drug release are 
observed [29-30], which can be seen by the higher release rates after initial burst 
release for the lower molecular weight PLGAs. In addition, once Tg is exceeded, the 
initial glassy device converts to a rubbery state with hydration which makes polymer 
chain segments more mobile [17]. This higher polymer mobility might cause a 
sealing of the film surface leading to a reduced initial burst release in case of RG 
502H and RG 503H upon exposure to the incubation solution at 37°C. In case of 
RG 504H, the incubation temperature is below the Tg and therefore the film remains 
in its glassy state leading to a higher initial burst release, because the surface 
sealing does not take place, followed by the continuous release controlled by 
diffusion and erosion. 
 
3.3 Cell compatibility of PLGA coatings 
In addition to their release characteristics, the cell compatibility of the different 
PLGA species was investigated. Cell compatibility is of great importance, especially 
for the intended use as biomaterial substrate to potentially enhance attachment, 
attraction, and endothelial cell growth, either by itself due to its properties, but also 
in its function as matrix for the release of for example endothelial cell specific 
growth enhancers, such as Vascular Endothelial Growth Factor (VEGF). PLGA 
constructs have been reported to be biocompatible, as well as, their degradation 
products lactic and glycolic acid [2, 4]. Therefore, it has been widely used in 
controlled release applications such as micro- and nanoparticles [5-6], film coatings 
[7-8], and scaffolds [9]. Two PLGA species, RG 503H representing the polymers of 
higher hydrophilicity due to its free carboxylic group and RG 503 a more 
hyrdrophobic polymer due to its esterified carboxylic group, were investigated 
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concerning their cell compatibility using HUVECs. PTFE discs were coated with 
either polymer, subsequently seeded with HUVECs and cells were allowed to attach 
and grow on the polymers and were stained using propidium iodide after 3 days. 
The stained cells were analyzed using CLSM concerning the cell morphology, cell 
viability, and proliferation on the discs. 
 
(a)        (b) 
   
Figure 3-6: Propidium iodide stained cells on PLGA coated PTFE discs after incubation for 3 
days on RG 503 (a) and RG 503H (b) 
 
Figure 3-6 shows the acquired pictures for the stained cells after a three day 
incubation period. All pictures showed a confluent monolayer of endothelial cells 
grown on the PLGA films with a morphology attributed to HUVECs. Therefore, it can 
be concluded that the applied polymers, as well as the polymers used for other 
studies (RG 502H and RG 504H) had good cell compatibility, which was in 
accordance to prior findings. 
 
3.4 Evaluation of cell quantification methods 
For the intended application of the PLGA films as potential coating for vascular 
grafts to enhance endothelialization through the incorporation of cell growth specific 
growth enhancers, such as VEGF165 [31], it was of importance to qualify methods of 
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quantification for the initiated cell growth on the PLGA film surfaces. Therefore, 
PTFE and glass discs were coated using PLGA, incubated with HUVECs, and 
quantified using several methods for cell quantification. 
 
3.4.1 Cell quantification using FACS 
For the cell quantification using FACS, different amounts of cells ranging from 
100,000 to 120,000 cells per well were cultured on PLGA RG 502H coated discs 
and were allowed to adhere for 24 hours. Subsequently, cells were harvested using 
Trypsin/EDTA incubation for 8 min at 37°C. After the addition of buffered 
formaldehyde solution (4%), cells were quantified using the BD FACSCanto II in 
High Throughput Screening (HTS) mode. Cell numbers present in the measured 
aliquots were then calculated back to the numbers of cells harvested per well. 
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Figure 3-7: Calculated cells per well after adhesion on PLGA RG 502H coated discs and 
subsequent detachment using Trypsin / EDTA and FACS analysis. (average ± SD; n=2). 
 
Figure 3-7 shows the calculated values of recovered cells after the harvesting 
process using Trypsin/EDTA and the FACS analysis for two sets of identically 
treated PLGA coated discs. Calculated values for one set of discs seeded with 
equal amounts of HUVECs showed a very low standard deviation indicating good 
reproducibility within one set of discs in one experiment. However, there was no 
correlation between the amount of seeded cells and the amount of recovered cells 
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for a concentration series investigated. For the first set, cell counts increased 
significantly from the discs incubated with 100,000 to 105,000 cells, however the 
recovered cell amounts for 110,000 and 120,000 seeded cells declined from 
thereon. In comparison, the second set of experiments showed different results, 
with a decrease of recovered cells after 100,000 seeded cells and a significant 
increase in recovered cell amounts for the discs seeded with 120,000 cells. Since 
no correlation between the amounts of cells seeded and the detected cell number 
was found, and even worse non-reproducibility between two sets of experiments 
was shown, this method of cell quantification was unsuitable for the quantification of 
HUVECs after growth on PLGA films. A possible cytotoxic effect of the coatings on 
HUVECs can be ruled out, since cell compatibility of the coatings was shown 
(compare 3.3). Low recovery and varying amounts of recovered cells might be 
explained by non adherence of cells during the incubation period resulting in a loss 
of cells during the washing procedure. In addition, an insufficient detachment of 
cells during the Trypsin/EDTA incubation time might have added to the low recovery 
of cells seeded. The incubation time was not further increased due to concerns of 
digestion of HUVECs by Trypsin. 
 
3.4.2 Cell quantification using propidium iodide dye 
Propidium iodide has already been shown to be a suitable detection method for the 
evaluation of cell compatibility of PLGA coatings (compare 3.3). Due to its 
fluorescence properties, it might also represent a possible alternative for cell 
quantification. Therefore, sets of 100,000 and 200,000 HUVECs were seeded on 
PLGA coated discs, incubated for 24 hours, and subsequently stained using 
propidium iodide. The amount of bound dye on the dried PLGA coated discs was 
then quantified using fluorescence spectroscopy. In addition, the dye was eluted 
using sodium hydroxid solution and was again measured using fluorescence 
spectroscopy. 
Chapter 3 
 
68 
0
500
1000
1500
2000
2500
3000
3500
100,000 200,000 100,000 200,000
bound dye eluted dye
fl
u
o
re
s
c
e
n
c
e
 in
te
n
s
it
y
seeded cells
first set
second set
 
Figure 3-8: Fluorescence intensity of propidium iodide stained cells in bound state and after 
elution using 0.1 M sodium hydroxide solution. (average ± SD; n=2). 
 
The results of the fluorescence measurements for both sets of investigations are 
shown in Figure 3-8. A fluorescence intensity difference of propidium iodide on discs 
incubated with 100,000 and 200,000 cells can be detected for both bound and 
eluted dye. A significant decrease in fluorescence was observed for the eluted dye 
in comparison to bound dye due to dilution and insufficient elution during the 
incubation procedure. However, reproducibility of these measurements with a 
second set of PLGA coated discs under the same conditions was not given as can 
be seen in Figure 3-8 (second set). Fluorescence intensity for all samples increased 
for all measured samples, making this an unsuitable method for cell quantification 
on PLGA surfaces. Again, low recovery and varying amounts of fluorescence might 
be explained by non adherence of cells during the incubation period resulting in a 
loss of cells during the washing procedure and hence, resulting in varying 
fluorescence intensities. 
 
3.4.3 Cell quantification using a cell counting chamber 
Since propidium iodide staining with subsequent fluorescence measurements failed 
to provide reproducible results for cell quantification on PLGA coated discs, 
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however, provided good properties for cell visualization on the surfaces, cell 
quantification using a cell counting chamber was evaluated. Therefore, cells were 
grown on PLGA RG 502H covered discs with varying cell amounts seeded per well. 
Cells were then subsequently stained using propidium iodide and evaluated using 
CLSM. 
(a)        (b) 
   
Figure 3-9: Propidium iodide stained cells on a PLGA RG 502H coated PTFE discs seeded 
with 100,000 cells after incubation for 3 days at center of disc (a) and border of disc (b). 
 
Figure 3-9 shows representative exemplary CLSM pictures of PLGA coated discs 
seeded with 100,000 cells stained with propidium iodide. Similar results were 
obtained for all other discs incubated with varying amounts of cells. Figure 3-9a 
shows the center of the disc investigated with non confluent amounts of cells 
detected. In contrast, Figure 3-9b shows the border of the identical disc with high 
amounts of endothelial cells present. This inhomogeneity made it impossible to find 
representative areas on discs suitable for cell quantification by the use of a cell 
counting chamber. The patches of no-cell growth in the center of the disc 
substantiate the prior findings using other techniques for cell quantification. The non 
reproducibility of cell quantification was most likely due to the loss of cells grown on 
the PLGA surface, which detached after hydrolysis of the PLGA. Cells and PLGA 
fragments were then lost in the necessary washing steps that were performed for 
the different quantification methods, leading to non reproducible and unreliable 
results as seen above. 
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3.4.4 Cell quantification using Cell Titer-Blue® 
In order to quantify cell growth on PLGA surfaces, a suitable method needed to be 
implemented that did not require washing steps after the incubation. Therefore, Cell 
Titer-Blue® a commercially available cell viability assay was evaluated. Cell Titer-
Blue® is based on the metabolic capacity of cells an indicator of their viability.  
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Figure 3-10: Conversion of resazurin to resorufin by metabolically active cells adapted from 
Promega [32] 
 
The indicator dye resazurin is used to measure the metabolic capacity of cells. Cells 
reduce resazurin into resorufin, which is highly fluorescent (Figure 3-10) and can be 
detected at an excitation wavelength of 550 nm and an emission wavelength of 
595 nm. Nonviable cells rapidly lose metabolic capacity, and therefore do not 
reduce the indicator dye, and thus do not generate a fluorescence signal. 
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Figure 3-11: Fluorescence intensity of Cell Titer-Blue
®
 after incubation for 6 hours on 
endothelial cell seeded PLGA RG 502H coated discs – broad cell number screening. (average 
± SD; n=2). 
 
In a first suitability screening, PLGA RG 502H coated discs were seeded with 
50,000 to 70,000 cells per well and were cultured for 24 hours. After the incubation 
time Cell Titer-Blue® was added to the wells and further incubated for 6 hours, 
sufficient time for the cells to reduce the indicator dye. Subsequently, aliquots of the 
incubation solution were measured using fluorescence spectroscopy. In order to 
investigate reproducibility of this method, a second set of PLGA coated discs were 
treated accordingly. The results represented in Figure 3-11 showed an increase in 
fluorescence with an increasing amount of cells seeded on the discs with low 
standard deviations. However, the increase in fluorescence was not in correlation to 
the increase in seeded cells. Therefore, an absolute quantitative measurement did 
not seem possible, however, a relative quantification appeared possible. The 
second set of experiments confirmed the reproducibility of the experiment, making 
the quantification with Cell Titer-Blue® the method of choice for cell quantification. 
Nevertheless, since the increase or difference in cell growth expected for discs 
coated with PLGA and cell growth stimulant were anticipated to be in a range of 
20%, further investigations were necessary to elucidate on the possibility of 
quantifying smaller amounts and differences in cell growth. 
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Therefore, another set of experiments was performed with a narrower distribution in 
cell numbers. PLGA coated discs were seeded with cells in a range of 20,000 to 
30,000 cells and treated according to the above described procedure. Again, two 
sets of experiments were performed in order to gain information about the 
reproducibility of the quantification method. 
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Figure 3-12: Fluorescence intensity of Cell Titer-Blue
®
 after incubation for 6 hours on 
endothelial cell seeded PLGA RG 502H coated discs – narrow cell number screening. 
(average ± SD; n=2). 
 
Employing the quantification method using Cell Titer-Blue® it was possible to 
differentiate between small amounts of cell growth differences with weaknesses in 
the range of 22,000 to 24,000 cells. Fluorescence of the incubated discs increased 
in accordance to the seeded cells (Figure 3-12). However, the correlation was not 
linear, making it a relative quantification method as described above. The 
reproducibility could be confirmed using the second set of experiments which 
showed results of similar fluorescence for the cell seeded incubated discs. 
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4 Conclusions 
PLGA films were investigated for potential coating of vascular grafts to improve 
endothelialization. The incorporation of endothelial cell specific growth enhancers, 
such as VEGF165, and its subsequent release from the matrix could be used to 
enhance the cell retention and cell growth on vascular grafts. Therefore, different 
PLGA species were investigated concerning their release properties using a model 
compound, FITC-dextran, with a molecular weight comparable to VEGF165. The 
influence of the polymer molecular weight on the release rates was shown. 
Resomer® RG 502H, a low molecular weight species of a commercially available 
polymer, was shown to be the only suitable polymer in the range of polymers 
investigated. Its release rate suited the intended purpose and the desired release 
time period of 1 to 2 weeks. In addition, it was shown that the influence of 
esterification of free carboxylic groups of the used polymers did not have a 
beneficial effect on the release rates of the coatings. The influence of the 
suspended model compound particles on the coating process and the subsequent 
release was investigated and was shown to have no influence on the outcome of 
release investigations, especially in respect of burst release from such coatings in 
contrary to previously reported findings. 
In addition, the cell compatibility of the applied PLGA coatings was shown using 
HUVECs. Detection methods to quantify the increase in cell growth on such 
coatings were investigated towards their ability to reveal small differences in cell 
growth. FACS analysis, propidium iodide staining in combination with fluorescence 
measurements, and using a counting chamber were shown to be unsuitable for this 
application. However, Cell Titer-Blue®, a commercially available cell viability assay, 
was found to be appropriate to detect minor changes in cell growth increase. 
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Chapter 4 
 
Investigation of collagen films for controlled release of VEGF165 
 
 
Abstract 
The influence of Vascular Endothelial Growth Factor (VEGF165) incorporated into 
collagen films for the coating of vascular grafts to enhance their endothelialization 
was investigated. Therefore, the release behavior of collagen films was initially 
investigated using Fluoresceinisothyocyanat (FITC) dextran as a model compound. 
In order to minimize initial burst release that was observed for unmodified collagen 
films, collagen was cross-linked using Ethyl(dimethyl-aminopropyl)-carbodiimide 
(EDC). Release rates for crosslinked collagen films showed a decrease in initial 
burst release in correlation to the crosslinking degree and increasing amounts of 
entrapped FITC-dextran in the collagen matrix. The modified release parameters 
were confirmed using VEGF165 that was incorporated in the collagen films. The 
biological activity of the incorporated VEGF165 in modified and unmodified collagen 
films was investigated using human umbilical vein endothelial cells (HUVECs) and 
rat aortic smooth muscle cells (SMCs). An increase in endothelial cell growth was 
observed in dependency of the concentration of incorporated VEGF165. No effect of 
VEGF on SMCs could be detected. The stability and biological activity of VEGF165 
was maintained throughout the production process and incubation of collagen films 
contrary to the generally low stability of this protein in vitro and in vivo, making this 
an interesting approach for vascular grafts to enhance their performance. 
 
Keywords: Collagen, crosslinking, VEGF, endothelial cell, controlled release 
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1 Introduction 
The controlled release of therapeutic agents from the vascular graft surface 
constitutes a promising approach for the improvement of vascular graft patency and 
the establishing of a functioning endothelial cell lining. A coating with biocompatible 
and biodegradable polymers for this approach and the subsequent local drug 
delivery for modifying the response of the surrounding tissue could induce 
spontaneous endothelialization and / or inhibit smooth muscle cell proliferation, and 
therefore overcome the limitations of small caliber vascular grafts. 
Collagen is the primary and major structural protein of vertebrates, representing 
almost 30% of total protein present in a body [1]. It has been widely used in the field 
of controlled release applications and biomaterials [2-4] due to its biocompatibility 
and biodegradability. Especially in the field of biomaterials, one of its advantages is 
the ease of production in aqueous media without the application of high 
temperatures, which still results in a variety of forms and applications, such as 
coatings, fibers, films, implants, injectable solutions, membranes, sheets, and 
sponges. Collagen crosslinking using physical and / or chemical methods can be 
applied to prevent rapid degradation of such collagen based biomaterials during in 
vivo application, improve its mechanical stability [5], and reduce tissue response [6]. 
Crosslinking is also useful when using collagen in controlled release applications.  
Several approaches using collagen for the improvement of vascular grafts have 
been undertaken, among others, collagen in combination with growth factors [7], 
heparin [8], or a combination thereof [6]. Among the growth factors investigated, 
basic fibroblast growth factors (bFGF) [7, 9-10] and VEGF [11-13] have been widely 
investigated. Yet, bFGF has been shown to have stimulatory effects on smooth 
muscle cell growth, which can lead to intimal hyperplasia and vessel occlusion [14-
15]. VEGF, on the other hand, has been shown to have very high endothelial cell 
specificity without mitogenic activity for other cell types [16].  
The aim of this study was to prove a successful incorporation of VEGF into collagen 
matrices, while maintaining its biological activity in order to stimulate endothelial cell 
growth without stimulating other cells after being released. Therefore, the first 
studies focused on the investigation of release behavior of FITC-dextran 40 kDa 
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from collagen matrices and the chemical modification of collagen via crosslinking in 
order to adjust the release profiles. The characterization of changes induced by 
crosslinking was important, in order to understand the effect of the treatment. DSC 
measurements and cell compatibility investigations were conducted for that 
purpose. Based on the results from the release experiments, two suitable collagen 
materials for the release of VEGF165 were to be selected and investigated using an 
enzyme linked immunosorbent assay (ELISA) to confirm the release behavior. In 
order to prove the preservation of biological activity and to get further insight into the 
cell growth enhancing properties, the influence of VEGF165 incorporated into 
collagen films towards its effect on HUVECs and SMCs was investigated. 
 
2 Materials and Methods 
2.1 Materials 
Equine collagen type I derived from tendon was provided by Innocoll GmbH 
(Saal/Donau, Germany) as lyophilized material, VEGF was kindly donated by 
Genentech (San Francisco, CA, USA), and rat aortic smooth muscle cells (SMCs) 
were provided by PD Dr. Wolgang Erl (Institut für Prophylaxe und Epidemiologie der 
Kreislaufkrankheiten, Ludwig-Maximilians-Universität München, Munich, Germany). 
EDC, Na2HPO4, N-Hydroxysuccinimide (NHS), 2-Amino-2-hydroxymethyl-propane-
1,3-diol (Tris), and FITC-dextran with a molecular weight of 40 kDa was purchased 
from Sigma Aldrich (Seelze, Germany), 1 M HCl, 1 M NaOH and glacial acetic acid 
from Merck KGaA (Darmstadt, Germany), 50 ml Falcon tubes from Greiner Bio-One 
GmbH (Frickenhausen, Germany), plastic Petri dishes (diameter: 5.5 cm) and cover 
glasses from VWR (Darmstadt, Germany), Polytetrafluoroethylene (PTFE) from GM 
GmbH (Freiham, Germany), 24-well plates from Corning (Amsterdam, The 
Netherlands) and TPP Techno Plastic Products (Trasadingen, Switzerland), 
collagenase A from Roche (Penzberg, Germany), endothelial cell growth medium 
from Provitro (Berlin, Germany), heat-inactivated fetal bovine serum from Biochrom 
(Berlin, Germany), M199 from PAA (Pasching, Austria), buffered formaldehyde 
solution (4%) from Polysciences, Inc. (Warrington, PA, USA), propidium iodide from 
Fluka (Steinheim, Germany), disposable Plastibrand® PMMA plastic cuvettes from 
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Brand (Wertheim, Germany), Human VEGF ELISA from Ray Bio® from Ray Biotech 
Inc. (Norcross, GA, USA), smooth muscle cell growth medium DMEM /F12 from 
PAA (Pasching, Austria), and Cell Titer-Blue® from Promega (Madison, WI, USA) 
The pH of the solutions was adjusted using hydrochloric acid or sodium hydroxide 
from Merck KGaA (Darmstadt, Germany) and measured with a pH meter Inolab 
level 1 from WTW (Weilheim, Germany). 
 
2.2 Methods 
2.2.1 Collagen crosslinking 
2.2.1.1 Crosslinking procedure 
Crosslinking of collagen with EDC was performed according to a protocol from 
Metzmacher [17]. Therefore, 1% (w/w) collagen in water was adjusted to pH 3.5 
with 1 M HCl and pre-swollen for 1 hour. After dispersion for 10 minutes with an 
Ultraturrax® (IKA-Werke GmbH Co. KG, Staufen, Germany), the pH was adjusted to 
pH 5.1 with 1 M Na2HPO4 and 10% stock solutions of EDC and NHS (molar ratio 
5:2) were added. Three different collagen / EDC-ratios were used: 1 g / 16.9 mg, 
1 g / 67.7 mg and 1 g / 203.1 mg. The dispersion was homogenized and the 
reaction was performed for 2 hours at room temperature under pH-control. 
Subsequently, the pH was adjusted to 9.1 by adding 1 M Na2HPO4 and 1 M NaOH. 
After another 2 hours of stirring, the pH was adjusted to 6.5 using 1 M HCl. 
Subsequently, each collagen dispersion was transferred into 50 ml Falcon tubes 
and centrifuged at 5,100 rpm for 20 minutes using a Sigma 4 K15 lab centrifuge 
(Sigma, Osterode, Germany). Each residue was washed using 50 ml of Milli-Q 
water with centrifugation at 5,100 rpm after each washing step to collect the 
residues. After 10 washing steps, residues were lyophilized (see 2.2.1.2). 
 
2.2.1.2 Lyophilization 
Lyophilization was performed in a ε2-6D special freeze-dryer (Martin Christ 
Gefriertrocknungsanlagen GmbH, Osterode, Germany) with EDC crosslinked 
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collagen dispersions prepared according to 2.2.1.1. Collageneous materials were 
cast in plastic Petri dishes (diameter: 5.5 cm) to a height of about 10 mm. Samples 
were lyophilized according to the following program: 
 
Table 4-1: Lyophilization protocol for the freeze-drying of EDC crosslinked collagen material. 
Step Time 
[hh:mm] 
Temperature 
[°C] 
Vaccum 
[mbar] 
Start 00:00 20 --- 
Ramp 02:00 - 20 --- 
Freezing 02:00 - 20 --- 
Ramp 00:05 - 20 0.1 
Ramp 03:00 15 0.1 
Primary Drying 25:00 15 0.1 
Ramp 01:00 25 0.1 
Ramp 00:03 25 0.045 
Secondary Drying 15:00 25 0.045 
 
2.2.1.3 Differential Scanning Calorimetry 
Samples were analyzed with a Mettler Toledo DSC 821e machine (Mettler-Toledo 
GmbH, Giessen, Germany). Samples of approximately 10 mg were incubated in 
1 ml 0.05 M Tris buffer pH 7.5 at room temperature for at least 2 hours. 
Subsequently, samples were transferred in aluminum pans (ME 26763 AL-Crucibles 
40 µl without pin, Mettler-Toledo GmbH, Giessen, Germany) and containers were 
sealed. Samples were heated from 20 to 90°C at 5 K/min. Analyses were performed 
in triplicates against an empty reference pan. 
 
2.2.1.4 Karl-Fischer titration 
Residual moisture of samples was determined by Karl-Fischer titration using an 
Aqua 40.00 titrator with Head-Space oven (Analytik Jena AG, Jena, Germany). 
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Sealed samples were fixed in the oven chamber and heated to 60°C for 30 minutes. 
Vaporized water was transported into the Karl-Fischer cell, determined 
coulometrically, and calculated as water amount in % (w/w). Measurements were 
carried out in triplicate. 
 
2.2.2 Collagen coating procedure 
2.2.2.1 Preparation of collagen dispersion 
Collagen dispersions were prepared by redispersion of collagen material in water at 
1% and 3% (w/w). The pH was adjusted to 3.5 using glacial acetic acid. Swelling 
was performed at room temperature for 4 hours with dispersion for 60 s using an 
Ultraturrax® (IKA-Werke GmbH Co. KG, Staufen, Germany) every 30 minutes at 
10,000 rpm and an additional dispersion step at the end of the swelling period of 
3 minutes at 10,000 rpm. The dispersion was then centrifuged at 5,000 rpm at 10°C 
for 10 minutes using a Sigma 4 K15 lab centrifuge (Sigma, Osterode, Germany) to 
remove air bubbles from the dispersion. Thereafter, the dispersion was used for the 
coating (compare 2.2.2.2 and 2.2.2.3) or stored at 2-8°C until further use. 
 
2.2.2.2 Coating procedure – cover coating 
Collagen dispersions (compare 2.2.2.1) were used to coat Polytetrafluoroethylene 
(PTFE) -discs, argon plasma activated with a plasmabrush® (Reinhausen Plasma 
GmbH, Regensburg, Germany) or cover glasses, both with a diameter of 15 mm. 
Therefore, the discs were placed in 24-well plates and covered with the collagen 
dispersions. The discs were air dried for 1 hour and subsequently dried under 
vacuum over night or until further use. For cell culture studies all these procedures 
were performed under a laminar flow workbench (Thermo, Langenselbold, 
Germany). 
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2.2.2.3 Coating procedure - squeegee 
The higher concentrated collagen dispersion (compare 2.2.2.1) was used to coat 
PTFE-discs, argon plasma activated with a plasmabrush® or cover glasses, both 
with a diameter of 15 mm. Therefore, the discs were covered with the collagen 
dispersion using a squeegee with a defined height of 1 mm (Figure 4-1). The discs 
were subsequently placed in 55 mm petri dishes, air dried for 1 hour, and 
subsequently dried under vacuum over night or until further use. For the cell culture 
studies, all these procedures were performed under a laminar flow workbench. 
 
1000 µm
 
Figure 4-1: Schematic of collagen coating using a squeegee. 
 
2.2.3 Cell compatibility 
The cell compatibility of collagen coated discs was evaluated using Human 
Umbilical Vein Endothelial Cells (HUVECs). HUVECs were prepared by digestion of 
umbilical veins with 0.1 g/l collagenase A. Cells were cultured in endothelial cell 
growth medium supplemented with 10% heat-inactivated fetal bovine serum in a 
humidified atmosphere at 5% CO2 and 37°C. Cells were used at passage no. 3. For 
visualization of cells on the different surfaces, cells were fixed with a buffered 
formaldehyde solution (4%) and were stained with propidium iodide in phosphate 
buffered saline (PBS) buffer with a final concentration of 50 µg/ml. Images were 
obtained with a Zeiss LSM 510 confocal laser scanning microscope (CLSM) (Zeiss, 
Oberkochen, Germany). 
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2.2.4 In-vitro release studies 
2.2.4.1 Release study of FITC-dextran from collagen matrices 
For the release study, plasma activated PTFE-discs were coated with collagen 
dispersions containing 0.1% (w/w) of FITC-dextran with a molecular weight of 
40 kDa based on the dry weight of collagen in accordance to 2.2.2.2 and 2.2.2.3. 
After coating, discs were left to dry at room temperature for 1 hour and 
subsequently under vacuum for several hours or until further use. Drying was 
performed under the exclusion of light, due to the light sensitivity of FITC-dextran. 
For the release analysis, triplicates of the coated discs were incubated in 10.0 ml 
PBS pH 7.4 in 50 ml Falcon tubes in a water bath (Haake SWB25, Haake, 
Karlsruhe, Germany) at 37°C and at 25 rpm horizontal shaking under exclusion of 
light. 2 ml samples were drawn and replaced with fresh PBS buffer at several time 
points. Released FITC-dextran was quantified using fluorescence spectroscopy, 
which was performed using a Varian Cary Eclipse fluorescence spectrometer 
(Varian GmbH, Darmstadt, Germany). Therefore, samples were measured in 
disposable Plastibrand® PMMA plastic cuvettes with an excitation wavelength of 
495 nm, an emission wavelength of 517 nm, and adjusted with a PBS buffer blank. 
Samples were diluted using PBS buffer, if necessary. The amount of released FITC-
dextran was calculated using a calibration curve. 
 
2.2.4.2 Release study of VEGF165 from collagen matrices 
For the release study, glass-discs were coated with collagen dispersions containing 
VEGF165 in accordance to 2.2.2.3. The amount of VEGF165 incorporated per disc 
was 1 µg, unmodified and crosslinked collagens were used in this study. After 
coating, discs were left to dry at room temperature for 1 hour and subsequently 
under vacuum for several hours or until further use. For the release analysis, 
triplicates of the coated discs were in incubated in 10.0 ml phosphate buffered 
saline (PBS) pH 7.4 in 50 ml Falcon tubes in a water bath (Haake SWB25, Haake, 
Karlsruhe, Germany) at 37°C and at 25 rpm horizontal shaking. In order to 
investigate the stability of VEGF165 in buffer, 1 µg VEGF165 was incubated in 10.0 ml 
PBS buffer pH 7.4 in 50 ml Falcon tubes, as well. These investigations were 
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performed in duplicate. 1 ml samples were drawn and replaced with fresh PBS 
buffer at several time points. Samples were frozen at -80°C until measurement. 
Released amounts of VEGF165 were quantified with a sandwich enzyme-linked 
immunosorbent assay (ELISA), using a commercially available kit for human VEGF 
from Ray Bio®. The ELISA was performed according to protocol; samples were 
measured at 450 nm using a Spectrafluor Plus plate reader (Tecan, Crailsheim, 
Germany). The amount of released VEGF165 was then calculated using a calibration 
curve. 
 
2.2.5 Influence on cell growth by incorporated VEGF165 
2.2.5.1 Rat aortic smooth muscle cells 
The influence of discs on the cell growth of smooth muscle cells was evaluated 
using rat aortic smooth muscle cells (SMCs). Cells were cultured in smooth muscle 
cell growth medium DMEM /F12 supplemented with 10% heat-inactivated fetal 
bovine serum in a humidified atmosphere at 5% CO2 and 37°C. 
 
2.2.5.2 Cell growth study 
For the study VEGF containing collagen coated discs holding varying amounts of 
VEGF were prepared. Therefore, collagen dispersions were prepared according to 
2.2.2.1 with VEGF added to the collagen dispersions prior to coating according to 
2.2.2.3. Control samples not carrying VEGF were treated accordingly. The discs 
were then placed on the bottom of 24-well plates and subsequently covered with 
500 µl of starvation medium: in case of HUVECs, containing 80% of M199 and 20% 
of endothelial cell growth medium, in case of SMCs, 100% of DMEM /F12. 20,000 
viable HUVECs (prepared according to 2.2.3) or SMCs (prepared according to 
2.2.5.1) were seeded per well. Thereafter, cells were cultured in a humidified 
atmosphere at 5% CO2 and 37°C. Cells on the discs were quantified at day 3 using 
Cell Titer-Blue®. Therefore, cells were incubated with Cell Titer-Blue® for 6 hours 
and an aliquot of the supernatant was analyzed using a Spectrafluor plus plate 
reader (Tecan, Crailsheim, Germany) with an excitation wavelength of 550 nm and 
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emission recording at 595 nm. The increase in cell growth was calculated as % 
increase in relation to cells grown on collagen coated discs without VEGF165. 
 
3 Results and Discussion 
3.1 Characterization of crosslinked collagen 
For a complete understanding of the properties of the collagen materials and the 
release behavior, it was of importance to characterize physical or chemical changes 
induced by the crosslinking process. Therefore, DSC and Karl-Fischer 
measurements of the different collagen materials were performed to determine the 
melting temperature and the residual moisture levels after drying. These two critical 
parameters are indicative for, on the one hand, a successful crosslinking in case of 
DSC [17], and on the other hand, can be a first indicator for the swelling properties 
and the release characteristics in case of residual moisture determination [18-20]. 
 
3.1.1 Differential Scanning Calorimetry 
Collagen variants were analyzed using DSC in order to determine the midpoint of 
transition, also known as melting temperature (Tm). It is of critical interest to 
evaluate this characteristic value since it gives insight in the physicochemical 
changes that can occur during in vitro and in vivo tests or be an indicator for 
variations that can occur during storage. The heating of collagen results in a loss of 
structural properties of the collagen, especially the helical structure and is therefore 
a valuable tool to determine the degree of crosslinking of swollen collagen samples 
[21-22]. Stronger interactions between the collagen fibers that result from 
crosslinking are responsible for an increase in melting temperature and this 
increase can be used to indirectly identify the degree of crosslinking of the analyzed 
samples [17]. Impartial to the degree of crosslinking, thermal denaturation occurs at 
temperatures above 100°C for collagen in a dried state [1], therefore indicating that 
a storage of dried collagen at room temperature is possible without risking 
temperature induced changes. 
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For the collagen material investigated in this study, the non crosslinked equine 
collagen raw material showed a denaturation temperature of 53°C (Figure 4-2). 
During subsequent cooling and a second heating step of the sample, no peaks were 
detectable. This was an indicator for the complete and irreversible denaturation of 
the collagen material, which was in accordance with literature [21]. EDC 
crosslinking resulted in an increase in melting temperatures of the collagen samples 
in correlation to the employed EDC : collagen ratios. For the collagen samples 
1:16.9 (g collagen : mg EDC), a melting temperature of 54°C was detected, which 
increased for the samples 1:67.7 to 59°C and a further increase to 65°C was 
detectable for the samples with a ratio of 1:203.1 (Figure 4-2). 
0
10
20
30
40
50
60
70
1 : 0 1 : 16.9 1 : 67.7 1 : 203.1
collagen : EDC mass ratio [g:mg]
T
m
 [
°C
]
 
Figure 4-2: Melting temperature of equine collagen raw material crosslinked with different 
EDC ratios determined by DSC (average ± SD; n=3). 
 
These results indicated a stronger interaction of the collagen fibers, which resulted 
in an increase in denaturation temperature for the EDC crosslinked collagen 
samples. Crosslinking collagen is a useful tool to control the properties of collagen 
and is often applied to prevent a rapid degradation of collagen-based biomaterials 
during in vivo application, in order to suppress its antigenicity and to improve 
mechanical properties [5, 17]. Overall, this data is consistent with data presented by 
Metzmacher, who showed an increase in Tm for EDC crosslinked equine collagen in 
a range of 54°C and 65°C [17].  
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3.1.2 Residual moisture of crosslinked collagen 
The residual moisture of EDC crosslinked collagen after freeze-drying was 
determined using Karl-Fischer titration in order to guarantee low moisture levels in 
the collagen material to ensure stability during storage. The untreated non 
crosslinked equine collagen starting material showed a residual moisture level of 
8.0% ± 0.16. In comparison, all EDC crosslinked materials showed lower levels in 
residual moisture decreasing with increasing collagen : EDC ratios. The collagen 
with the lowest degree of cross-linking exhibited residual moisture levels of 7.4% ± 
0.15, medium crosslinked material showed 7.1% ± 0.10, and highest crosslinked 
collagen 7.0% ± 0.23 residual moisture.  
These lower numbers for residual moisture of crosslinked collagen material could 
be associated with the swelling behavior of crosslinked collagen that was reported 
in literature. In studies, decreases in swelling were shown for crosslinked collagen 
matrices, which were caused by a decrease in the amounts of penetrating solvents 
[18-20]. 
 
3.2 Cell compatibility of collagen variants 
In addition to collagen melting temperature and residual moisture, the different 
crosslinked collagen species were analyzed concerning their cell compatibility. Cell 
compatibility is of great importance, especially for the intended use as biomaterial 
substrate to enhance attachment, attraction, and endothelial cell growth, either by 
itself due to its properties as a natural collagenous tissue, and also in its function as 
matrix for the release of endothelial cell specific growth enhancers, such as 
VEGF165. Studies of collagen in a similar application have been performed before, 
but only for native collagen with human origin [23] or with cells of different origin 
than endothelial cells [24]. Thus, it was of interest how collagen of different origins 
and after chemical crosslinking would perform. Therefore, the collagen materials 
were used to coat glass discs, which were subsequently seeded with HUVECs. 
Cells were allowed to attach and grow on the modified and unmodified materials 
and were stained using propidium iodide after 3 days. The stained cells were 
Investigation of Collagen Films for controlled release of VEGF165 
 
89 
analyzed using CLSM concerning the cell morphology, cell viability, and proliferation 
on the discs. 
(a) (b) (c) (d) 
    
Figure 4-3: CLSM images of propidium iodide stained collagen coated discs after incubation 
with endothelial cells on native collagen (a), crosslinked collagen 1:16.9 (b), crosslinked 
collagen 1:67.7 (c) and crosslinked collagen 1:203.1 (d). 
 
Figure 4-3 shows the acquired pictures for the stained cells after a 3 day incubation 
period. All pictures showed a confluent monolayer of endothelial cells grown on the 
collagen films with a morphology attributed to HUVECs. The different intensities 
originated from different levels of background staining of collagen. Crosslinking of 
the collagen material did not influence the growth behavior of endothelial cells; 
hence a treatment with EDC and NHS did not leave behind any cytotoxic residues 
and thereby did not affect cyctotoxicity of the collagen material. However, the issue 
of blood compatibility, especially thrombogenicity could not be elucidated by these 
investigations. This is one of the main concerns that arise when working in the field 
of vascular graft applications, which can be seen by the multitude of studies 
performed to overcome this problem [25-28]. Collagen itself has a thrombogenic 
potential [29], and therefore, several groups have investigated this effect and have 
come to the conclusion that collagen in combination with Heparin can lower this 
thrombogenic potential [8, 30]. In addition, it has been reported that crosslinking of 
collagen could lower the tissue reaction of surrounding tissue [6], thus being a first 
indicator that crosslinking can be beneficial in itself to lower thrombogenicity. 
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3.3 In vitro release studies 
In the previous section, the collagen raw and crosslinked material was 
characterized with respect to physical behavior and cell compatibility. Consequently, 
the aspect of release behavior of higher molecular weight compound from collagen 
film coatings had to be elucidated. In our case, collagen was used to establish thin 
films on vascular graft raw materials, such as PTFE and later glass as model 
substrate. For first release investigations, FITC-dextran 40 kDa was incorporated in 
the films and its release from films investigated. Subsequently, the model compound 
was substituted by the endothelial cell specific growth enhancer VEGF165 [31] with a 
molecular weight of 42 kDa and its release was studied. 
Collagen devices exhibit strong swelling behavior in contact with water depending 
on their crosslinking degree [18]. Sano et al. observed that penetrating solvent 
dissolved water soluble drugs, which were incorporated into a matrix and that the 
release of the dissolved compound was controlled by the swelling behavior of the 
collagen matrix rather than the speed of dissolution [32]. These findings were 
confirmed by Maeda et al. who additionally suggested that the release occurs 
through water filled pores, and therefore an increasing release rate can be observed 
for porous structures [33]. In general, collagen devices, specifically collagen films, 
exhibit fast release of incorporated compounds [3]. 
 
3.3.1 Influence of coating procedure on FITC-dextran release profile 
During preliminary FITC-dextran release investigations, highly variable release 
profiles were observed for drip coating collagen coated discs, with up to 60% 
difference in the totally released percentages. Release of model compound during 
these investigations was completed within 2 hours, which was in accordance with 
findings reported in literature [1, 3, 34]. Therefore, a 24 hour time period was 
chosen for the investigation of further release experiments. It was postulated that 
the coating procedure applied had a strong influence on drug liberation. 
Consequently, this influence was investigated by applying a different coating 
technique in comparison to the applied drip coating method. 
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Drip coating was performed by covering discs that were placed in a well plate with 
collagen dispersion. The discs were subsequently air dried for several hours before 
being dried under vacuum over night. Thereafter, discs were removed from the well 
plates, which lead to the loss of some of the coating material at the disc-well plate 
interface due to strong adherence of the collagen coating. The alternative coating 
approach was performed using a squeegee that enabled the application of higher 
concentrated collagen dispersions with a defined height on the discs. Since coating 
was performed outside of well plates, a loss of collagen after drying was 
circumvented. This coating procedure posed several advantages over the 
previously applied drip coating procedure. Due to the application of collagen 
dispersion with a defined height, a more homogenous coating with a constant 
thickness could be applied that might result in better drying of the coating, as well 
as faster drying due to the higher concentrations of collagen applied. In addition, the 
increase in concentration should lead to a slower diffusion of the incorporated 
compound, resulting in a more consistent distribution within the matrix, since the 
first dry spots are formed next to still high concentration collagen gel areas. 
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Figure 4-4: Cumulative in-vitro FITC-dextran release from drip coating collagen coated discs 
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Figure 4-4 shows the cumulative release of the incorporated FITC-dextran. 
Collagen coated discs manufactured by drip coating exhibited an initial burst 
release of approximately 60% within the first hour which stayed constant throughout 
the entire investigated 24 hour time period. In contrast, the collagen coated discs 
manufactured by squeegee coating exhibited an almost complete release of FITC-
dextran within the first hour that was constant throughout the investigated time 
period. It was apparent that the standard coating procedure resulted in a lower total 
release after the incubation period, indicating a loss of FITC-dextran, whereas the 
squeegee coated discs exhibited a close to 100% release of the model compound. 
These findings suggested a loss of FITC-dextran during the coating procedure or 
the subsequent retrieval of samples. However, the described loss of collagen 
coating after drying could not account for the high loss of incorporated model 
compound, assuming its even distribution in the film. Maeda et al. had observed 
cluster formation of their model compound during drying and hypothesized that this 
phenomenon occurred due to phase separation. Since their model compound did 
not exhibit significant affinity with collagen, a cluster formation was therefore 
possible [33]. This cluster formation and phase separation phenomenon was 
presumed to be the reason for the significant loss of FITC-dextran. Evidently, the 
phase separation caused an accumulation of FITC-dextran in the peripheral region 
of the discs and the well plate, thus leading to a substantially higher loss of FITC-
dextran when amounts of collagen coating were lost during sample retrieval. These 
results indicated a superiority of the squeegee method over the standard coating 
method to coat discs for release investigations. 
 
3.3.2 Influence of crosslinking on FITC-dextran release profile 
An almost complete release of FITC-dextran from unmodified collagen films, as 
seen in 3.3.1, took place within the first hour after incubation. For an application of 
controlled release in the field of vascular grafts to stimulate endothelialization, a 
constant release over a prolonged period of time is desirable. Therefore, the 
influence of crosslinking on the release rate of the model compound was 
investigated in order to minimize the initial burst release and establish a steady 
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release to stimulate endothelial cells. In accordance to Sano et al. [32], it was 
expected that the higher collagen crosslinking degree would result in lower swelling 
of the established films and therefore would reduce the initial release and allow for a 
more constant release profile.  
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Figure 4-5: Cumulative in-vitro FITC-dextran release from native collagen coated discs (
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The acquired release profiles can be seen in Figure 4-5. All systems investigated 
exhibited a strong burst release within the first 30 minutes of incubation. A complete 
release for the non-crosslinked collagen occurred within 1 hour. Lower total 
amounts of FITC-dextran were released from all other samples in correlation to their 
crosslinking degree. The samples with a collagen : EDC ratio of 1:16.9 showed a 
total cumulative release of 70%, followed by the samples with a ratio of 1:67.7 with 
a release of 60%, and the samples with a ratio of 1:203.1, which showed a release 
of 30%. Burst release rate for the unmodified samples, as well as, the two collagen 
varieties with the lower crosslinking degree were similar, however, the highest 
crosslinked collagen’s burst release rate was lowered. It has been reported in 
literature that, especially for high molecular weight compounds, the release rates 
decrease with an increase in crosslinking degree. This phenomenon was observed 
independent of the method applied for crosslinking [1]. In contrast, low molecular 
weight substrates showed no differences in release rates in accordance to the 
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crosslinking degree [1]. The initial release can be explained by the presence of 
model compound that was released through the porous structure of the film, 
immediately after incubation. The remaining fraction of FITC-dextran was 
mechanically fixed within the collagen after drying and was released to a lesser 
degree due to lower swelling resulting from crosslinking [1, 35-36]. This mechanical 
fixation, however, can be beneficial for the intended application of such coatings on 
vascular grafts to enhance endothelialization. Collagenolytic enzymes are 
expressed in endothelial cells [37], therefore the trapped compounds can be 
released upon digestion of the matrix by the endothelial cells and become available 
to attract further cells and stimulate their proliferation. 
 
3.3.3 Release of VEGF165 from collagen matrices 
After having successfully characterized the in vitro release profiles for the model 
compound FITC-dextran from non-modified and modified collagen films, the in vitro 
release profile of VEGF165 incorporated in collagen films was to be tested. Non-
modified and crosslinked collagen with a collagen : EDC ratio of 1:67.7 were used 
to coat glass discs carrying amounts of VEGF165. In parallel to the release study, the 
stability of VEGF165 under release conditions was analyzed and the equivalent 
amount of VEGF165 incorporated in the collagen films was incubated in PBS buffer 
alone. 
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Figure 4-6: Cumulative in-vitro VEGF165 release from native collagen coated discs (
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The release profiles for VEGF165 from native and crosslinked collagen are 
presented in Figure 4-6. Burst release was seen for VEGF165 for both versions of 
collagen films. The initial release for the protein embedded in the unmodified 
collagen film was complete within the first hour of incubation. The corresponding 
release from the crosslinked collagen was finished in the same period of time. 
However, the amount of total released protein was approximately 40% lower than 
observed for the umodified collagen. This was in accordance to the findings for 
FITC-dextran. These results also corresponded with findings in literature, as 
mentioned before, that the release of higher molecular weight compounds 
decreases with increasing crosslinking degree [1]. This was anticipated since the 
molecular weights of the model compound FITC-dextran and VEGF165 are in a 
similar range of 40 kDa. However, after the initial release of VEGF165, the amount 
present in the release medium drastically decreased within the following 48 hours 
and stabilized at a level of 30% for the unmodified collagen and 5% for the 
crosslinked collagen. A similar instability was observed for the VEGF165 incubated in 
PBS buffer at 37°C over a time period of 7 days (Figure 4-7). After 24 hours only 5% 
of the initially present VEGF could be detected. 
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Figure 4-7: VEGF165 stability in PBS. (average ± SD; n=2) 
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Contradictory findings about the stability of VEGF165 in buffer have been reported in 
literature [38-39]. The present findings suggested a fast degradation and low 
recovery of VEGF165 in solution at 37°C, which was in accordance to other in vitro 
findings [39]. However, it has been reported in literature that the addition of BSA to 
formulations containing VEGF can have a beneficial effect on VEGF recovery [38, 
40]. Therefore, the low recovery of VEGF in these investigations determined by 
ELISA might be due to the adsorption of VEGF to container surfaces. Other 
possible explanations for the low recovery could be the loss of affinity of VEGF 
towards the antibody used during the ELISA measurements resulting in low 
recovery, but not reflecting loss of biological activity. Thus, more important than the 
amount of recovered VEGF165 in the stability investigations is the availability and 
biological activity of released VEGF165 in a cell growth setting (compare 3.4). 
In conclusion, it can be said that native and crosslinked collagen showed 
comparable release profiles for VEGF as previously determined using FITC-
dextran. Native collagen stabilized VEGF165 in solution, as seen by higher levels of 
cytokine present in solution, in comparison to crosslinked collagen and VEGF in 
buffer alone over a time period of 170 hours. The biological activity of entrapped 
VEGF165 in the crosslinked collagen matrix could not be investigated in this setting, 
however, it is suggested that due to the limited swelling of this collagen and 
therefore lower amounts of penetrating solvent, the biological activity of VEGF in the 
matrix was conserved. Furthermore, the high concentration of the obviously 
stabilizing agent collagen in the environment added to the preservation of biological 
activity. However, the cell growth experiments on pre-incubated samples should 
give further insight into the stability of the remaining VEGF (compare 3.4). 
 
3.4 Influence of incorporation of VEGF165 in collagen matrices on cell 
growth 
The influence of incorporated VEGF165 and its release on cells is a very important 
prerequisite for the application of collagen films for the intended purpose of vascular 
graft coating to improve the cell adhesion and growth of endothelial cells. VEGF165 
has been widely used in the field of vascular graft applications to enhance the 
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proliferation of endothelial cells in order to improve the performance of grafts [11-
13]. Therefore, the goal of this study was to investigate the different effects of 
incorporated VEGF165 on endothelial and smooth muscle cells in an in vitro setting. 
Additionally, it was crucial for the success of the application of collagen coatings for 
vascular grafts to examine the stability and biological activity of VEGF throughout 
the coating process, the incorporation into the collagen, and drying of the collagen 
films.  
Therefore, glass discs were coated with non-modified and crosslinked collagen with 
a collagen : EDC ratio of 1:67.7 and varying VEGF165 concentrations. The influence 
on the cell growth of SMCs and HUVECs was investigated in comparison to control 
samples not carrying VEGF. In order to identify a suitable concentration for cell 
growth stimulation, a wide range of VEGF concentrations of 1, 10 and 100 µg per 
disc, in case of HUVECs, were tested in a cell growth assay (compare 2.2.5.2). In 
order to investigate the stability of VEGF remaining in wet collagen films after initial 
burst release and its effect on SMCs and HUVECs, discs coated with both collagen 
carrying 10 µg VEGF165 were incubated over night in PBS buffer, subsequently 
rinsed to ensure removal of adsorbed VEGF to the collagen surface and then 
transferred to fresh well plates to examine them in the same cell growth setting. 
 
3.4.1 Smooth muscle cells 
Contradictory findings concerning the effect of VEGF165 on the proliferation and 
migration of SMCs are reported in literature. It has been reported, that VEGF165 can 
have a positive effect on SMC growth and migration induced through various 
pathways [41-42]. However, other groups have identified VEGF165 to have no 
stimulating effect on SMCs [11, 43]. In our case, no differences for the SMCs grown 
on the VEGF165 collagen matrices were observed independent of the amount of 
VEGF165 incorporated (Figure 4-8).  
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Figure 4-8: Smooth muscle cell growth on collagen (
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coated discs with 1 or 10 µg incorporated VEGF165 and after prior 24h incubation. 
(average ± SD; n=3) 
 
All samples except the crosslinked collagen sample carrying 1 µg VEGF showed a 
SMC growth comparable to the control samples without VEGF. The crosslinked 
collagen matrix carrying 1 µg VEGF showed a decrease in cell growth of 15% 
compared to all other samples. This decrease could not be attributed to the effect of 
crosslinked collagen on SMCs, since all other crosslinked samples carrying higher 
amounts of VEGF did not show a reduction of cell growth. Pre-incubation of 
collagen samples with 10 µg VEGF showed neither a beneficial, nor a detrimental 
effect on SMC growth.  
 
3.4.2 Vascular endothelial cells 
VEGF is a widely investigated growth factor. It is a secreted protein ligand that 
activates transmembrane receptors on endothelial cells and it consists of a 
disulfide-linked homodimer. It exists in several isoforms, four of which consist of 
121, 165, 189 and 206 amino acids [31] and are produced from a single human 
gene as a result of alternate splicing [11]. This growth factor has been shown to 
have very high endothelial cell specificity without mitogenic activity for other cell 
types [16], making it an ideal candidate for the specific stimulation of endothelial cell 
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growth in vascular graft applications. Multiple ways of presenting these growth 
factors have been investigated, including extracellular matrix coatings [13], 
electrostatic interaction [12], and fibrin matrices [11, 44] that have shown promising 
results. 
The stability and remaining biological activity of VEGF within dried collagen 
matrices and after release from the coating is of great importance for the application 
of collagen coatings for the controlled release of VEGF to enhance 
endothelialization of vascular grafts. Therefore, the goal of these investigations was 
to show the influence of VEGF165, which had been incorporated and dried in 
collagen matrices, on endothelial cells. 
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Figure 4-9: Endothelial cell growth on collagen (
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The results of the cell growth investigations are presented in Figure 4-9. Endothelial 
cells grown on both collagen variations, the non-modified and crosslinked collagen 
films, exhibited good growth when grown on control samples without VEGF, 
ensuring the cell compatibility and non toxicity of the materials as shown before 
(see 3.2). Endothelial cell growth on films carrying 1 µg VEGF165 increased by 
almost 60%, when grown on either collagen variety. No differences could be 
observed for the different collagen samples. When the film load increased to 10 µg 
VEGF165 per film endothelial cell growth on non-modified collagen dropped to 100%, 
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comparable to the cells grown on control samples without VEGF. However, cells 
grown on crosslinked collagen films containing 10 µg VEGF showed comparable 
growth to those containing 1 µg. For the samples carrying films with 100 µg 
VEGF165, the cell growth decreased to 70% for samples coated with non-modified 
collagen and 30% for those coated with crosslinked collagen. This decrease, as well 
as the decrease for the collagen coated samples containing 10 µg VEGF, could be 
ascribed to the immediate release of high amounts of VEGF165, which led to an over 
stimulating effect of the cytokine on endothelial cells, which slowed proliferation. 
The preservation of cell growth increase observed for the samples coated with 
crosslinked collagen and 10 µg VEGF can be attributed to the lower immediate 
release during incubation, as also seen for FITC-dextran (compare 3.3.2), which 
resulted in a prolonged stimulatory effect of the cytokine on endothelial cells. 
For the samples that were incubated in buffer prior to cell seeding to eliminate the 
effect of burst released VEGF and to investigate on the stability of the cytokine in 
swollen collagen matrices, an increase of 25% for the non-modified collagen and a 
40% increase for crosslinked collagen could be observed. This is in agreement with 
findings from prior in vitro release experiments (compare 3.3) where varying 
amounts of model substrate and VEGF165 remained in the collagen film depending 
on the crosslinking degree. Under in vitro conditions, the remaining substrate could 
not be released through further incubation for several hours, due to the higher 
molecular weight of the compounds and the entrapment in the pores of the collagen 
film that results from it [1]. However, in the case of the growth of endothelial cells, a 
stimulation of cells after incubation and rinsing was observed, which leads to the 
conclusion that the collagenolytic activity of the endothelial cells [45] was 
responsible for degradation of the collagen film and a further release of VEGF165, 
which stimulated further cell growth. These findings show a sustained biological 
activity of VEGF165 in the collagen film, despite the short half life and in vitro 
recovery as seen before (compare 3.3.3). Therefore, it can be concluded that the 
incorporation of VEGF165 into collagen films stabilized the protein and its biological 
activity was sustained as shown by cell growth stimulation of collagen coated 
samples incubated for more than 24 hours. 
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4 Conclusions 
The goal of the study was to show the cell growth stimulatory effect of VEGF165 
released from collagen films as potential coatings for vascular grafts to enhance 
their in vivo endothelialization. 
Early results for the release of FITC-dextran showed fast release rates from 
collagen films within the first 2 hours. In order to modify these release 
characteristics, collagen crosslinking was performed using carbodiimide chemistry. 
Characterization of the crosslinked material was performed using DSC 
measurements to confirm the efficiency of the procedure and the successful 
crosslinking. In addition, the postulated low toxicity of carbodiimide crosslinked 
collagen was successfully confirmed using endothelial cells. Release studies, using 
FITC-dextran 40 kDa, showed modified release rates for the crosslinked collagen 
materials. It was shown that with increasing crosslinking degree, the initial release 
of model compound was reduced in accordance to the crosslinking degree. 
Therefore, crosslinking of collagen was shown to be an effective tool to modify 
release properties of collagen without risking the good biocompatibility of this 
material. Furthermore, the results obtained for FITC-dextran formed the basis for 
the investigation of VEGF165 containing films concerning their release behavior. The 
predetermined release properties could be successfully confirmed for the 
endothelial cell specific growth factor. Therefore, the modified collagen materials 
constitute a suitable carrier for controlled release of VEGF. 
Furthermore, it was of central interest to investigate the biological activity of the 
incorporated VEGF, after processing of the collagen films and subsequent release 
on cells. Therefore, VEGF incorporated into collagen films was investigated towards 
its effect on endothelial and smooth muscle cells. No stimulatory effect on SMCs 
could be shown. This is an important prerequisite for the application in vascular 
grafts, since an excessive growth could lead to vessel occlusion, the reason for the 
unsuitability of i.e. basic fibroblast growth factor. Furthermore, and more importantly, 
an increase in endothelial cell growth by VEGF released from collagen films was 
shown. Thus, it was possible to maintain the biological activity of a sufficient amount 
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of VEGF throughout the manufacturing and drying process of collagen films and the 
subsequent release to stimulate endothelial cell growth. 
Therefore, Collagen film coatings carrying VEGF165 constitute an interesting 
alternative for the modification of vascular grafts to enhance their endothelialization, 
and thereby their long term performance. 
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Chapter 5 
 
Cell growth stimulation by VEGF165 covalently linked to a 
modified PLGA-matrix 
 
 
Abstract 
It was the goal to investigate the effect of Vascular Endothelial Growth Factor 
(VEGF) irreversibly linked to a modified poly(lactic-co-glycolic acid) (PLGA) on the 
growth of endothelial and smooth muscle cells (SMCs). In doing so, it was to be 
shown whether the irreversible linkage interfered with the mechanism of action of 
VEGF and its receptor internalization. Commercially available PLGA was modified 
using a homobifunctional polyethylene glycol (PEG) spacer for protein attachment. 
VEGF165 was covalently attached via succinimidyl ester to discs coated with the 
modified polymer. Successful binding, potentially maintained VEGF integrity, and 
optimization of coating and coupling procedures could be shown by employing an 
antibody staining method, whereas FTIR and other adapted staining methods could 
not provide further insight.  
The preservation of the biological activity of VEGF165 was shown by a substantial 
growth increase of endothelial cells. Furthermore, PEG-PLGA could be shown to 
have a limiting effect on the proliferation of SMCs, due to its cell-adhesion-resistant 
properties, in comparison to unmodified PLGA matrices. Furthermore, it was shown 
that irreversibly linked VEGF165 was still able to interact with its receptor and to 
stimulate endothelial cells. 
 
Keywords: PLGA, VEGF, vascular graft, endothelial cell, covalent linkage, PEG 
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1 Introduction 
After implantation of biomaterial surfaces in a body, the body generally identifies 
these surfaces as foreign objects resulting in a repair response rather than a 
regenerative response [1]. These repair responses lead to unwanted side effects 
which, in the case of vascular grafts for vessel replacement, can lead to 
complications [2-4]. Local treatment with bioactive molecules constitutes an 
interesting approach to overcome these problems. The easiest approach for site 
specific delivery of bioactive molecules to an implantation site is the pre-incubation 
of the implantable biomaterial in a solution containing the active ingredient, a 
method commonly used to treat vascular graft infection [5]. However, this method 
provides little, if any, control over the local delivery which is strongly influenced by 
the environment of the site of implantation and the patient’s condition. A more 
controlled approach for delivery is the use of matrices or scaffolds that incorporate 
biomolecules that are released after implantation [6-7]. One big advantage is the 
controlled release of these molecules over an extended period of time. However, it 
also poses the risk of dose dumping and systemic side effects once released into 
the blood in case of vascular grafts. 
Another alternative is the chemical attachment of these biomolecules to surfaces to 
enable a direct interaction of cells of interest with growth enhancers and provide a 
more controlled approach over cell – biomaterial interactions. However, the question 
arises whether the chemical attachment of such molecules interferes with their 
mechanism of action, especially in regards of binding sites being shielded due to 
linkage, sterical hindrance, conformational changes [8], or loss of receptor 
internalization [9-11] due to irreversible linkage. Several promising attempts have 
been carried out to immobilize a variety of proteins on biomaterial surfaces [12-13]. 
It has also been shown that the introduction of spacer molecules between the 
substrate surface and the attached biomolecule can be beneficial for the 
maintenance of the biological activity [14-15]. Furthermore, the use of PEG as a 
spacer might have the advantage of increasing the half life of used molecules [16-
17], resulting in a longer activity, which is a common approach in pegylation of 
therapeutic proteins [18-20]. Approaches for the chemical attachment of proteins 
have made use of functional groups present within the sequence of proteins, such 
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as amino, carboxyl [21], and aldehyd groups [15]. VEGF165, the predominant 
isoform from the VEGF family [22], carries these functional groups within its 
sequence and makes it accessible for covalent attachment to biomaterials. 
VEGF165, a 42 kDa protein, has been widely investigated for the controlled release 
and use in artificial graft applications [13, 23-24]. VEGF is involved in several 
endothelial cell specific activities, such as proliferation and migration [25], at the 
same time limiting the mitogen-induced vascular SMC proliferation [26]. Therefore, 
it seems a very promising approach for the improvement of vascular grafts by 
controlled presentation of VEGF165 at the graft surface by chemically attaching the 
protein to a modified matrix. 
The objective of this study was to show a successful covalent linkage of VEGF165 to 
modified PLGA, a commonly used polymer in controlled release applications with 
biodegradable and biocompatible attributions [27-28], while maintaining the 
biological activity. The polymer was to be chemically altered using a 
homobifunctional PEG spacer carrying succinimidyl ester groups to attach the PEG 
structur to amino moieties within the protein sequence.  
The first focus was the evaluation of the linkage of VEGF to the matrix. Therefore, a 
suitable detection technique using infrared spectroscopy and several staining 
methods had to be identified. A suitable antibody staining method to determine 
bound protein needed to be developed and was used to optimize linkage conditions 
and examine the unspecific adsorption of VEGF on matrices. More importantly, the 
cell compatibility of the modified PLGA material and the preservation of the 
biological activity of the attached VEGF were evaluated. Therefore, their effect on 
HUVECs and SMCs was investigated  
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2 Materials and Methods 
2.1 Materials 
Resomer® (RG 502H and RG 504H) was provided by Boehringer Ingelheim 
(Ingelheim, Germany), VEGF165 was kindly donated by Genentech (San Francisco, 
CA, USA), and rat aortic smooth muscle cells were provided by PD Dr. Wolgang Erl 
(Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Ludwig-
Maximilians-Universität München, Munich, Germany). O,O′-Bis(2-amino-propyl) 
polyethylene glycol (PEG(NH2)2) with a molecular weight of 500 Da, succinic 
anhydride, N-Hydroxysuccinimide (NHS), N,N'-Dicyclohexylcarbodiimide (DCCI), 
dimethyl sulfoxide (DMSO), 2,4,6-Trinitrobenzenesulfonic acid solution (TNBS), 
Bovine Serum Albumin (BSA), and Reversible Protein Detection Kit were purchased 
from Sigma (Steinheim, Germany), toluene, and diethyl ether from Merck KGaA 
(Darmstadt, Germany), triethylamine, dichloromethane, ethylenediamine, 
ethanolamine, cover glasses, plastic petri dishes from VWR (Darmstadt, Germany), 
polytetrafluoroethylene (PTFE) from GM GmbH (Freiham, Germany), SilverXPress® 
Silver Staining Kit, and goat-anti-rabbit antibody Alexa Fluor 488 from Invitrogen 
(Karlsruhe, Germany), Deep Purple™ Total Protein Stain from GE Healthcare 
(Freiburg, Germany), rabbit Anti-Human VEGF antibody from Pepro Tech GmbH 
(Hamburg, Germany), collagenase A from Roche (Penzberg, Germany), endothelial 
cell growth medium from Provitro (Berlin, Germany), heat-inactivated fetal bovine 
serum from Biochrom (Berlin, Germany), smooth muscle cell growth medium 
DMEM /F12 and M199 from PAA (Pasching, Austria), 24-well plates from TPP 
Techno Plastic Products (Trasadingen, Switzerland), and Cell Titer-Blue® from 
Promega (Madison, WI, USA). 
The pH of the solutions was adjusted using hydrochloric acid or sodium hydroxide 
from Merck KGaA (Darmstadt, Germany) and measured with a pH meter Inolab 
level 1 from WTW (Weilheim, Germany). 
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2.2 Methods 
2.2.1 PLGA modification 
2.2.1.1 Synthesis of PEG-spacer 
A bifunctional PEG-spacer was synthesized using O,O′-Bis(2-aminopropyl) 
polyethylene glycol (PEG(NH2)2) with a molecular weight of 500 Da as starting 
material. In a first reaction step (Figure 5-1), the amine groups of the PEG were 
modified into carboxylic groups using succinic anhydride. The reaction was carried 
out in anhydrous toluene with the addition of triethylamine at room temperature over 
night. 
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Figure 5-1: Reaction mechanism for the synthesis of PEG-(COOH)2. 
 
The resulting functionalized PEG carrying two carboxylic groups was subsequently 
activated (Figure 5-2) using N-Hydroxysuccinimide (NHS) and N,N'-
Dicyclohexylcarbodiimide (DCCI) to carry two succinimidyl ester. The reaction was 
carried out in anhydrous dichloromethane at 0°C for 3 hours and subsequently at 
room temperature over night. The product was recovered and purified by 
precipitation in cold diethyl ether. The final compound was desiccated under 
vacuum for several hours and the activity was determined by a TNBS assay 
(compare 2.2.1.3). 
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Figure 5-2: Reaction mechanism for the synthesis of PEG-(NHS)2. 
 
2.2.1.2 Synthesis of PEG-PLGA 
The free carboxylic groups of two variants of non end-capped PLGA (RG 502H and 
RG 504H) were activated (Figure 5-3) in a first step using NHS and DCCI. The 
reaction was carried out in anhydrous dichloromethane at 0°C for 3 hours and 
subsequently at room temperature over night. 
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Figure 5-3: Reaction mechanism for the synthesis of activated PLGA. 
 
The resulting activated PLGA carrying a succinimidyl ester was subsequently 
coupled to ethylenediamine in anhydrous dichloromethane at room temperature 
over night (Figure 5-4).  
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Figure 5-4: Reaction mechanism for the synthesis of PLGA-Ethylenediamine. 
 
In a last step, the PLGA carrying the amine group was coupled to the PEG-spacer 
in anhydrous dichloromethane at room temperature over night (Figure 5-5).  
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Figure 5-5: Reaction mechanism for the synthesis of PEG-PLGA. 
 
The product was recovered and purified by precipitation in boiling diethyl ether. The 
final compound was desiccated under vacuum for several hours and the activity 
was determined by a TNBS assay (compare 2.2.1.3). 
 
2.2.1.3 TNBS assay 
The degree of ability of the activated species of PLGA and PEG to couple with 
primary amines within protein sequences was determined using a modified assay 
according to Snyder et al [29]. Therefore, the activated species were dissolved in 
anhydrous DMSO and were coupled with the primary amine of ethanolamine 
(Figure 5-6). 
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Figure 5-6: Conjugation reaction of activated species with ethanolamine. 
 
In a next step, the free ethanolamine was quantified using TNBS in a 0.1 molar 
borate buffer pH 8.3. The yellow conjugate (Figure 5-7) formed was quantified via 
UV-spectroscopy at 420 nm using the Agilent 8453 (Agilent Technologies, 
Böblingen, Germany). The degree of activation was calculated as % of coupled 
ethanolamine compared to reference samples containing no activated species. 
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Figure 5-7: Quantification reaction for free ethanolamine. 
 
2.2.2 Coating procedure for PEG-PLGA 
Different species of PLGA (RG 504H, activated PLGA and PEG-PLGA) were used 
to coat PTFE-discs, argon plasma activated with a plasmabrush® (Reinhausen 
Plasma GmbH, Regensburg, Germany) or cover glasses, both with a diameter of 
15 mm. Therefore, the discs were placed in a 24-well aluminum well plate and 
covered with different concentrations of the synthesized PLGA-species dissolved in 
anhydrous dichloromethane. The discs were air dried for one hour and 
subsequently removed from the wells and dried under vacuum over night or until 
further use. For the cell culture studies all these procedures were performed under 
a laminar flow workbench (Thermo, Langenselbold, Germany). 
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2.2.3 VEGF165 linkage to modified PLGA matrix 
For the linkage of VEGF165, PLGA, and PEG-PLGA, coated discs were transferred 
to plastic petri dishes and covered with different concentrations of VEGF165 in 
phosphate buffered saline (PBS) buffer pH 7.4 for 30 minutes. Reference samples 
not carrying VEGF165 were treated with either PBS buffer alone or with PBS 
containing 1 mg/ml BSA to block unspecific binding. After incubation, the discs were 
intensely washed in Milli-Q water and stored in PBS buffer for immediate use. For 
the cell culture studies all these procedures were performed under a laminar flow 
workbench. The approach for protein attachment is shown in Figure 5-8. 
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Figure 5-8: Idealized scheme for protein attachment to PEG-PLGA matrix. 
 
2.2.4 Evaluation of detection methods for surface bound VEGF165 
2.2.4.1 Attenuated Total Reflection- FT-IR Spectroscopy (ATR-FTIR) 
FT-IR measurements were performed on a Tensor 27 FT-IR spectrometer (Bruker 
Optics GmbH, Ettlingen, Germany) using the Miracle ATR unit. In addition, 
measurements were also performed using a Hyperion 3000 FT-IR microscope 
(Bruker Optics GmbH, Ettlingen, Germany) using the ATR object lense. The 
recorded spectra were obtained from 4000 to 900 cm-1 wavenumbers in attenuated 
total reflectance mode at 20°C. Each measurement was the average of 240 scans 
for the Miracle ATR unit and 64 scans in case of the ATR FT-IR microscope. While 
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data acquisition was performed, the optical bench was purged with dry nitrogen to 
reduce interference from water vapour IR absorption and each spectrum was 
corrected for the background. 
 
2.2.4.2 VEGF165 detection using staining methods 
For the detection of surface bound VEGF165, several staining techniques were 
evaluated. Silver staining of the discs was performed using a SilverXPress® Silver 
Staining Kit, Reversible Protein Detection Kit, and Deep Purple™ Total Protein 
Stain. The stained discs were air dried and the coating was analyzed using an 
Axiovert 25 microscope (Zeiss, Göttingen, Germany) using a 200fold magnification 
in case of silver staining and the Reversible Protein Detection Kit. In case of Deep 
Purple™ Total Protein Stain, stained samples were analyzed using the Zeiss LSM 
510 confocal laser scanning microscope (CLSM) (Zeiss, Oberkochen, Germany). 
 
2.2.4.3 Antibody detection 
For VEGF165 detection, discs were incubated with a rabbit Anti-Human VEGF 
antibody in PBS buffer pH 7.4 at 2-8°C over night. Thereafter, discs were rinsed with 
PBS buffer three times to eliminate unbound primary antibody. In a second step, 
samples were incubated with a secondary goat-anti-rabbit antibody Alexa Fluor 488 
for 2 hours at room temperature under exclusion of light. Samples were again 
rinsed with PBS and subsequently analyzed using the Zeiss LSM 510 confocal laser 
scanning microscope (Zeiss, Oberkochen, Germany). 
 
2.2.5 Influence on cell growth by covalent linkage of VEGF165 
2.2.5.1 Vascular endothelial cells 
The influence of discs on the cell growth of vascular endothelial cells was evaluated 
using Human Umbilical Vein Endothelial Cells (HUVECs). HUVECs were prepared 
by digestion of umbilical veins with 0.1 g/l collagenase A. Cells were cultured in 
endothelial cell growth medium supplemented with 10% heat-inactivated fetal 
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bovine serum in a humidified atmosphere at 5% CO2 and 37°C. Cells were used at 
passage no. 3.  
 
2.2.5.2 Rat aortic smooth muscle cells 
The influence of discs on the cell growth of SMCs was evaluated using rat aortic 
SMCs. Cells were cultured in smooth muscle cell growth medium DMEM /F12 
supplemented with 1% heat-inactivated fetal bovine serum in a humidified 
atmosphere at 5% CO2 and 37°C. 
 
2.2.5.3 Cell growth study 
For the study, discs were placed on the bottom of 24-well plates  and subsequently 
covered with a layer of starvation medium in case of HUVECs containing 80% of 
M199 and 20% of endothelial cell growth medium, in case of SMCs 90% of 
DMEM /F12 and 10% heat-inactivated fetal bovine serum. 20,000 viable HUVECs 
or SMCs were seeded per well. Thereafter, cells were cultured in a humidified 
atmosphere at 5% CO2 and 37°C. Cells on the discs were quantified at day 3 using 
Cell Titer-Blue®. Therefore, cells were incubated with Cell Titer-Blue® for 6 hours 
and an aliquot of the supernatant was analyzed using a Spectrafluor plus plate 
reader (Tecan, Crailsheim, Germany) with an excitation wavelength of 550 nm and 
emission recording at 595 nm. The increase in cell growth was calculated as % 
increase in relation to cells grown on coated discs without VEGF165. 
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3 Results and Discussion 
3.1 PLGA modification 
The goal of the PLGA modification was the introduction of a functionalized PEG-
spacer into the PLGA matrix in order to covalently bind VEGF165. It has been shown 
in literature that the use of spacer molecules between the substrate and the 
biomolecule to be attached can be beneficial for the maintenance of the biological 
activity [14-15]. Furthermore, the use of PEG as a spacer might have the advantage 
of increasing the half life of VEGF165 in solution, as seen for other proteins reported 
in literature [16-17] and results in a longer activity, which is a common approach in 
pegylation of therapeutic proteins [18-20].  
In a first attempt to chemically modify PLGA, RG 502H with a molar ratio of 50:50 of 
D,L-lactide to glycolide and an approximate molecular weight of 15,000 Dalton was 
used in combination with a homobifunctional PEG-spacer carrying succinimidyl 
ester for chemical linkage of amine groups that had a molecular weight of 
approximately 2,000 Dalton. The activity of all intermediates carrying succinimidyl 
ester was determined using a modified TNBS assay, and a binding activity of more 
than 90 % was assured before proceeding with synthesis of the following 
intermediates or the final product. For the last reaction step to form functionalized 
PEG-PLGA, the PLGA carrying amine groups was combined with the 
homobifunctional PEG-spacer. The final product was felled in boiling diethyl ether. 
However, the recovery of a solid precipitate was not possible. The product that was 
obtained was a viscous material that did not solidify after desiccation under vacuum 
for several hours and further additional felling steps to ensure the removal of any 
byproducts of the synthesis. 
PEG has been reported to have a plasticizing effect on polymers in the case of 
PLGA:PEG di-block copolymers by lowering their glass transition temperature [30]. 
The plasticizing effect of PEG is based on the reduction of the attractive forces 
among the polymer chains, which leads to a decrease in the attractive forces 
leading to an increase in the mobility of the macrochains, resulting in the decrease 
of the glass transition temperature [31]. Furthermore, studies have shown that in 
dependency of the molecular weight of the PEG and PLGA employed the glass 
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transition temperature of resulting conjugates was drastically decreased [30-32]. In 
one reported case, the combination of PLGA RG 502 with PEG 2000 and 5000 
formed compolymers with glass transition temperatures of 1.2°C and -29.9°C 
respectively [30]. Accordingly, in the case of the combination of the 
homobifunctional PEG-spacer with RG 502H, the plasticizing effect of PEG resulted 
in a decrease of the glass transistion temperature, leading to the viscous product. 
Consequently, for the second approach to synthesize a functional PEG-PLGA 
material, the molecular weight of the PEG used for the synthesis of the PEG-spacer 
was reduced to 600 Dalton. Furthermore, the higher molecular weight PLGA variety 
RG 504H, with a molecular weight of approximately 50,000 Dalton, was used. 
Again, a binding activity of above 90 % was assured before proceeding with 
synthesis of the following intermediates or the final product. The final product was 
successfully felled in boiling diethyl ether and dried under vacuum for several hours. 
The product was a solid, white cluster that could be transformed into a white 
powder. Therefore, it was concluded that the adjustment of molecular weight for 
PEG and PLGA had lowered the plasticizing effect of PEG leading to solid product. 
The final product showed a succinimidyl ester activity of 94.4 % and was stored in a 
desiccator under the exclusion of moisture, due to the moisture sensitivity of the 
functional group. 
Thus, an active PEG-PLGA material was successfully synthesized, but further 
experiments were necessary to show that the activity of the material was 
maintained throughout the coating process. Furthermore, the ability to covalently 
attach VEGF165, while maintaining its biological activity, to the PEG spacer needed 
to be investigated. 
 
3.2 Covalent linkage of VEGF165 to modified PLGA matrices 
3.2.1 Comparison of VEGF165 detection methods 
The successful linkage of VEGF165 was an important prerequisite for further cell 
studies and a reliable method of detection therefore a crucial requirement. In order 
to determine a suitable detection method, commonly used methods for protein 
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detection, such as gel staining methods [33-34], FT-IR spectroscopy for insight into 
secondary structural changes [35], and antibody staining were adapted for the use 
on PLGA matrices and the evaluation of VEGF linkage. 
 
3.2.1.1 FT-IR Spectroscopy 
FT-IR spectroscopy is a commonly used method for the investigation of protein 
secondary structure [35]. This method was anticipated to not only provide 
information about the presence of VEGF165, but could have also been used to 
characterize the protein’s conformational status. Fu et al. were able to demonstrate 
that in case of PLGA microsphere formulations the C=O stretching vibration 
occurring at approximately 1750cm-1 of the PLGA polymer was well separated from 
the typical amid I vibration of proteins occurring at 1600 – 1700 cm-1 [36]. However, 
in our case, no differences between the recorded FT-IR spectra of surface bound 
VEGF165 carrying samples and control samples could be detected (Figure 5-9). This 
was true for either discs coated with activated PLGA as well as PEG-PLGA. In 
general, spectra recorded for PLGA were consistent with literature [37]. 
 (a) 
900190029003900
wavenumber [cm-1]
 
Cell growth stimulation by VEGF165 covalently linked to a modified PLGA-matrix 
 
121 
 (b) 
900190029003900
wavenumber [cm-1]
 
 
Figure 5-9: FT-IR spectra of PEG-PLGA (a) and activated PLGA (b), both with (
900190029003900
wavenumber [cm-1]
PEG-PLGA
PEG-PLGA + VEGF) and 
without (
900190029003900
wavenumber [cm-1]
PEG-PLGA
PEG-PLGA + VEGF
) VEGF165 with adjusted intensity for better comparability. 
 
Spectra recorded using the more site specific and sensitive FT-IR microscope, 
confirmed the previous findings. No differences between blanks and the samples 
carrying VEGF165 could be detected. Figure 5-10 shows a close-up of the spectra 
obtained for PEG-PLGA within the region of 1900 to 1400 cm-1, the region 
commonly allotted to protein secondary structure, especially at 1650 cm-1 assigned 
to α-helical segments and at 1620 cm-1 assigned to intermolecular ß-sheet 
structures [38] were of interest. However, no changes were observable in this 
region, nor throughout the whole spectra. 
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Figure 5-10: FT-IR microscopy spectra of PEG-PLGA with (
900190029003900
wavenumber [cm-1]
PEG-PLGA
PEG-PLGA + VEGF) and without (
900190029003900
wavenumber [cm-1]
PEG-PLGA
PEG-PLGA + VEGF
) VEGF165. 
 
The main reason for the unsuccessful detection of VEGF165 using FT-IR 
spectroscopy is most likely the very low concentrations of protein (10 µg/ml) applied 
on the surfaces, resulting in even lower concentrations bound on the surface. Even 
with the more site specific FT-IR microscopy the sensitivity for this method could not 
be increased to a sufficient level to detect VEGF165. 
 
3.2.1.2 Reversible Protein Detection Kit 
The subsequently applied staining methods were adapted from either gel staining or 
filter staining procedures, more sensitive methods in comparison to FT-IR 
spectroscopy. The Reversible Protein Detection Kit is commonly used to detect 
protein on filter membranes. However, when trying to determine whether the binding 
procedure for VEGF165 on activated PLGA and PEG-PLGA was successful no 
staining could be detected for the coupled discs and the reference material. Thus, 
the covalent conjugation of VEGF165 to the modified PLGA matrices could not be 
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determined. A reason for this phenomenon could be the fact that according to Li et 
al. this rather simple staining method is specific to insoluble protein aggregates on 
membranes and therefore, no single molecules in native state bound on a surface 
could be detected [33]. 
 
3.2.1.3 Silver staining of covalently linked VEGF165 
Silver staining is commonly used for protein detection on SDS-PAGE gels when a 
very high sensitivity is necessary and smallest amounts of protein need to be 
detected, therefore, silver staining could be useful to determine the covalent binding 
of VEGF165 on discs. The staining was carried out on discs coated with PLGA and 
PEG-PLGA both coupled with VEGF165 and placebo, as negative control. The 
microscopic images of the discs carrying VEGF165 (Figure 5-11c and d) showed 
areas of black staining compared to the negative controls (Figure 5-11a and b), 
therefore indicating the presence of protein on the surface of the coated discs. 
Moreover, a difference in intensity can be seen for the samples carrying PEG-PLGA 
and VEGF165 in comparison to those being coated with activated PLGA and carrying 
the protein.  
(a) (b) (c) (d) 
    
Figure 5-11: Microscopic images of silver stained discs coated with activated PLGA without 
VEGF as control (a), PEG-PLGA without VEGF as control (b), activated PLGA incubated with 
10 µg/ml VEGF (c), and PEG-PLGA incubated with 10 µg/ml VEGF (d). 
 
This was a first indicator for the hypothesis that the PEG-spacer is necessary to 
ensure accessibility of the linker presented at the surface to the binding sites within 
the protein structure. Prior findings in literature investigating the influence of spacer 
length on the effect of surface immobilized VEGF on endothelial cells [15], as well 
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as other studies investigating the increase in effectiveness by introduction of 
spacers [39-40] further support this hypothesis. Overall, silver staining provides a 
useful tool to characterize coated discs and to determine the successful linkage of 
protein. However, the detection method is very unspecific. An interference of the 
immobilized PEG-spacer could be ruled out due to previously reported studies that 
employed silver staining to detect protein in PEG environments [41]. 
 
3.2.1.4 Deep Purple™ Total Protein Stain for the detection of VEGF165 
As an alternative, Deep Purple™ Total Protein Stain was used to stain PEG-PLGA 
coated discs incubated with buffer and VEGF165 (c = 10 µg/ml), in order to 
determine the successful linkage of the cytokine to the modified PEG-PLGA matrix. 
Deep PurpleTM is a naturally occurring compound, epicocconone, extracted from the 
fungal species Epicoccum nigrum. Epicocconone reacts reversibly with primary 
amines in proteins and the result is a highly fluorescent enamine [34]. The stain is 
commonly used for gel staining and has been shown to be more sensitive towards 
proteins in comparison to other commercially available gel stains. 
(a)        (b) 
   
Figure 5-12: CLSM images of Deep Purple™ stained discs coated with PEG-PLGA without 
VEGF as control (a) and PEG-PLGA incubated with 10 µg/ml VEGF (b). 
 
Figure 5-12 shows the CLSM images for the samples incubated with buffer as 
control and VEGF165. For the samples incubated with the cytokine, a stronger 
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fluorescence could be detected, however a slight fluorescence was also observed 
for the control samples. Since the Deep PurpleTM stain is a rather unspecific stain 
interacting with primary amines an unspecific interaction with other adsorbed 
proteins or unmodified primary amines, in the PEG-PLGA backbone that might have 
resulted from incomplete modification can not be ruled out. Therefore, the Deep 
PurpleTM Total Protein Stain was another indicator for the linkage of VEGF165, but 
could not provide final proof. 
 
3.2.1.5 Antibody detection of covalently linked VEGF165  
In order to further characterize and to provide final proof of linkage of VEGF to the 
coated discs, a more specific approach was required. Therefore, a staining 
procedure utilizing a VEGF-specific antibody was established. Preliminary results 
(Figure 5-13) with the antibody detection performed on PEG-PLGA coated discs 
coupled with and without VEGF165 using the primary and secondary antibody 
indicated a good specificity of the employed method towards the coated and 
coupled discs and gave first evidence of the sustained integrity of the attached 
protein. 
 (a)        (b) 
   
Figure 5-13: CLSM images of antibody stained discs coated with PEG-PLGA incubated 
without VEGF as control (a) and PEG-PLGA incubated with 10 µg/ml VEGF (b). 
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However, further investigations, including control experiments with unmodified 
PLGA coated discs (Figure 5-14), suggested unspecific protein adsorption. Samples 
coated with PLGA and incubation with VEGF165 and samples coated with PLGA and 
incubation with PBS buffer, stained with both antibodies, showed fluorescence in 
CLSM (Figure 5-14 a and b). However, samples coated with PLGA, incubation with 
VEGF165, and detection with solely the secondary antibody did not show 
fluorescence (Figure 5-14 c). These findings support the theory of unspecific protein 
adsorption of either VEGF165 or the primary anti-human-VEGF antibody on the 
surface of the unmodified PLGA, since there seemed to be no unspecific interaction 
of the secondary antibody. 
 (a)     (b)     (c) 
   
Figure 5-14: CLSM images of antibody stained discs coated with PLGA without VEGF as 
control (a), PLGA incubated with 10 µg/ml VEGF (b), and PLGA incubated with 10 µg/ml VEGF 
as control using only the secondary antibody (c). 
 
To further identify and investigate these findings, control experiments using BSA 
solutions to block unspecific adsorption of VEGF165 or the detection antibodies were 
performed. Therefore, the following incubations (Table 5-1) and analysis were 
performed and evaluated using CLSM. 
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Table 5-1: Overview of incubation and detection procedures for the evaluation of unspecific 
adsorption on PEG-PLGA and PLGA coated discs and order of incubation for PLGA-04 and 
PLGA-05, as well as PEG-PGLA-04 and PEG-PLGA-05. 
 incubation solution detection antibodies 
Sample PBS 
VEGF165 
[20 µg/ml] 
BSA 
[1 mg/ml] 
anti-VEGF 
goat-anti-
rabbit 
PLGA-01  X  X X 
PLGA-02 X   X X 
PLGA-03  X   X 
PLGA -04  1.) X 2.) X X X 
PLGA-05  2.) X 1.) X X X 
PLGA-06   X X X 
PLGA-07   X  X 
PEG-PLGA-01  X  X X 
PEG-PLGA-02 X   X X 
PEG-PLGA-03  X   X 
PEG-PLGA-04  1.) X 2.) X X X 
PEG-PLGA-05  2.) X 1.) X X X 
PEG-PLGA-06   X X X 
PEG-PLGA-08   X  X 
 
PLGA coated samples showed a strong fluorescence for several of the incubated 
samples. A very high fluorescence could be seen for the samples incubated with 
VEGF165, PBS buffer, and those incubated with BSA solutions and VEGF165 
subsequently (Figure 5-15 a, b and e). A slightly lower fluorescence could be 
detected for the samples incubated with VEGF165 and subsequently BSA (Figure 5-
15 d). The sample incubated with BSA, on the other hand, showed an irregular 
pattern of fluorescence, displaying areas of no intensity (Figure 5-15 g) or areas of 
spotted intensity (Figure 5-15 f). The control samples incubated with VEGF165 and 
BSA (Figure 5-15 c and g), for which only the interaction of the secondary antibody 
was evaluated, showed no significant fluorescence.  
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(a) (b) (c) (d) 
    
(e) (f) (g) (h) 
    
Figure 5-15: CLSM images of antibody stained discs PLGA-01 (a), PLGA-02 (b), PLGA-03 (c), 
PLGA-04 (d), PLGA-05 (e), PLGA-06.1 (f), PLGA-06.2 (g), and PLGA-07 (h). 
 
Therefore, it can be concluded that there was no unspecific interaction of the 
secondary goat-anti-rabbit antibody with the surfaces, since no fluorescence could 
be observed for the samples treated solely therewith. However, there was an 
interaction observed for the anti-VEGF-antibody with the surface which can be 
clearly seen by the high fluorescence of the sample being incubated with buffer 
alone and to a lesser degree the sample being incubated with BSA. The interaction 
of VEGF165 with the unmodified PLGA matrix could not be assessed. The unspecific 
interaction of the primary anti-VEGF-antibody made it impossible to determine the 
origin of the fluorescence, whether it was due to the antibody interacting with 
VEGF165 or solely with the surface. The sample incubated with BSA and 
subsequently with VEGF165 could be seen as a first indicator for the interaction of 
VEGF165 with the surface. The increased fluorescence compared to the sample 
solely incubated with PBS buffer must have originated from VEGF165 adsorbed onto 
the PLGA surface since an interaction of the primary antibody with the surface can 
be eliminated due to the prior incubation with BSA. The incubation with BSA could 
be shown to lower the unspecific interaction of the primary antibody. However, it 
was not possible to eliminate the interaction entirely. 
Cell growth stimulation by VEGF165 covalently linked to a modified PLGA-matrix 
 
129 
(a) (b) (c) (d) 
    
(e) (f) (g)  
   
 
Figure 5-16: CLSM images of antibody stained discs PEG-PGLA-01 (a), PEG-PLGA-02 (b), 
PEG-PLGA-03 (c), PEG-PLGA-04 (d), PEG-PLGA-05 (e), PEG-PLGA-06 (f), and PEG-PLGA-07 
(g). 
 
Images obtained using CLSM for the samples coated with PEG-PLGA, on the other 
hand, were in accordance with previous findings and could not support the theory of 
unspecific protein binding on the surface of the coatings in contrast to the results 
obtained for PLGA matrices. The control samples using only the secondary 
detection antibody (Figure 5-16 c and g) exhibited no fluorescence, as well as the 
samples incubated with BSA solutions and PBS buffer detected with both antibodies 
(Figure 5-16 b and f). These findings are in accordance with literature, where the 
influence of PEG to modify the cell and protein adhesive properties has been 
investigated. It has been shown that the incorporation of PEG into polymer and 
biomaterial surfaces can decrease the unspecific adhesion of proteins, but allowed 
a controlled attachment of cells [42-44]. The samples incubated with BSA solution 
and subsequently VEGF165 showed slight fluorescence, indicating the existence of 
still active functional groups that are able to couple VEGF165 even after the 
incubation with BSA, in contrary to literature, where half lives of succinimidyl esters 
of less than 30 minutes are documented [45]. Samples incubated with VEGF165 and 
those additionally treated with BSA demonstrated a strong fluorescence (Figure 5-
16 a and d). 
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Therefore, it can be concluded, that a successful linkage of VEGF165 to the modified 
PLGA-matrix was accomplished. Furthermore, unspecific adsorption of VEGF on 
the PEG-PLGA matrix could be ruled out and more importantly, the integrity of 
VEGF165 throughout the preparation process was conserved, as seen by successful 
binding of the anti-VEGF antibody. 
 
3.2.2 Influence of PLGA coating concentration on VEGF165 linkage 
Since the main objective of the present study was to investigate the effect of 
covalently attached VEGF on endothelial cells and smooth muscle cells, rather than 
to examine the dose-dependent effects of immobilized VEGF, the goal was to bind a 
maximal amount of VEGF on the surface. Therefore, in order to elucidate the effect 
of coating thickness or ablation of PEG-PLGA on the effectiveness of VEGF linkage, 
as well as to identify the conditions for maximum VEGF attachment, PTFE discs 
were coated with varying concentrations of PEG-PLGA. The coating solutions had a 
concentration of 0.1, 0.5, 1.0 and 3.0 % of PEG-PLGA in dichloromethane. 
Subsequently, all discs were incubated with VEGF165 solution (20 µg/ml) or PBS-
buffer. The bound VEGF165 was detected with the antibody detection method as 
described above (compare 2.2.4.3). 
The images that were obtained using CLSM (Figure 5-17) showed an increase in 
fluorescence with increasing concentration of PEG-PLGA that was used to coat the 
samples up to 1.0 %. The fluorescence reached a maximum for the samples coated 
with 1.0 % PEG-PLGA that was not further increased when increasing the 
concentration to 3.0 %. 
(a) (b) (c) (d) 
    
Figure 5-17: CLSM images of antibody stained discs coated with 0.1% (a), 0.5% (b), 1.0% (c), 
and 3.0% (d) PEG-PLGA and subsequent incubation with 20.0 µg/ml VEGF165. 
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An increase in fluorescence observed in CLSM has a direct correlation with the 
amount of VEGF bound on the surface of the matrices. Since a maximum coverage 
of the surface with VEGF seems favorable to ensure a lasting effect of the cytokine 
during incubation and cell growth experiments, the coatings with the highest 
fluorescence observed appeared advantageous over the one’s with lower 
fluorescence. Furthermore, in order to eliminate the risk of ablation of coating due to 
increased coating thickness, it was decided to proceed with the 1 % PEG-PLGA 
concentration for the further studies. 
 
3.2.3 Influence of VEGF165 concentration on the linkage procedure 
A second parameter investigated was the effect of VEGF165 concentration in the 
incubation solutions on VEGF binding. Again, the goal was to achieve good linkage 
efficiency with maximum coverage of the PEG-PLGA surface with VEGF. Therefore, 
discs were coated with PEG-PLGA in dichloromethane (compare 2.2.2) with a 
concentration of 1 % (w/v), and incubated for 30 minutes with varying 
concentrations of 2.0, 10.0, and 20.0 µg/ml VEGF165 and analyzed using the 
antibody detection method. 
 (a)     (b)     (c) 
   
Figure 5-18: CLSM images of antibody stained PEG-PLGA discs incubated with 2.0 µg/ml (a), 
10.0 µg/ml (b), and 20 µg/ml (c). 
 
No clear difference in fluorescence between the samples incubated with 2.0 and 
10.0 µg/ml were detectable (Figure 5-18 a and b), but the fluorescence seemed to 
intensify for the samples incubated with 20 µg/ml VEGF165 (Figure 5-18 c) 
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suggesting better linkage efficiency. Consequently, since the goal was to bind a 
maximal amount of VEGF on the PEG-PLGA surfaces, rather than to examine the 
dose-dependent effects of immobilized VEGF, it was decided to perform all further 
linkage experiments with a concentration of VEGF165 in the incubation solution of 
20 µg/ml. 
 
3.3 Influence of covalently linked VEGF165 on cell growth 
3.3.1 Vascular endothelial cells 
In order to evaluate the activity of the covalently linked VEGF165 and therewith the 
accessibility of the VEGF surface receptor (VEGFR-1) [15, 22] on the endothelial 
cells towards the covalently linked protein, cell growth studies were performed. In 
addition, these experiments were also meant to give further insight into the 
necessity of internalization of the receptor complex in order for the cytokine to 
stimulate proliferation of the cells, as described before in literature [9-11]. 
Additionally, several control experiments were performed to elucidate the effect of 
loosely adsorbed protein on the surface of unmodified coated discs. Therefore, 
PLGA and PEG-PLGA coated discs were treated with different incubation solutions 
in accordance to Table 5-2 and immediately thereafter rinsed and incubated with 
endothelial cells. After a 3 day incubation period, cells were quantified using Cell 
Titer-Blue®. The increase in cell growth was calculated as % increase in relation to 
the amount of cells grown on the PLGA and PEG-PLGA coated discs incubated with 
PBS buffer. 
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Table 5-2: Overview of incubation solutions for the evaluation of endothelial cell growth on 
PEG-PLGA and PLGA coated discs and order of incubation solutions applied. 
 incubation solution 
Sample PBS buffer 
VEGF165 
[20 µg/ml] 
BSA 
[1 mg/ml] 
PLGA (control) X   
PLGA (VEGF)  X  
PLGA (BSA)   X 
PLGA (BSA + VEGF)  2.) X 1.) X 
PLGA (VEGF + BSA))  1.) X 2.) X 
PEG-PLGA (control) X   
PEG-PLGA (VEGF)  X  
PEG-PLGA (BSA)   X 
PEG-PLGA (BSA + VEGF)  2.) X 1.) X 
PEG-PLGA (VEGF + BSA))  1.) X 2.) X 
 
The results showed an increase in cell growth for PLGA coated discs incubated with 
VEGF165 of around 30% compared to the discs incubated with buffer alone (Figure 
5-19). The same increase in cell growth was detected for PLGA coated discs 
incubated with BSA and VEGF165 subsequently. This leads to the conclusion that 
BSA could not be used to block all unspecific adsorption of VEGF165 on the PLGA 
surface. PLGA discs incubated with BSA alone showed an extent of cell growth 
comparable to the discs incubated with buffer solely, therefore, eliminating an 
interference of BSA with the cell growth study. Investigations reported in literature 
for hydrophobic and hydrophilic surfaces came to the conclusion that the incubation 
procedure for BSA, especially such parameters as concentration and incubation 
time, had a strong influence on the blocking efficiency [46-47], which leads to the 
conclusion that the incubation conditions chosen for this setting needed further 
optimization. Furthermore, it has been reported that incubation of BSA only blocked 
50 % of unspecific binding sites on hydrophobic surfaces [48] under various 
incubation conditions. Discs coated with PLGA incubated with VEGF165 and 
subsequently with BSA showed an increase in cell growth comparable to the 
aforementioned discs. Therefore, all variations of incubation solutions containing 
VEGF165 on PLGA coated discs showed comparable cell growth increase for 
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endothelial cells. Therefore, these results suggested an insufficient blockage of 
unspecific binding sites by BSA, which might have caused unspecific interaction of 
the cytokine VEGF165 with the unmodified surface, leading to the increase in cell 
growth. 
The modified PEG-PLGA discs that were incubated with VEGF165 also showed an 
increase in cell growth. The effect was more pronounced as compared to the 
unmodified PLGA discs incubated with the same solution. VEGF165 coupled PEG-
PLGA discs exhibited a cell growth increase of approximately 50%, 20% more than 
the unmodified species. The same holds true for the PEG-PLGA discs incubated 
with VEGF165 and subsequently BSA and vice versa. No differences could be 
observed for the order of incubation for VEGF165 and BSA. It was expected to see a 
lower cell growth increase for the samples first incubated with BSA, due to 
inactivation of the active binding site for VEGF165. Yet, this observation was not 
made, which leads to the proposition that the incubation time with BSA was not 
sufficient to inactivate the PEG-PLGA coating, which was therefore still carrying 
functional groups able to bind to VEGF165. This was already observed in previous 
experiments when determining the linking sufficiency by antibody detection 
(compare 3.2.1.5). The surface charge of the different reaction partners under the 
chosen conditions might have influenced the efficiency of the linkage. BSA exhibits 
a negative surface charge [49], in contrast to VEGF, which has a positive charge at 
the chosen pH [50]. Taking into consideration that PLGA is reported to have a 
negative overall charge due to its carboxylic groups [51] at physiological pH, the 
repulsion between the also negatively charged BSA might have led to a decrease in 
linking efficiency and thus leading to residual active functional groups able to bind 
VEGF165. Furthermore, PEG-PLGA coated discs incubated with BSA alone 
exhibited a cell growth increase of approximately 20 % compared to the control 
group grown on PEG-PLGA. This difference might be attributed to the cell repellent 
properties of PEG [52-53] present on the control group. These repellent properties 
might have been compensated by the covalent attachment of BSA leading to an 
increased cell growth. 
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Figure 5-19: Endothelial cell growth on PLGA (
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These results indicate an unspecific interaction of the cytokine VEGF165 with 
unmodified PLGA matrices and an adjunctive increase in cell growth. In addition, it 
was shown that the incubation with BSA was not able to block unspecific adsorption 
on unmodified PLGA, as well as linkage of VEGF165 on PEG-PLGA, as was already 
seen for earlier investigations using the antibody staining method (compare 3.2.1.5) 
However, the linkage of VEGF165 to modified PLGA matrices shows superiority over 
this unspecific effect, which can be seen by an increased cell growth. Covalent 
attachment of VEGF165 did not interfere with the mechanism of action, as seen by 
the stimulation of endothelial cell growth increase, which was in accordance with 
findings reported in literature [15]. VEGF165 was still capable to interact with the 
endothelial cell receptor and stimulate proliferation. Yet, it is still unclear whether 
VEGF165 had to be separated from the PEG-PLGA back bone through degradation 
or digestion to be internalized to show an effect as reported in literature [9-11], or 
was able to activate the proliferation while still being attached to the surface [15]. 
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3.3.2 Cell growth comparison study for smooth muscle and endothelial cells 
In order to further elucidate the influence of the coupled VEGF165 on other cells, a 
further study was initiated to investigate the effect on SMCs in comparison to 
endothelial cells. Therefore, discs were coated with PLGA and PEG-PLGA and 
subsequently incubated in buffer, BSA or VEGF165. The samples were intensely 
rinsed after incubation and consequently incubated with endothelial cells and 
smooth muscle cells according to 2.2.5.3. After a 3 day incubation period, cells were 
quantified using Cell Titer-Blue®. The increase in cell growth was calculated as % 
increase in relation to the amount of cells grown on the PLGA and PEG-PLGA 
coated discs incubated with PBS buffer. 
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Figure 5-20: Endothelial and smooth muscle cell growth on PLGA (
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Figure 5-20 shows the effect on endothelial and smooth muscle cell growth for the 
PLGA and PEG-PLGA samples incubated with buffer, BSA, and VEGF165. As 
described before (compare 3.3.1), an increase in cell growth could be detected for 
the samples incubated with VEGF165. The increase for PLGA after incubation with 
VEGF165 was in accordance with previous findings (compare 3.3.1), most likely 
originating from unspecific interaction of VEGF with the PLGA matrix. Furthermore, 
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cell growth on discs incubated with BSA alone was also in accordance with previous 
findings (compare 3.3.1). 
The cell growth for the SMCs on the other hand showed no increase for all PEG-
PLGA discs independent of the incubation solution and an increase of 10 % for PLGA 
discs incubated with BSA and VEGF165. The superiority of the PEG-PLGA material in 
contrast to the PLGA matrices towards the reduction of SMC growth might be 
attributed to the cell-adhesion-resistant properties of PEG [54-55]. In case of 
endothelial cells, these adhesion-resistant-properties might have been overcome by 
the stimulating effect of the coupled VEGF165 [25]. Thus, the cell growth comparison 
study successfully demonstrated the beneficial effect of VEGF165 coupled PLGA 
matrices, PEG-PLGA matrices in particular, for the stimulation of endothelial cell 
growth. In addition, the slight decrease of SMC growth for the PEG-modified PLGA 
matrices provides an additional benefit of the PEG-PLGA matrices for the coating of 
vascular grafts to specifically enhance endothelial cell growth without stimulating 
SMC growth that is commonly attributed with vascular graft complications, such as 
neointimal hyperplasia [4, 56]. 
Chapter 5 
 
138 
4 Conclusions 
A functionalized PLGA polymer carrying a PEG-spacer with an activated 
succinimidyl ester was successfully synthesized. It was shown that this 
functionalized PEG-PLGA was able to covalently bind VEGF165 using several 
staining techniques, such as silver staining and Deep PurpleTM Total Protein Stain. 
Other techniques, for example FT-IR spectroscopy, which could have provided 
additional information about conformational changes of the protein in its bound state 
if successful, could not determine the presence of bound cytokine due to the low 
concentrations applied on the surface. However, another VEGF specific method, an 
antibody staining, could be developed to determine the presence of VEGF165 on the 
modified surface and thereby confirming successful linkage of the cytokine to the 
effectively modified PLGA matrix. The interaction of the bound VEGF165 with the 
antibody was a first indicator of the sustained functionality of the cytokine. 
The modified PLGA matrix was used to coat model substrates, was subsequently 
coupled with VEGF165, and was tested in several cell assays to investigate its effect 
on endothelial cells and smooth muscle cells. Covalently attached VEGF had a 
positive effect on the growth of endothelial cells. The effect was superior to effects 
for loosely adsorbed VEGF165 on PLGA matrices that were observed during the 
investigations. Furthermore, PEG-PLGA could be shown to have a limiting effect on 
the proliferation of SMCs, due to its cell-adhesion-resistant properties, in 
comparison to unmodified PLGA, therefore, adding to the beneficial properties of 
the modified PLGA material. Thus, successful attachment of VEGF165 could be 
shown whilst preserving the biological activity and endothelial cell specific growth 
stimulation. Moreover, it was shown, that the irreversible linkage of VEGF165 still 
allowed for interaction of VEGF165 with its receptor. 
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Abstract 
The effect of covalently attached Vascular Endothelial Cell Growth Factor (VEGF165) 
to a modified collagen matrix on the growth of endothelial and smooth muscle cells 
(SMCs) was investigated. Therefore, collagen coated substrates were modified 
using a homobifunctional polyethylene glycol (PEG) spacer and VEGF165 was 
covalently attached. A method for the detection of small amounts of attached protein 
was established, using an anti-human VEGF antibody. Successful binding of the 
protein and optimization of coating and coupling procedures could be shown. 
In addition, in vitro cell growth experiments were performed to determine the effect 
of bound VEGF165 on the cell growth of endothelial cells and smooth muscle cells. 
The biological activity of VEGF165 was sustained, which was shown by the 
substantial growth increase of endothelial cells in comparison to control samples. 
Furthermore, the effect on SMCs was investigated and an unchanged growth 
behavior of SMCs was observed when grown on VEGF coupled matrices. It was 
also shown that the linkage and functionality of VEGF165 to the collagen matrix was 
sustained, even after incubation in buffer medium for more than 24 hours, indicating 
a prolonged stability of the attached protein in vitro. Therefore, successful 
attachment of VEGF165 was shown while preserving biological activity and 
endothelial cell specific growth stimulation. 
Keywords: Collagen, VEGF, vascular graft, endothelial cell, covalent linkage, PEG 
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1 Introduction 
The main objective of tissue engineering is the regeneration or replacement of cells 
or biological material and therewith the function formerly performed by the tissue [1]. 
However, after implantation of biomaterial surfaces in a body, the body generally 
identifies these surfaces as foreign objects resulting in a repair response rather than 
a regenerative response [2], which causes severe problems especially in case of 
vascular grafts [3-5]. A manifold of approaches to overcome these problems have 
been investigated, among others, the chemical attachment of proteins to biomaterial 
surfaces [6-8]. For the chemical attachment, functional groups present within the 
sequence of proteins, such as amino, carboxyl [9], and aldehyd groups [7] are 
commonly used. VEGF165, the predominant isoform from the VEGF family [10], 
carries these functional groups within its sequence and makes it accessible for 
covalent attachment to biomaterials. VEGF165, a 42 kDa protein, has been widely 
investigated for the controlled release and use in artificial graft applications [6, 8, 
11]. VEGF is involved in several endothelial cell specific activities, such as 
proliferation and migration [12], at the same time limiting the mitogen-induced 
vascular SMC proliferation [13]. Therefore, it seems a very promising approach for 
the improvement of vascular grafts by controlled presentation of VEGF165 at the 
graft surface by chemically attaching the protein to a modified matrix. 
Collagen has been widely used in biomaterial applications [14-16] due to its 
biocompatibility and degradation products that can be metabolized and excreted 
[17]. It is a well tolerated substrate for endothelial cell growth, which can be seen by 
its previous use in vascular graft applications [18-20]. In contrast to PLGA 
investigated in Chapter 5, collagen represents a naturally occurring polymer in 
mammals representing almost 30% of total protein present in a body [21]. 
Therefore, collagen constitutes an interesting and promising approach for the 
chemical modification and the covalent attachment of VEGF165. 
The main goal of this study was to prove a successful covalent linkage of VEGF165 
on collagen matrices while maintaining its biological activity in order to specifically 
stimulate endothelial cell growth without stimulation of other cells. For the 
attachment, the use of a homobifunctional PEG-spacer was investigated. Therefore, 
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first studies focused on the evaluation of an antibody staining method previously 
developed to detect VEGF attached to PLGA matrices (compare Chapter 5) to 
determine the successful linkage, an important precondition for the cell growth 
investigations. Furthermore, the results were to be used to optimize linkage 
conditions. More importantly, the cell compatibility of the modified collagen material 
and the preservation of the biological activity of the attached VEGF were evaluated. 
Therefore, their effect on HUVECs and SMCs was investigated  
 
2 Materials and Methods 
2.1 Materials 
VEGF165 was kindly donated by Genentech (San Francisco, CA, USA), rat aortic 
smooth muscle cells were kindly gifted by PD Dr. Wolgang Erl (Institut für 
Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Ludwig-Maximilians-
Universität München, Munich, Germany), and equine collagen type I derived from 
tendon provided as lyophilized material was provided by Innocoll GmbH 
(Saal/Donau, Germany). O,O′-Bis(2-amino-propyl) polyethylene glycol (PEG(NH2)2) 
with a molecular weight of 500 Da, succinic anhydride, N-Hydroxysuccinimide 
(NHS), N,N'-Dicyclohexyl-carbodiimide (DCCI), dimethyl sulfoxide, 2,4,6-
Trinitrobenzenesulfonic acid solution (TNBS), and Bovine Serum Albumin (BSA) 
were purchased from Sigma (Steinheim, Germany), toluene, diethyl ether, and 
glacial acetic acid from Merck KGaA (Darmstadt, Germany), triethylamine, 
dichloromethane, ethanolamine, cover glasses, plastic petri dishes from VWR 
(Darmstadt, Germany), polytetrafluoro-ethylene (PTFE) from GM GmbH (Freiham, 
Germany), goat-anti-rabbit antibody Alexa Fluor 488 from Invitrogen (Karlsruhe, 
Germany), rabbit Anti-Human VEGF antibody from Pepro Tech GmbH (Hamburg, 
Germany), collagenase A from Roche (Penzberg, Germany), endothelial cell growth 
medium from Provitro (Berlin, Germany), heat-inactivated fetal bovine serum from 
Biochrom (Berlin, Germany), smooth muscle cell growth medium DMEM /F12 and 
M199 from PAA (Pasching, Austria), 24-well plates from TPP Techno Plastic 
Products (Trasadingen, Switzerland), and Cell Titer-Blue® from Promega (Madison, 
WI, USA). 
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The pH of the solutions was adjusted using hydrochloric acid or sodium hydroxide 
from Merck KGaA (Darmstadt, Germany) and measured with a pH meter Inolab 
level 1 from WTW (Weilheim, Germany). 
 
2.2 Methods 
2.2.1 Synthesis of PEG-spacer 
A bifunctional PEG-spacer was synthesized using O,O′-Bis(2-aminopropyl) 
polyethylene glycol (PEG(NH2)2) with a molecular weight of 500 Da as starting 
material. In a first reaction step (Figure 6-1), the amine groups of the PEG were 
modified into carboxylic groups using succinic anhydride. The reaction was carried 
out in anhydrous toluene with the addition of triethylamine at room temperature over 
night. 
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Figure 6-1: Reaction mechanism for the synthesis of PEG-(COOH)2. 
 
The resulting functionalized PEG carrying two carboxylic groups was subsequently 
activated (Figure 6-2) using NHS and DCCI. The reaction was carried out in 
anhydrous dichloromethane at 0°C for 3 hours and subsequently at room 
temperature over night. The product was recovered and purified by precipitation in 
cold diethyl ether. The final compound was desiccated under vacuum for several 
hours and the activity was determined by a TNBS assay (compare 2.2.2). 
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Figure 6-2: Reaction mechanism for the synthesis of PEG-(NHS)2. 
 
2.2.2 TNBS assay 
The degree of ability of the activated species of the PEG-spacer to couple with 
primary amines within protein sequences was determined using a modified assay 
according to Snyder et al [22]. Therefore, the activated species were dissolved in 
anhydrous DMSO and were coupled with the primary amine of ethanolamine 
(Figure 6-3). 
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Figure 6-3: Conjugation reaction of activated species with ethanolamine. 
 
In a next step, the free ethanolamine was quantified using TNBS in a 0.1 M borate 
buffer pH 8.3. The yellow conjugate formed (Figure 6-4) was quantified via UV-
spectroscopy at 420 nm using the Agilent 8453 (Agilent Technologies, Böblingen, 
Germany). The degree of activation was calculated as percentage of coupled 
ethanolamine compared to reference samples containing no activated species. 
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Figure 6-4: Quantification reaction for free ethanolamine. 
 
2.2.3 Collagen coating procedure 
2.2.3.1 Preparation of collagen dispersion 
The collagen dispersion was prepared by redispersion of equine collagen type I 
derived from tendon in water at 1% (w/w). The pH was adjusted to 3.5 using glacial 
acetic acid. Swelling was performed at room temperature for 4 hours with dispersion 
for 60 s using an Ultraturrax® (IKA®-Werke GmbH Co. KG, Staufen, Germany) every 
30 minutes at 10,000 rpm and an additional dispersion step at the end of the 
swelling period of 3 minutes at 10,000 rpm. The dispersion was then centrifuged at 
5,000 rpm at 10°C for 10 minutes using a Sigma 4 K15 lab centrifuge (Sigma, 
Osterode, Germany) to remove air bubbles from the dispersion. Thereafter, the 
dispersion was used for the coating (compare 2.2.3.2) or stored at 2-8°C until 
further use. 
 
2.2.3.2 Coating procedure 
The collagen dispersion (compare 2.2.3.1) was used to coat PTFE-discs, argon 
plasma activated with a plasmabrush® (Reinhausen Plasma GmbH, Regensburg, 
Germany) or cover glasses, both with a diameter of 15 mm. Therefore, the discs 
were placed in 55 mm petri dishes and covered with 150 µl of collagen dispersion. 
The discs were air dried for one hour and subsequently dried under vacuum over 
night or until further use. For the cell culture studies, all these procedures were 
performed under a laminar flow workbench (Thermo, Langenselbold, Germany). 
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2.2.4 VEGF165 linkage 
2.2.4.1 PEG-spacer coupling 
In order to attach the bifunctional PEG-spacer to the free amino groups on the 
collagen matrix, the dried collagen covered discs were placed in an aluminum 24-
well plate and covered with a 1% (w/v) solution of the PEG-spacer in anhydrous 
dichloromethane for 30 minutes at room temperature under gentle shaking. The 
derivatization reaction is shown in Figure 6-5. 
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Figure 6-5: Idealized scheme for PEG-spacer attachment to collagen matrix. 
 
The evaporated dichloromethane was replaced with fresh solvent if drying of the 
discs was anticipated. After 30 minutes the dichloromethane was removed by 
aspiration and the discs were washed with fresh dichloromethane in order to 
remove unbound PEG-spacer. Thereafter, discs were dried under vacuum for 
several hours. For the cell culture studies, all these procedures were performed 
under a laminar flow workbench. 
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2.2.4.2 VEGF165 linkage procedure 
For the linkage of VEGF165, collagen and PEG-collagen coated discs were 
transferred to plastic petri dishes and covered with VEGF165 in phosphate buffered 
saline (PBS) buffer pH 7.4 for 30 minutes. Reference samples not carrying VEGF165 
were treated with either PBS buffer alone or with PBS containing 1 mg/ml BSA to 
block unspecific binding. After the incubation, the discs were intensely washed in 
Milli-Q water and stored in PBS buffer for immediate use. For the cell culture 
studies, all these procedures were performed under a laminar flow workbench. The 
approach for protein attachment is shown in Figure 6-6. 
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Figure 6-6: Idealized scheme for protein attachment to PEG-collagen matrix. 
 
2.2.5 Antibody detection of surface bound VEGF165 
For VEGF165 detection discs were incubated with a rabbit Anti-Human VEGF 
antibody in PBS buffer pH 7.4 at 2-8°C over night. Thereafter, discs were rinsed with 
PBS buffer three times to eliminate unbound primary antibody. In a second step, 
samples were incubated with a secondary goat-anti-rabbit antibody Alexa Fluor 488 
for 2 hours at room temperature under exclusion of light. Samples were again 
rinsed with PBS and subsequently analyzed using the Zeiss LSM 510 confocal laser 
scanning microscope (CLSM) (Zeiss, Oberkochen, Germany). 
 
Cell growth stimulation by covalent linkage of VEGF165 to a modified collagen-matrix 
 
151 
2.2.6 Influence of covalently linked VEGF165 on cell growth 
2.2.6.1 Vascular endothelial cells 
The influence of discs on the cell growth of vascular endothelial cells was evaluated 
using Human Umbilical Vein Endothelial Cells (HUVECs). HUVECs were prepared 
by digestion of umbilical veins with 0.1 g / l collagenase A. Cells were cultured in 
endothelial cell growth medium supplemented with 10% heat-inactivated fetal 
bovine serum in a humidified atmosphere at 5% CO2 and 37°C. Cells were used at 
passage no. 3.  
 
2.2.6.2 Aortic smooth muscle cells 
The influence of discs on the cell growth of SMCs was evaluated using rat aortic 
smooth muscle cells. Cells were cultured in smooth muscle cell growth medium 
DMEM /F12 supplemented with 1% heat-inactivated fetal bovine serum in a 
humidified atmosphere at 5% CO2 and 37°C. 
 
2.2.6.3 Cell growth comparison study 
For the study discs were placed on the bottom of 24-well plates and subsequently 
covered with a layer of starvation medium in case of HUVECs containing 80% of 
M199 and 20% of endothelial cell growth medium, in case of SMCs 90% of 
DMEM /F12 and 10% heat-inactivated fetal bovine serum. 20,000 viable HUVECs 
or SMCs were seeded per well. Thereafter, cells were cultured in a humidified 
atmosphere at 5% CO2 and 37°C. Cells on the discs were quantified at day 3 using 
Cell Titer-Blue®. Therefore, cells were incubated with Cell Titer-Blue® for 6 hours 
and an aliquot of the supernatant was analyzed using a Spectrafluor plus plate 
reader (Tecan, Crailsheim, Germany) with an excitation wavelength of 550 nm and 
emission recording at 595 nm.  
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3 Results and Discussion 
3.1 Covalent VEGF165 linkage to modified collagen matrices 
In order to evaluate the effect of modified collagen matrices on cell growth, it was 
important to evaluate the successful linkage of VEGF165. Therefore, a previously 
identified and optimized antibody staining method (compare Chapter 5) was first 
evaluated towards its suitability to detect surface bound VEGF165 on collagen 
matrices. Furthermore, it was used to evaluate the coating procedure and to rule out 
unspecific adsorption of VEGF. 
 
3.1.1 Evaluation of antibody staining method 
For the evaluation of the antibody staining method, PEG-Collagen coated discs 
were incubated with buffer as control sample and VEGF165 solution with a 
concentration of 20 µg / ml for 30 minutes. The discs were subsequently stained 
and investigated using CLSM.  
 
 (a)     (b)     (c) 
   
Figure 6-7: CLSM images of antibody stained collagen coated discs for PEG-Collagen control 
(0 µg/ml VEGF) (a), PEG-Collagen VEGF (20 µg/ml) secondary antibody only (b), and PEG-
Collagen VEGF (20 µg/ml) (c). 
 
The obtained images shown in Figure 6-7 indicated successful linkage of VEGF165 
to the PEG-Collagen matrix, which can be seen by the fluorescence of the 
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secondary antibody in Figure 6-7c compared to the considerably lower fluorescence 
of the control sample seen in Figure 6-7a. In addition, the interaction of the 
secondary antibody with either VEGF165 or the PEG-Collagen matrix could be 
excluded, as seen by the lack of fluorescence for the sample only incubated with 
this antibody (Figure 6-7b). Therefore, it could be concluded that the previously 
established antibody staining method was also suitable to detect VEGF on collagen 
matrices. It also indicated the successful preservation of biological activity of VEGF, 
covalently attached to the collagen surface, throughout the preparation procedure. 
 
3.1.2 Analysis of the linkage procedure of VEGF to PEG-Collagen 
In order to further evaluate the suitability of the antibody detection method to identify 
bound VEGF165 on the surface of the collagen matrix, a set of control experiments 
was performed. In addition, these experiments were performed to optimize the 
linkage conditions and procedure, as well as, to understand the process of VEGF 
coupling. Furthermore, it was the aim to rule out the unspecific adsorption of 
VEGF165 on the modified collagen matrix. Thus, unmodified and modified collagen 
matrices were incubated with BSA, VEGF165, or buffer. VEGF was detected with 
varying combinations of detection antibodies (compare Table 6-1). 
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Table 6-1: Overview of incubation and detection procedures for the evaluation of unspecific 
adsorption on PEG-PLGA and PLGA coated discs and order of incubation for Collagen-04 and 
Collagen-05, as well as PEG-Collagen-04 and PEG-Collagen-05. 
 incubation solution detection antibodies 
Sample PBS 
VEGF165 
[20 µg/ml] 
BSA 
[1 mg/ml] 
Anti-VEGF 
goat-anti-
rabbit 
Collagen-01  X  X X 
Collagen-02 X   X X 
Collagen-03  X   X 
Collagen-04  1.) X 2.) X X X 
Collagen-05  2.) X 1.) X X X 
Collagen-06   X X X 
Collagen-07   X  X 
PEG-Collagen-01  X  X X 
PEG-Collagen-02 X   X X 
PEG-Collagen-03  X   X 
PEG-Collagen-04  1.) X 2.) X X X 
PEG-Collagen-05  2.) X 1.) X X X 
PEG-Collagen-06   X X X 
PEG-Collagen-07   X  X 
 
The results obtained for the unmodified collagen coated discs can be seen in Figure 
6-8. All samples, independent of their incubation solution, showed very little to no 
fluorescence in the pictures obtained using CLSM. Only the samples incubated with 
VEGF165 and BSA (Figure 6-8 d and e) exhibited slight fluorescence to the same 
extent that is in no correlation to the order of incubation solutions. The increased 
fluorescence in comparison to the other samples might be attributed to the 
increased background fluorescence when using a fluorescently labeled secondary 
antibody for detection and to the increased incubation time, which was double the 
time for the samples Collagen-04 and -05. 
Cell growth stimulation by covalent linkage of VEGF165 to a modified collagen-matrix 
 
155 
(a) (b) (c) (d) 
    
(e) (f) (g)  
   
 
Figure 6-8: CLSM images of antibody stained discs Collagen-01 (a), Collagen-02 (b), Collagen-
03 (c), Collagen-04 (d), Collagen-05 (e), Collagen-06 (f), and Collagen-07 (g) 
 
The results obtained from the control experiments, with non modified collagen 
matrices, showed that there was no unspecific interaction or adsorption of VEGF165 
that was detectable using this antibody staining method.  
The aim of the second set of experiments was to further investigate the binding 
efficiency and conditions of incubation for PEG-collagen matrices. Therefore the 
same set of incubations (compare Table 6-1) as for the non-modified collagen 
matrices were performed on PEG-collagen coated discs. The results obtained for 
these experiments can be seen in Figure 6-9. Figure 6-9a and b show the pictures 
of the samples incubated with VEGF165 and buffer respectively. It can be seen that 
there was a strong fluorescence for the VEGF165 incubated samples in contrast to 
the samples incubated with buffer alone, which indicated that the binding of 
VEGF165 antibody is specific for covalently attached VEGF and shows no interaction 
with the PEG-collagen matrix. The control samples incubated with VEGF165 and the 
fluorescently labeled secondary antibody showed no fluorescence (compare Figure 
6-9c), proving that there is no unspecific interaction or attachment of the secondary 
antibody with the attached VEGF165 and the PEG-collagen matrix. For the samples 
incubated with VEGF165 and BSA solution (Figure 6-9d) a slight decrease in 
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fluorescence could be observed in comparison to the samples only incubated with 
VEGF165. This decrease can be attributed to the increased incubation time of 
60 minutes compared to 30 minutes and a therewith associated further rinsing step. 
In addition to the increased incubation time, the blocking of binding sites due to the 
BSA incubation can also account for the decrease in fluorescence. 
(a) (b) (c) (d) 
    
(e) (f) (g)  
   
 
Figure 6-9: CLSM images of antibody stained discs PEG-Collagen-01 (a), PEG-Collagen-02 (b), 
PEG-Collagen-03 (c), PEG-Collagen-04 (d), PEG-Collagen-05 (e), PEG-Collagen-06 (f), and 
PEG-Collagen-07 (g) 
 
Interestingly, the sample first incubated with BSA solution and subsequent 
incubation with VEGF165 showed fluorescence (Figure 6-9e). It was expected that 
BSA would block all the active functional groups and hamper VEGF165 attachment. 
In addition, it is reported in literature that the half life of activated succinimidyl ester 
is around 30 minutes [23], and therefore, a subsequent attachment of VEGF165 was 
not expected. However, the fluorescence indicated successful linkage of the protein, 
which leads to the conclusion that the functional group was still active after BSA 
incubation. An interaction of BSA with the primary VEGF165 antibody or the 
fluorescently labeled secondary antibody could be excluded, since both control 
samples with BSA and incubation with either both antibodies or the secondary 
antibody only showed no fluorescence (Figure 6-9f and g).  
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These experiments proved that an unspecific adsorption of VEGF165 or the 
secondary fluorescently labeled antibody to the modified collagen matrix can be 
ruled out, as seen by the various control experiments using unmodified and 
modified collagen. Furthermore and more importantly, the successful linkage of 
VEGF165 to the modified collagen matrix was shown. 
 
3.2 Influence of VEGF165 covalently linked to PEG-Collagen on cell growth 
3.2.1 Vascular endothelial cells 
In order to evaluate the activity of the covalently linked VEGF165, and therewith the 
accessibility of the VEGF surface receptor (VEGFR-1) [10] on the endothelial cells 
towards the covalently linked protein, cell growth studies were performed. 
Additionally, several control experiments were performed to investigate the effect of 
loosely adsorbed protein on the surface of unmodified collagen coated discs. 
Therefore, collagen and PEG-collagen coated discs, respectively, were treated with 
different incubation solutions in accordance to Table 6-2 and immediately thereafter 
rinsed and incubated with endothelial cells. After a 3 day incubation period, cells 
were quantified using Cell Titer-Blue®. The results were calculated as % increase in 
relation to the amount of cells that had grown on the collagen and PEG-collagen 
coated discs incubated with PBS buffer. 
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Table 6-2: Overview of incubation procedures for the evaluation of cell growth on PEG-
collagen and collagen coated discs and order of incubation. 
 incubation solution 
Sample PBS buffer 
VEGF165 
[20 µg/ml] 
BSA 
[1 mg/ml] 
Collagen (control) X   
Collagen (VEGF)  X  
Collagen (BSA)   X 
Collagen (BSA + VEGF)  2.) X 1.) X 
Collagen (VEGF + BSA))  1.) X 2.) X 
PEG-Collagen (control) X   
PEG-Collagen (VEGF)  X  
PEG-Collagen (BSA)   X 
PEG-Collagen (BSA + VEGF)  2.) X 1.) X 
PEG-Collagen (VEGF + BSA))  1.) X 2.) X 
 
The results presented in Figure 6-10 showed no significant increase in cell growth 
for the collagen coated discs incubated with VEGF, BSA, or combinations thereof 
compared to the control group incubated with buffer irrespective of the incubation 
solution used. Only a decrease in cell growth of approximately 20 % for the cells 
grown on discs incubated with BSA solution was observed. However, the discs 
coated with the modified PEG-collagen material exhibited different growth behavior 
for the endothelial cells, depending on the incubation solution. Discs incubated with 
VEGF165 alone showed an increase in cell growth compared to the buffer incubated 
samples of approximately 40%. An increase in cell growth was also observed for the 
samples incubated with VEGF165 and BSA. Those samples first incubated with 
VEGF165 and subsequent incubation with BSA showed an increase of approximately 
35% in contrast to the samples incubated with BSA first and subsequent incubation 
with VEGF165, which showed an increase of around 20%. This difference in increase 
can be explained by the lower amount of VEGF attached to the modified collagen 
surface, as observed before during antibody detection (compare 3.1.2). The 
increase in cell growth for these samples can not be attributed to the influence of 
BSA, since control samples incubated with BSA solely showed an extent of 
endothelial cell growth comparable to the control samples incubated with buffer. 
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Therefore, it can be concluded, that VEGF165 was successfully attached to the 
modified PEG-collagen matrix without losing its biological activity. No unspecific 
interaction of VEGF with the unmodified collagen matrix could be observed in the 
cell growth study. In addition, it can be deducted that the attached VEGF on the 
PEG-collagen matrix was capable to stimulate the proliferation of endothelial cells. 
 
3.2.2 Cell growth comparison study 
In a second cell growth study, the influence of the covalently attached VEGF165 on 
endothelial cells in addition to SMCs was investigated. Therefore collagen and 
PEG-collagen coated discs were incubated with buffer, BSA, and VEGF165. The 
discs were subsequently rinsed using Milli-Q water and incubated with endothelial 
cells or smooth muscle cells for 3 days (compare 2.2.6.3). After the 3 day incubation 
period, cells were quantified using Cell Titer-Blue®. The results were calculated as 
% cell growth in relation to the amount of cells present on the collagen and PEG-
collagen coated discs incubated with PBS buffer. In addition, one set of VEGF165 
exposed discs was incubated over night in PBS buffer and thereafter rinsed, placed 
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in a fresh 24-well plate, and treated accordingly. The additional experiment was 
performed to elucidate the stability of covalently attached VEGF. It was of interest 
whether the biological activity and the effect on endothelial cells could be sustained 
for an extended period of time during incubation in solution.  
 
0
20
40
60
80
100
120
140
160
180
200
control BSA VEGF VEGF inc.
c
e
ll
 g
ro
w
th
 [
%
]
incubation solution  
Figure 6-11: Endothelial cell growth on Collagen (
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The findings for the endothelial cells can be seen in Figure 6-11. Again, it was 
observed that BSA incubated discs demonstrated a decrease in cell growth 
compared to the buffer incubated samples after 3 days incubation, which was in 
accordance to the findings in previous endothelial cell growth studies (compare 
3.2.1). These results were in contrast to previously determined endothelial cell 
growth on modified PLGA matrices carrying VEGF covalently attached (see Chapter 
5). It has been reported in literature that positively charged surfaces are beneficial 
for endothelial cell adhesion [24-25]. At physiological conditions, BSA exhibits a 
negative surface charge [26] in contrast to VEGF that displays a positive charge 
under those conditions [27], which could explain the decrease in endothelial cell 
growth on the PEG-Collagen material incubated with BSA. In addition, a denser 
PEG coverage on the collagen modified material resulting from a higher density of 
modifiable amine groups in contrast to carboxylic groups on PLGA might have 
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caused the differences in cell growth observed for these two materials, since PEG is 
known to have protein repellent and cell adhesion resistant properties [28-29]. 
In contrary to prior findings, VEGF incubated collagen discs exhibited an increase in 
cell growth of approximately 20%, which was not observed before. Previous 
incubation of the samples over night in PBS buffer did not have an effect on the 
extent of cell growth increase in the case of collagen coated discs. However, PEG-
collagen coated discs that were treated with VEGF165 and discs that were 
subsequently incubated with buffer over night showed an increase in endothelial cell 
growth of approximately 45% and 80%, respectively. Therefore, the resulting 
difference in growth increase between VEGF incubated collagen and PEG-collagen 
discs was in a range of 25% and above, which was in accordance with prior findings 
(compare 3.2.1) where a growth increase for PEG-collagen discs with VEGF165 in a 
range of 20 – 35% was achieved.  
The considerable increase in cell growth of the VEGF165 coupled PEG-collagen 
discs that were incubated prior to cell seeding showed the sustainable effect of the 
VEGF attachment to the surface. VEGF165 was not lost during incubation or 
immediately eliminated from the surface, but showed an extended effect. It is a first 
indicator for a presentation possibility of VEGF165 at the matrix surface enabling a 
prolonged interaction and stimulation of endothelial cells. In contrast, contradictory 
findings about the stability of free VEGF165 in buffer have been reported in literature 
[30-31]. In this case, in accordance to findings reported in Chapter 4, the biological 
activity of VEGF165 and its endothelial cell specific growth stimulation could be 
maintained in solution for more than 24 hours incubation. Similar results have been 
reported by Sharon et al. for the immobilization of VEGF using dihydrazide spacers 
[7].  
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Figure 6-12: Smooth muscle cell growth on Collagen (
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In contrast to the findings observed for endothelial cells presented to VEGF165 
coupled discs, SMCs exhibited a different growth rate effect when grown on 
collagen and PEG-collagen coated discs (Figure 6-12). The growth of SMCs was 
not stimulated when presented with collagen coated discs irrespective of their 
incubation medium. A slight decrease was observed for cells grown on BSA 
incubated discs, as also seen for endothelial cells. The covalent attachment of 
VEGF165 to the PEG-collagen matrix did not affect this observed pattern. All discs 
showed a cell growth comparable to the buffer incubated samples. 
Therefore, it could be concluded that VEGF165 had no stimulatory effect on SMCs, 
however increased the growth of endothelial cells. This is in accordance with 
previous findings documented in literature [8, 12, 13, 32, 33]. Thus, the cell growth 
comparison study successfully showed a beneficial effect of VEGF165 coupled to 
PEG collagen matrices for the stimulation of endothelial cell growth. In addition, 
these experiments also gave further insight into the ability of internalization of the 
receptor complex in order for the cytokine to stimulate proliferation of the cells, as 
described before in literature [34-36]. Covalent attachment of VEGF165 did not 
interfere with the mechanism of action as seen by the stimulation of endothelial cell 
growth increase, which was in accordance with findings reported in literature [7]. 
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Furthermore, the matrices showed no stimulatory effect on SMC, which provides an 
additional benefit of the PEG-collagen matrices for the coating of vascular grafts to 
specifically enhance endothelial cell growth without increasing smooth muscle cell 
growth and therefore raising the risk of neointimal hyperplasia [5]. 
 
4 Conclusions 
A functionalized collagen coating was developed for the covalent linkage and 
immobilization of VEGF to surfaces. Therefore, collagen, a naturally occurring 
polymer was used to coat PTFE and glass disc as model substrates for vascular 
prosthesis surfaces. The collagen matrix was successfully functionalized using a 
homobifunctional PEG-spacer carrying succinimidyl ester to covalently bind to 
amino moieties within protein sequences. In our case, VEGF165, an endothelial cell 
specific growth stimulator, was used to be covalently attached to the modified 
polymer surface. The successful linkage of this protein was shown using an 
antibody staining method. The specificity and integrity of the method towards the 
target protein was shown using several control experiments. 
In addition, the effect of covalently immobilized VEGF on endothelial cells was 
shown in cell growth experiments using endothelial cells and smooth muscle cells. 
The effect of the attached VEGF165 to PEG-collagen matrices was superior to 
effects seen for loosely adsorbed protein on collagen matrices. In addition, the 
sustainable effect on endothelial cells of the attached protein was shown, proving 
the effective linkage. This is an advantage in regards to loosely adsorbed or in 
matrices incorporated protein, which can be washed away after release or during 
incubation. It is an important aspect especially with regards to vascular grafts that 
are used for vessel replacement and are placed in regions of varying flow 
conditions. Furthermore, it was shown, that the covalently attached VEGF did not 
have an effect on smooth muscle cells. Therefore, this approach is an interesting 
alternative for the modification of vascular grafts that can be used to improve the 
functionality of existing grafts. The next step to ensure its applicability to modify 
vascular grafts is the investigation of the performance of these coatings under flow 
conditions. 
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Chapter 7 
 
Summary of the Thesis 
 
The goal of this thesis was the improvement of vascular grafts to enhance 
endothelialization by applying surface coatings on existing commercially available 
grafts. Polytetrafluoroethylene (PTFE), chosen for its similar composition compared 
to expanded PTFE, which is used for vascular grafts, and glass, as models, were 
utilized as substrates for the coating. The general introduction gave an overview of 
frequently encountered problems when using vascular grafts in vessel replacement, 
especially for those employed in regions of low blood flow and of small diameter. 
In order to establish functional coatings on the surface of PTFE, atmospheric 
plasma treatment with a plasmabrush® using argon gas was performed. Changes 
induced by the plasma treatment process were evaluated using several methods to 
detect and characterize the alterations in surface morphology and composition, 
such as Fourier transform infrared (FT-IR) spectroscopy, scanning electron 
microscopy, X-ray photoelectron spectroscopy and surface energy determination. 
Effects were successfully characterized by surface energy determination and were 
stable for several weeks. After optimization of the process conditions, treatment 
time and ignition voltage it was possible to increase the surface energy of PTFE 
samples by 10-15 mN/m. The characterization of modifications, by means of other 
methods than surface energy determination, did not reveal radical structural or 
chemical alterations. However, the methods might have not been sensitive enough 
to detect the effects induced by the atmospheric plasma treatment. The established 
plasma activation process significantly increased the coating adhesion to PLGA and 
collagen films applied on the modified surfaces, in contrast to the non adhesion of 
these films on unmodified PTFE surfaces. In addition, it was shown that the plasma 
modification greatly improved the adherence of endothelial cells on the plasma 
treated surfaces. 
For the controlled presentation of VEGF165, an endothelial cell specific growth 
enhancer, two approaches, matrix embedding combined with sustained release and 
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covalent attachment, were pursued. For the matrix release approach, PLGA was the 
first polymer used due to the experience with this polymer in biomaterial 
applications. The polymers investigated in the process of this study were Resomer® 
RG 502H, RG 503, RG 503H, and RG 504H. The influence of molecular weight on 
the release of FITC-dextran as model compound was shown. Resomer® RG 502H, 
the lowest molecular weight species investigated, was shown to be the most 
suitable in the range of polymers examined. Its release rate suited the intended 
purpose and the desired release time period of 1 to 2 weeks. In addition, it was 
shown that the influence of esterification of free carboxylic groups of the used 
polymers did not have a beneficial effect on the release rates of coatings. The 
influence of the suspended model compound particles on the coating process and 
the subsequent release was investigated and was shown to have no influence on 
the outcome of release investigations, especially in respect of burst release from 
such coatings in contrary to previously reported findings. In addition, the cell 
compatibility of the applied PLGA coatings was shown using human umbilical cord 
endothelial cells. Fluorescent activated cell sorting analysis, propidium iodide 
staining in combination with fluorescence measurements, and using a counting 
chamber were shown to be unsuitable to reveal small differences in cell growth. 
However, minor changes in cell growth increase were successfully detected using 
Cell Titer-Blue®, a commercially available cell viability assay. 
The second polymer investigated for the matrix release approach was collagen, 
chosen for its ease of production in aqueous media and good cell compatibility. 
Crosslinking of collagen was performed and it was shown to be an effective tool to 
modify release properties of collagen without risking the good biocompatibility of this 
material. It was shown that in accordance with increasing crosslinking degree, the 
initial release of model compound was reduced and higher amounts, of up 70 % for 
the highest crosslinked material, were entrapped in the matrix. The predetermined 
release properties for the model compound, FITC-dextran, could be successfully 
confirmed for VEGF165. VEGF incorporated into collagen films was investigated 
towards its effect on endothelial and smooth muscle cells and no stimulatory effect 
on smooth muscle cells could be shown. More importantly, an increase in 
endothelial cell growth by VEGF released from collagen films was demonstrated. 
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Therefore, biological activity of a sufficient amount of VEGF was maintained 
throughout the manufacturing and drying process of collagen films and the 
subsequent release to stimulate endothelial cell growth. 
For the second approach, the influence of VEGF165 covalently attached to modified 
PLGA and collagen matrices on endothelial cells and smooth muscle cells was 
investigated. The modification was accomplished using a homobifunctional 
polyethylene glycol (PEG) spacer carrying succinimidyl ester groups to bind to 
amine groups within the protein sequence, the collagen, and the modified PLGA. 
For PLGA, it was shown that the functionalized PEG-PLGA was able to covalently 
bind VEGF165 using several staining techniques, such as silver staining and Deep 
PurpleTM Total Protein Stain. Other techniques, such as FT-IR spectroscopy, were 
not sensitive enough to detect VEGF. An antibody staining method was developed 
to determine the presence of VEGF165 on the modified PLGA and collagen surfaces, 
and thereby confirming successful linkage of the cytokine to the effectively modified 
polymers. The interaction of the bound VEGF165 with the antibody was a first 
indicator of the sustained functionality of the cytokine. In cell assays, covalently 
attached VEGF could be shown to have a positive effect on the cell growth of 
endothelial cells. Furthermore, PEG-PLGA exhibited a limiting effect on the 
proliferation of smooth muscle cells, due to its cell-adhesion-resistant properties. 
PEG-collagen matrices did not exhibit any effect on smooth muscle cell growth. The 
successful attachment of VEGF165 could be shown while preserving the biological 
activity and endothelial cell specific growth stimulation for an extended period of 
time in solution. Moreover, it was proven, that the irreversibly linked VEGF165 was 
still able to interact with its receptor and to stimulate endothelial cells. 
Within the scope of this thesis, several approaches for the improvement of vascular 
grafts using an endothelial cell specific growth stimulant were successfully 
developed and could be shown to have a positive effect on the stimulation of 
endothelial cells without stimulating the growth of smooth muscle cells. Especially 
the covalent linkage of active VEGF165 to a modified collagen or PLGA matrix 
appeared to be a promising tool to improve the performance of vascular grafts. 
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